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Introduction: Hepatorenal syndrome (HRS) is a common complication of advanced cirrhosis with a 
high mortality rate and limited treatment options. Central to its pathogenesis is severe, but potentially 
reversible, renal vasoconstriction leading to functional renal failure. Current pharmacological 
treatment using splanchnic vasoconstrictors is suboptimal and prognosis without liver transplantation 
is dismal.  The peptide hormone relaxin (RLN) mediates haemodynamic adaptations to pregnancy 
including increased renal blood flow (RBF) and glomerular filtration rate (GFR). I hypothesised that 
exogenous RLN could be used therapeutically to improve RBF and renal function in the context of 
experimental cirrhosis and HRS. 
Methods: To address this I generated pathologically distinct rat models of liver cirrhosis with 
features of human HRS including renal vasoconstriction and renal failure. Compensated cirrhosis 
was induced in male rats by 16 weeks of i.p. carbon tetrachloride (CCl4) and decompensated 
cirrhosis by bile duct ligation (BDL). I studied the effects of acute i.v. or sustained (72 hr) s.c. 
infusion of RLN compared with vehicle on systemic haemodynamics, RBF, GFR and kidney 
histology. I used blood oxygen dependent-magnetic resonance imaging (BOLD-MRI) to detect 
changes in kidney parenchymal oxygenation and Doppler ultrasound to monitor changes in RBF 
(velocity time integral, VTI) and renal arterial resistance (resistive index, RI). Hepatic and renal 
expression of the relaxin receptor RXFP1 was determined by quantitative polymerase chain reaction 
(qPCR) and immunohistochemistry (IHC). Vascular functional responses in isolated renal arteries 
were assessed by wire myography. Relaxin mediated changes in key vaso-regulatory signalling 
pathways in the kidney and renal vessels were analysed by qPCR, IHC and ELISA. 
Results: I showed using in vitro myography that the pathophysiological mechanism that underlies 
renal vasoconstriction in experimental cirrhosis models is an impairment of endothelium-dependent 
vasodilatation. Selective targeting of renal vasoconstriction using relaxin improved renal blood flow, 
tissue oxygenation, and normalized glomerular filtration rate in both compensated and 
decompensated rat cirrhosis. Furthermore, relaxin treatment restored endothelium-dependent 
vasodilation in isolated renal vessels from CCl4 cirrhotic rats. Relaxin-induced effects on renal blood 
flow and glomerular filtration rate were mediated though activation of the AKT/eNOS/nitric oxide 
signalling pathway in kidney, though systemic nitric oxide levels were unaffected. Crucially for 
human translation, relaxin did not reduce mean arterial blood pressure even in advanced cirrhosis.   
Conclusion: My findings identify relaxin as the first potential targeted treatment reversing the 
vascular dysfunction which causes HRS and directly improving renal function in HRS.  Clinical 
translation in carefully selected populations is warranted. 
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In this thesis, work supported by the Wellcome Trust, I investigated a hormone called Relaxin which is 
known to be responsible for the maternal adaptations to pregnancy including increasing blood supply to the 
kidney and improving kidney function. The reason this research was undertaken on this hormone is that there 
is a condition called hepatorenal syndrome, which is a very distinct complication of severe liver dysfunction, 
which is caused by a critical reduction in blood flow to the kidney leading to decreasing kidney function.  
Current therapy works in only 40% of patients and death rates from this condition near 80% unless they are 
able to receive a liver transplant. There is therefore a need for different therapies to try to reverse this 
condition.  
 
I have used animal models of liver disease, in particular end stage liver disease termed cirrhosis, that mimic 
human disease to a good extent with reducing blood flow to kidney and decreasing function. When relaxin 
was given to these models the blood flow to the kidney acutely rose over 30-60 minutes. This has been 
shown in many ways including using different imaging modalities, ultrasound and MRI. The later measures 
changes in kidney oxygen levels and we observed that relaxin improved kidney oxygen levels.  When relaxin 
is given over several days not only is the kidney blood supply increased to 60-75% of normal but kidney 
function was nearly restored.  Importantly these effects seemed selective to the kidney and were not 
associated with any side effects such as a drop in blood pressure.   
 
I have also found, in these models of cirrhosis, that the arteries that supply the kidney do not open up 
properly (termed vasodilatation) and this appears to be due to a problem with an important mediator of 
vasodilatation called nitric oxide synthase (NOS).  NOS works by producing a substance that allow arteries to 
dilate and is produced in the inner lining of the artery, which is called the endothelium.  Relaxin improves 
this problem by increasing NOS, allowing the artery to dilate normally. 
 
Bringing all these results together I have shown that relaxin is a very promising therapy for hepatorenal 













1.1 The Clinical Burden of chronic liver disease 
 
Chronic liver disease results from a range of conditions including chronic alcohol excess, non-
alcoholic fatty liver disease (NAFLD), chronic viral infection with Hepatitis B or C, parasitic worm 
infections and numerous immune mediated and metabolic conditions.  The prevalence of chronic 
liver disease is rapidly increasing with 600 000 people having some form of liver disease in England 
and Wales, of whom 60 000 have cirrhosis. This represents an increase of 62% in liver disease and 
40% in cirrhosis in 10 years (Williams, Aspinall et al. 2014). This is predominantly secondary to 
excess alcohol consumption, NAFLD with obesity and metabolic syndrome and viral hepatitis.  
Chronic liver injury eventually leads to cirrhosis, portal hypertension (PHT) and its complications. 
This has resulted in increasing hospital admissions with patients presenting with variceal bleeding, 
hepatic encephalopathy (HE), ascites, hepatorenal syndrome (HRS), hepatocellular cancer or liver 
failure requiring treatment.  As a result mortality rates have increased 400% since 1970 and in people 
younger than 65 years has risen by almost five times. Compared to other systems, deaths from liver 
disease are currently rising (Fig. 1.1) and liver disease is now the 3rd commonest cause of premature 
mortality in the UK. 
Although prevention and treatment of the causative agent is an important approach to reducing this 
burden, much of liver damage is asymptomatic resulting in patients presenting only when they 
develop cirrhosis and its complications.  At which point there are limited therapeutic strategies and 
the only cure is, for a limited few, liver transplantation.  Currently, the demand for organs far 
outweighs the supply and this will only worsen with the increasing problem.  There is therefore a real 
need for novel therapies that can both reverse the fibrotic process but also treat the complications of 
cirrhosis and PHT to reduce the mortality and morbidity we are currently seeing and will see more of 




In this thesis, I focus on one of the most important complications of cirrhosis, HRS.  This functional 
kidney failure in the presence of advanced liver disease dramatically reduces life expectancy, 
presents a significant burden on the NHS with patients requiring prolonged hospital stay, occasional 
renal replacement therapy and potentially some patients may require a kidney transplant alongside 
their liver transplant.  Importantly, post-transplant outcomes in patients with HRS are not as good as 
those without HRS (Marik, Wood et al. 2006).  Integral to developing novel therapies is the need to 
fully understand the pathogenic mechanisms that result in this complication. 
 
 
Figure 1.1 Standardised UK Mortality Rate Data 









Cirrhosis is primarily a histological diagnosis characterised by loss of the normal lobular liver 
architecture with fibrotic septa separating abnormal nodules of regenerating hepatocytes.  The 
normal liver is relatively free of fibrous tissue, however with chronic liver injury there is progressive 
accumulation of extracellular matrix proteins including collagen, which distorts the normal liver 
architecture by producing a scar (Bataller and Brenner 2005).  The development of cirrhosis is 
normally an insidious process that takes 15-30 years, depending on the underlying liver injury.  
Different chronic liver diseases cause distinct patterns of fibrosis, however the development of 
cirrhosis represents the final common stage which then leads to similar clinical consequences 
(Pinzani, Rombouts et al. 2005).  It has been shown from rodent models of cirrhosis, autoimmune 
hepatitis and viral hepatitis in humans that cirrhosis is dynamic and has the capacity to reverse to 
different degrees (Ramachandran and Iredale 2009; Snowdon and Fallowfield 2011).  This evidence 
has subsequently challenged previous thinking that cirrhosis was a relentlessly progressive and 
irreversible process.    
 
The idea that cirrhosis represents a single stage of disease is far too simplistic.  Our current 
understanding is that the term cirrhosis represents a spectrum (Fig 1.2) of histological parameters 
(scar thickness and reversibility), clinical parameters (presence or absence of clinically significant  
PHT) and other complications (Garcia-Tsao, Friedman et al. 2010).  Clinically, cirrhosis remains 
classified according to whether the patient is compensated or decompensated.  This is done by the 
presence of clinically evident complications of cirrhosis, particularly those related to PHT or those 
secondary to liver failure (i.e. jaundice).  However, this terminology should be challenged as the key 
to defining pathogenesis requires a better understanding of the different histological stages and 
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biological changes in relation to PHT and clinically evident complications. This would allow better 
prognostication and therapeutic targeting of ‘high risk’ cirrhotic populations. 
 
 
Figure 1. 2 Classification of chronic liver disease 
Classification of chronic liver disease based on histological, clinical, haemodynamic and biological 










1.3 Portal Hypertension 
 
Portal hypertension (PHT) is the most important consequence of cirrhosis and is a major contributory 
factor for most of the morbidity and mortality associated with cirrhosis including variceal bleeding, 
ascites, HRS and HE (Bosch and Garcia-Pagan 2000).  PHT is defined as an increase in the pressure 
within the portal vein and the current gold standard for measuring PHT and its severity is 
measurement of the hepatic venous pressure gradient (HVPG).  The HVPG is measured invasively 
by measuring the difference between the wedged hepatic venous pressure (WHVP) and the free 
hepatic venous pressure (FHVP). A value of 3-5 mmHg is normal with a reading over 10 mmHg 
being a predictor of clinically significant PHT (de Franchis 2010).  
 
The prognostic value of PHT measurement at different stages in the natural history of chronic liver 
disease has been well demonstrated, with robust cut-off values for the development of complications 
(HVPG>10 mmHg) and variceal rupture (HVPG>12 mmHg)  (Groszmann, Garcia-Tsao et al. 2005; 
Ripoll, Groszmann et al. 2007).  A reduction in HVPG below 12 mm Hg or by > 20% from baseline 
is associated with a significant reduction in complications and death.  The importance of PHT is 






Figure 1.3 Importance of HVPG in Predicting Clinical Outcomes 
Table showing the importance of hepatic venous wedge pressure gradient (HVPG) as a surrogate 
marker of portal hypertension (PHT) and the clinical relevance of its measurement. Adapted from 
(Snowdon, Guha et al. 2012). 
 
In cirrhosis, PHT is initiated by an increase in intrahepatic vascular resistance (IHVR) and then 
exacerbated by changes in the systemic and splanchnic circulation that increase the portal inflow. 
Increased IHVR is caused by mechanical factors (e.g. fibrotic scars and regenerative nodules that 
distort the hepatic vascular architecture), but also by a reversible dynamic component mediated by an 
increase in vascular tone due to the active contraction of myofibroblasts around the hepatic sinusoids 
and in fibrous septa.   This dynamic component (which accounts for ~30% of increased IHVR) 
reflects a functional disturbance of the liver circulation, secondary to increased production of 
vasoconstrictors (e.g. endothelin-1) and reduced release of endogenous vasodilators (mainly nitric 
oxide, NO) (Bhathal and Grossman 1985; de Franchis 2000; Rockey 2001; Iwakiri and Groszmann 
2007).  Decreased expression of endothelial NO synthase (eNOS) protein, decreased phosphorylation 
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of eNOS by the serine-threonine kinase AKT, the presence of inhibitory substances (e.g. asymmetric 
dimethylarginine, ADMA) and hypo responsiveness to NO have all been shown to contribute to this 
endothelial dysfunction (Rockey and Chung 1998; Laleman, Omasta et al. 2005; Iwakiri 2011).  In 
contrast, extra-hepatic endothelial cells have the opposite phenotype producing excessive NO which 
contributes to splanchnic vasodilation, increased portal blood flow and an increase in PHT.   
 
Angiogenesis has also been shown to influence PHT, with studies demonstrating that the 
maintenance of increased portal pressure, the hyperkinetic circulation, splanchnic neovascularization 
and porto-systemic collateralization are regulated by vascular endothelial growth factor (VEGF) and 
platelet derived growth factor (PDGF) (Fernandez, Mejias et al. 2007). By blocking VEGF and 
PDGF after development of PHT in rodents, portal pressure and mesenteric blood flow were 
significantly reduced with no effect on collaterals.  In contrast, no anti-portal hypertensive effect was 
seen in models where PHT was developing, though there was reduced collateral formation.  
 
Most of the research, to date, has focussed on PHT and variceal bleeding, as the latter is a clearly 
defined end-point whereas there has been less attention on its definitive role in the pathogenesis of 
the topic of my thesis, HRS.  There is no doubt that this is likely to be due to the heterogeneity of this 
condition and subsequent difficulty in clear diagnosis limiting clinical studies.  Although PHT is an 
important contributory factor, as evidenced by work showing that acutely blocking trans-jugular 
intrahepatic porto-systemic shunts (TIPSS) causes a robust reduction in renal blood flow (RBF) 
(Jalan, Forrest et al. 1997)  and data showing that responders to treatment of PHT have a lower risk 
of development of HRS (Abraldes, Tarantino et al. 2003), what is not entirely clear is whether this 
condition can exist without PHT and more importantly, what the relative contribution of other 




1.4 Acute kidney injury (AKI) in cirrhosis 
 
Acute kidney injury (AKI) is commonly seen in decompensated cirrhotic patients, occurring in 
approximately 20% of hospitalized individuals (Garcia-Tsao, Parikh et al. 2008).  Not only does this 
confer a significantly increased mortality with a 7-fold increase in death and a 1 month mortality 
nearing 50% (Fede, D'Amico et al. 2012), but it is also a challenge to differentiate the underlying 
cause for AKI.  This can be secondary to  volume depletion from diuretics or paracentesis, or 
intrinsic kidney injury due to sepsis, shock or nephrotoxic drug therapy, or related to HRS (Hartleb 
and Gutkowski 2012).  Conventional criteria for AKI in cirrhosis defined it as an increase in serum 
creatinine (sCr) over 50% to a final value of over 1.5mg/dL (133 µmmol/L).  Recently this definition 
has been challenged owing to evidence from non-cirrhotics where smaller rises in creatinine were 
shown to have a detrimental effect on morbidity and mortality (Mehta, Kellum et al. 2007).  
Substantial work has been undertaken by the International Club of Ascites (ICA-AKI) to establish 
clear guidance in the cirrhotic population and the resultant definition of AKI is an increase in serum 
Creatinine (sCr) over 0.3 mg/dL (>26.5µmol/L) within 48 hours, or a percentage increase in sCr 
>50% from baseline which is known, or presumed, to have occurred within the prior 7 days (Angeli, 






Figure 1.4 International Club of Ascites (ICA-AKI) new definitions for 
the diagnosis and management of AKI in patients with cirrhosis 
Table showing the new classification of acute kidney injury (AKI). Adapted from (Angeli, Gines et 
al. 2015) 
 
1.5 Hepatorenal syndrome (HRS) 
 
In the presence of cirrhosis and PHT or severe liver dysfunction there is a distinct form of renal 
failure that can develop, which has been termed HRS.  It has been estimated that HRS develops in 
around 11 % of patients with cirrhosis and ascites (Planas, Montoliu et al. 2006) and the annual 
incidence of HRS is estimated at 18% by 1 year and 39% by 5 years (Gines, Escorsell et al. 1993).  
The frequency of HRS in severe acute alcoholic hepatitis and in fulminant liver failure is about 30% 
and 55%, respectively (Moore 1999; Verma, Ajudia et al. 2006) .  HRS is a reversible form of acute 
or sub-acute renal failure traditionally described as ‘functional’ largely due to the absence of 
significant morphological changes in renal histology and largely preserved tubular function, with 
conservation of sodium and reduced urinary sodium levels.  The evidence for functional renal failure 
stems from the observation that HRS resolves following liver transplantation (Iwatsuki, Popovtzer et 
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al. 1973) and from the fact that kidneys from patients with HRS function normally when they are 
transplanted into patients with end-stage renal failure (Koppel, Coburn et al. 1969).  
 
1.6 Classification of HRS (past and present) 
 
Historically, two types of HRS have been recognized and classified according to the intensity and 
form of presentation of renal dysfunction/AKI.  Type 1 HRS is characterized by severe and rapidly 
progressive renal failure and is commonly precipitated by bacterial infections (such as spontaneous 
bacterial peritonitis).  It has a median survival time of only 2 weeks (Arroyo, Guevara et al. 2002; 
Gines, Guevara et al. 2003). Type 2 HRS is characterized by a moderate and steady decrease in renal 
function, is usually associated with diuretic-resistant ascites, and carries a slightly better prognosis 
with a median survival time of about 6 months (Arroyo, Guevara et al. 2002; Gines, Guevara et al. 





Figure 1.5 Kaplan-Meier plot showing reduced survival in presence of 
Hepatorenal Syndrome 
Graph highlighting the increased mortality in presence of HRS, with Type 1 HRS having a median 
survival of 2 weeks and Type 2 HRS having a median survival of 4-6 months. Adapted from (Arroyo, 
Terra et al. 2007). 
 
The recent change in definition of AKI has led to a change in the definition of HRS-AKI updating 
the above, with the following criteria needing to be fulfilled to allow diagnosis. Adapted from 
(Angeli, Gines et al. 2015): 
1. Diagnosis of cirrhosis and ascites 
2. Diagnosis of AKI according to ICA-AKI criteria (Fig 1.4) 
3. No response after 2 consecutive day of diuretic withdrawal and plasma volume expansion 
with albumins 1g/kg bodyweight 
4. Absence of shock 
5. No contrast or recent use of nephrotoxic drugs (NSAIDs, aminsoglycosides etc) 
6. No macroscopic signs of structural kidney injury, as defined: 
a. Absence of proteinuria (>500 mg/day) 
b. Absence of micro haematuria (>550 RBC’s per high power field) 
c. Normal findings on renal ultrasonography 
 
1.7 Presumed Pathogenesis of HRS 
 
At the centre of HRS pathogenesis is functional renal vasoconstriction as demonstrated by Epstein et 
al. (1970) using renal angiography in cirrhotic patients with renal failure showing profound 
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vasoconstriction of the renal vasculature associated with re-distribution of blood flow away from the 
cortex (Fig 1.6) (Epstein, Berk et al. 1970).   
 
 
Figure 1.6 Angiogram of the renal vasculature in a patient with 
cirrhosis and renal failure 
Profound vasoconstriction is seen (A) and after death normal vasculature is seen (B) showing that 
this is not a structural phenomenon. Adapted from (Epstein, Berk et al. 1970) 
 
This profound vasoconstriction is believed to be the hallmark of HRS (Platt, Ellis et al. 1994; Dagher 
and Moore 2001) .  Renal blood flow in cirrhotic patients has been shown to diminish with 
increasing severity of liver disease and when this reaches a critical level of hypo-perfusion to the 
kidney, renal dysfunction and HRS develop (Ring-Larsen 1977). 
 
The current paradigm for HRS pathogenesis is based upon the ‘vasodilatation’ hypothesis.    
Vasoconstriction occurs in response to splanchnic and peripheral arterial vasodilatation and 
impairment of cardiac function (cirrhotic cardiomyopathy) that lead to a reduction in effective 
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circulating volume and compensatory activation of the renin-angiotensin-aldosterone system 
(RAAS), sympathetic nervous system (SNS) and increased activity of antidiuretic hormone (Schrier, 
Arroyo et al. 1988; Krag, Bendtsen et al. 2010).  As previously described in section 1.3, in PHT the 
splanchnic vascular bed is vasodilated thought mainly due to endothelial overproduction of NO and 
VEGF driven angiogenesis (Iwakiri and Groszmann 2007; Huang, Haq et al. 2011).   Other 
vasodilators have also been implicated in this process such as prostacyclins, prostaglandins E2, atrial 
naturetic peptide (ANP) and kinins.   As a result of splanchnic vasodilatation, there is activation of 
the SNS, RAAS and other vasoconstrictors as effective blood volume is perceived as low (Ring-
Larsen, Hesse et al. 1982; Schrier, Arroyo et al. 1988).  Renal vascular resistance correlates closely 
with the activity of the RAAS and SNS and so activation of these systems leads to renal 
vasoconstriction.   HRS is thought to be associated with extreme stimulation of these pathways.  
Progression of these haemodynamic alterations in cirrhosis and an intra-renal imbalance between 
vasoconstrictor and vasodilator systems, results in renal blood flow becoming critically dependent on 
arterial blood pressure, with small changes in perfusion pressure translating into intense renal 
vasoconstriction and the precipitation of HRS (Stadlbauer, Wright et al. 2008).  The plasma 
concentration of endothelin-1 (ET-1), a vasoconstrictor peptide of endothelial origin, is also 
increased in cirrhosis and has been proposed as an additional factor in the pathogenesis of HRS 
(Anand, Harry et al. 2002).   Importantly, any process that increases splanchnic vasodilatation 
(infection, systemic vasodilators or paracentesis) or reduces vascular filling (diarrhoea, diuretics or 
bleeding) will precipitate this cycle (Belcher, Parikh et al. 2013). 
 
Evidence for the above hypothesis is strong, as standard treatment for HRS aimed at improving mean 
arterial blood pressure (MAP) using intravascular volume expansion with human albumin solution 
(HAS) and splanchnic vasoconstrictors (octreotide or terlipressin) results in improved renal function 
in 40-50% of patients (Angeli, Volpin et al. 1999; Nazar, Pereira et al. 2010). Indeed, in patients that 
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demonstrated an improvement in serum creatinine there was a strong association with an increase in 
MAP (Velez and Nietert 2011).  However, although HRS reversal significantly improved survival at 
day 180 and treatment with terlipressin and HAS significantly improved renal function and HRS 
versus HAS alone, treatment with terlipressin was not associated with improved overall survival 
(Sanyal, Boyer et al. 2008; Boyer, Sanyal et al. 2011). This was likely related to the significant 
presence of non-responders in the terlipressin arm.  The proportion of patients who do not respond to 
vasoconstrictor treatment have a dreadful prognosis, with one study showing 100% mortality by 3 
months (Moreau, Durand et al. 2002).   
 
As a result of this, it has been more recently hypothesised that other pathogenic mechanisms are 
likely to be involved as well and that renal dysfunction in cirrhosis may be even more heterogeneous 
than previously thought.  Pooling of blood in the splanchnic circulation (so-called ‘splanchnic steal 
syndrome’)  likely alters gut permeability and induces bacterial translocation, with the release of 
endotoxin and various cytokines, which amplify the dysregulated circulation in cirrhosis priming the 
kidneys for further insults (Newby and Hayes 2002).  Evidence for this comes from studies showing 
gut decontamination with prophylactic antibiotics (norfloxacin) reduced the incidence of renal 
dysfunction and improved survival (Fernandez, Navasa et al. 2007).  This has also been shown in a 
rodent bile duct ligation (BDL) model of cirrhosis, with norfloxacin treatment reducing pro-
inflammatory cytokines (TNFα) and Toll like receptor 4 (TLR) expression in the kidney (Shah, Dhar 
et al. 2012) .  Further evidence for an inflammatory component comes from human studies showing 
an increased rate of renal dysfunction in cirrhotic patients with systemic inflammatory response 
syndrome (SIRS) (Thabut, Massard et al. 2007).  More recent histological and biomarker studies 
report that tubular injuries are actually increased in the cirrhotic population, including patients with 
associated HRS, perhaps explaining why some individuals do not respond to circulatory support even 
when instigated early (Trawale, Paradis et al. 2010; Fagundes, Pepin et al. 2012). Additionally, a 
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recent study in cirrhotic patients highlighted the potential contribution of endothelial dysfunction in 
the development of renal vasoconstriction and renal failure (Garcia-Martinez, Noiret et al. 2014).  
 
Overall, the pathogenesis of HRS remains to be fully elucidated. There is a school of thought that the 
sepsis/pro-inflammatory renal phenotype may not represent ‘true’ HRS but an alternative form of 
renal failure in cirrhosis (Adebayo, Morabito et al. 2015), but this remains unproven and the concept 
of non-responders may relate to the true possibility that indirectly targeting the renal circulation with 
albumins and splanchnic vasoconstrictors is insufficient to reverse HRS .  All of this is summarised 






Figure 1.7 Precipitants, Mechanisms and Clinical correlates of HRS 
and ATN in cirrhosis 
Schematic showing proposed vasodilation hypothesis, adapted from (Belcher, Parikh et al. 2013) 
Portal hypertension leads to splanchnic and systemic vasodilatation with a decreased perceived 
effective arterial blood volume. This decrease stimulates activation of the SNS, RAAS, and ADH 
systems. The increased activity of these vasoconstrictor systems causes renal vasoconstriction and 
decreased renal perfusion. Any factor that worsens vasodilatation (infection, large volume 
paracentesis (LVP), vasodilators) or decreases blood volume (diarrhoea, diuretics, bleeding) can 
decrease renal perfusion further and lead to AKI. In advanced cirrhosis renal blood flow becomes 
dependent on the MAP and a decline in cardiac output leads to severe renal hypoperfusion and 
development of HRS.  Alternatively, precipitants may be severe enough to produce structural tubular 
injury (e.g. septic or hypovolemic shock) and AKI. The extent to which prolonged severe HRS can 
progress to ATN remains unclear and is shown with a dotted line. GI, gastrointestinal; MAP, mean 
arterial pressure; NSAIDs, nonsteroidal anti-inflammatory drugs; SVR, systemic vascular resistance. 
 
 
1.8 Current treatment of HRS  
 
Current drug therapy for HRS is limited to splanchnic vasoconstrictors. Off label use of intravenous 
terlipressin (in combination with HAS (Sort, Navasa et al. 1999)) constitutes the treatment of choice 
for type-1 HRS in the UK, but this is only effective in around 40-50% of patients (Fabrizi, Dixit et al. 
2006; Martin-Llahi, Pepin et al. 2008; Sanyal, Boyer et al. 2008; Nazar, Pereira et al. 2010), confers 
no long term survival advantage, and is associated with a significant increase in cardiovascular side 
effects (Krag, Moller et al. 2007; Krag, Moller et al. 2011; Gluud, Christensen et al. 2012).  Liver 
transplantation is the optimal treatment for HRS, with the majority of patients recovering renal 
function.  There is, however, a shortfall of donor organs and post-transplant outcomes are inferior 
compared to non-HRS cirrhotic patients (Gonwa, Morris et al. 1991; Marik, Wood et al. 2006).  
Additionally, insertion of a TIPSS may be effective in highly selected patients with preserved hepatic 
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function,  where improvement in renal function and ascites and increased survival have been 
demonstrated in both Type 1 (Guevara, Gines et al. 1998) and 2 HRS (Brensing, Textor et al. 2000; 
Testino, Ferro et al. 2003).  The issues that limit the widespread use of TIPSS are that it is only a 
viable option in patients with relatively well preserved hepatic function, without hepatic 
encephalopathy or cardiac impairment, and can only be performed in specialist centers (Salerno, 
Gerbes et al. 2007).   
 
There is, therefore, an unmet clinical need for new and effective therapies to both treat and prevent 
AKI/HRS thus reducing mortality in patients with decompensated cirrhosis, and also to improving 
outcomes after liver transplantation for patients with AKI/HRS. 
 
1.9 Relaxin  
 
Relaxin (RLN), a 6kD endogenous peptide hormone (Fig 1.8), has been shown to have anti-fibrotic, 
anti-inflammatory and vasoactive effects in a range of tissues in normal and pathological situations 
(Samuel, Hewitson et al. 2007; Teichman, Unemori et al. 2009). RLN is secreted by the corpus 
luteum in females and has well described physiological effects in pregnancy, including remodeling 
and relaxation of the pelvic ligaments, cervical softening, and mediating the maternal haemodynamic 
and renovascular adaptations to pregnancy (Sherwood 2004; Conrad 2010). Three RLN genes are 
present in humans but only one gene product, human-2 (H2-) RLN, is detected in the circulation.  
H2-RLN circulates in women at low concentrations during the luteal phase of the menstrual cycle 
(~50 pg/mL) and at increased levels (~1 ng/mL) throughout pregnancy, beginning in the first 
trimester. Women with ovarian failure who have egg donation and subsequent pregnancy, or 
pregnant rats treated with RLN neutralizing antibodies, do not exhibit the renovascular adjustments 
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to the same degree (Novak, Danielson et al. 2001; Smith, Murdoch et al. 2006) suggesting its 




Figure 1.8 Relaxin peptide 





Relaxin’s activity is initiated by binding to its cognate G-protein coupled receptor (GPCR), 
LGR7/RXFP1 (Fig 1.9).  LGR7/RXFP1 is a member of the leucine-rich repeat containing family of 
GPCRs which include the relaxin family peptide receptors (RXFP).  RXFP1 has been shown to be 
expressed in a wide range of organs including the renal and systemic vasculature in rodents and 
humans at the transcript and protein level (Hsu, Nakabayashi et al. 2002; Novak, Parry et al. 2006; 
Vodstrcil, Tare et al. 2012). The importance of RXFP1 in mediating the effects of RLN were shown 
in  Rxfp1 knockout mice, which exhibited a complete absence of vasodilation in response to RLN 




There is a paucity of data on the exact location of RXFP1 in the vasculature and in particular the 
renal vasculature.  In rodents, RXFP1 has been localized to the small renal and mesenteric arteries 
and the thoracic aorta in both sexes (Novak, Parry et al. 2006).  RXFP1 expression has been shown 
by RT-PCR and immunohistochemistry, to be greatest in vascular smooth muscle rather than in 
endothelium, although the relative contribution of receptors in each location in mediating the 
vasoactive effects of RLN is unknown (Conrad 2010).  It has also been shown from myographic 
studies of isolated vessels that removal of the endothelium obliterates the vascular response to RLN, 
suggesting that the endothelium is critical, either through the presence of the receptor or through 
post-receptor signalling pathways (Novak, Ramirez et al. 2002). 
 
 
Figure 1.9 Relaxin - RXFP1 axis 
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Schematic of RXFP1 showing multiple possible pathways activated after H2-relaxin binds to its G 
protein coupled receptor.  After binding to RXFP1 there is activation of adenylate cyclase, increasing 
cAMP and protein kinase A (PKA) with subsequent altered gene transcription or activation of PI3K 
with activation of endothelial nitric oxide synthase (eNOS) and ERK. Additionally RLN can bind 
directly to a glucocorticoid receptor (GR). Adapted from (Du, Bathgate et al. 2010). 
 
1.11 Relaxin and renal haemodynamics 
 
The haemodynamic changes modulated by RLN in the pregnant rodent include the following - in the 
systemic circulation:  cardiac output (CO),  systemic vascular resistance (SVR),  global 
arterial compliance, with maintenance of the mean arterial pressure (MAP) ; and in the renal 
circulation: renal vascular resistance (RVR),  RBF,  GFR,  myogenic reactivity of small 
renal arteries and vasoconstrictor response to angiotensin II.  Exogenous H2-RLN treatment in 
male and non-pregnant female rats recapitulated the haemodynamic profile associated with 
pregnancy (Danielson and Conrad 2003; Danielson, Welford et al. 2006).  Fig 1.10 summarises the 
experiments contributing to these conclusions.  Systemic infusion of recombinant H2-RLN elicited a 
rapid increase in renal plasma flow, measured by para-aminohippurate, in healthy male and female 
human volunteers (Smith, Danielson et al. 2006).  Additionally, a study in patients with mild 
scleroderma showed that long-term administration of RLN (for 6 months) resulted in a 15-20% 
increase in predicted creatinine clearance (Seibold, Korn et al. 2000).  Finally, data from clinical 
studies in acute (Teerlink, Cotter et al. 2013) and chronic (Dschietzig, Teichman et al. 2009) heart 
failure showed that RLN treatment increased creatinine clearance and reduced serum creatinine, 
respectively. Importantly, in both preclinical and human studies augmentation of renal blood flow 
(RBF) by RLN was not accompanied by a significant reduction in systemic arterial blood pressure 




Figure 1.10 Summary of in vivo experiments using exogenous RLN 
Summary of in vivo experiments using exogenous relaxin in short term (hours) and long term (days) 
and its effects on cardiac output (CO), systemic vascular resistance (SVR), global arterial 
compliance, mean arterial pressure (MAP), renal vascular resistance (RVR), renal blood flow (RBF), 
glomerular filtration rate (GFR), myogenic reactivity of small renal arteries and vasoconstrictor 
response to angiotensin II.  Adapted from (Conrad 2010). 
 
1.12 Proposed mechanisms for the haemodynamic role of relaxin 
 
The molecular mechanisms that underpin the haemodynamic effects of RLN have not been fully 
defined.  The duration of hormone exposure seems to be paramount, and both rapid and sustained 
vasodilatory responses to RLN have been shown (Fisher, MacLean et al. 2002; Jeyabalan, Novak et 
al. 2003; McGuane, Debrah et al. 2011). Mechanistic studies using specific inhibitor compounds 
suggest that RLN induces its sustained vasoactive effects indirectly through the endothelin type-B 
(ETB) receptor and NO signalling pathway.  Administration of a NO synthase (NOS) inhibitor or 
ETB antagonist inhibited the RLN mediated decrease in renal vascular resistance, with an associated 
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reduction in glomerular filtration rate (GFR) and RBF (Danielson, Sherwood et al. 1999).  
Furthermore, the inhibition of myogenic reactivity seen in renal arteries isolated from rats 
chronically treated with RLN was restored to control levels after treatment with a NOS inhibitor, 
ETB antagonist or removal of the endothelium (Novak, Ramirez et al. 2002).  No evidence was found 
for RLN causing a direct increase in expression of ETB.   Further studies have suggested that 
sustained vasodilatory responses to relaxin are likely to be mediated by up-regulation of arterial 
gelatinases matrix metalloproteinase-2 (MMP2, MMP9), whereby gelatinase  activity leads to 
processing of big ET to form ET 1-32 which subsequently activates the endothelial ETB/NO 
vasodilatory pathway (Jeyabalan, Novak et al. 2003; Jeyabalan, Novak et al. 2007).  Elegant studies 
performed by Jayabalan et al, using inhibitors to MMP2 and 9 in vivo and using isolated vessels from 
RLN treated rats, showed obliteration of the normal vasodilatory and myogenic response to RLN.   
Recent evidence has also suggested that angiogenic growth factors (e.g. VEGF) may also play a role 
(McGuane, Danielson et al. 2011). Fig 1.11 highlights the proposed sustained RLN vasodilation 
pathway.  
 
Further research is emerging that the effects of chronic administration of RLN (days to weeks) may 
also be exerted through collagen breakdown and increase in passive compliance of the vasculature.  
RLN is known to increase vascular collagen degradation through activation of MMPs and down-
regulation of expression of tissue inhibitors of metalloproteinases (TIMPs).  Administration of 
exogenous RLN to mice reduced the ratio of collagen to total protein in small renal arteries (Debrah, 
Debrah et al. 2011).   
 
Very rapid vasodilatory responses to RLN (within minutes) have also been observed in isolated 
gluteal and subcutaneous human arteries and small rodent renal arteries.  In culture, human 
endothelial cells briefly treated with RLN demonstrated G-protein coupling to PI3 kinase, 
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phosphorylation of Akt and endothelial NOS activation (Gαi/o-PI3K-AKT-eNOS mechanism) 
(Fisher, MacLean et al. 2002; McGuane, Debrah et al. 2011). The pathophysiological importance of 
RLN and RXFP1 signalling pathways in the kidney are completely unknown in the context of 
cirrhosis and AKI/HRS.    
 
 
Figure 1.11 Proposed mechanism for relaxin's sustained vasodilatory 
effects 
Schematic of the proposed mechanism of RLN’s haemodynamic effects.  RLN upregulates vascular  
Matrix metalloproteinase: MMP9 (hours) and MMP2 (days), which cleave Big Endothelin (ET) to 
ET1-32 which bind to the Endothelial ETB receptor which activates eNOS, with subsequent release of 
NO to the smooth muscle relaxing vascular tone.  Inhibition at any of these stages reduces/abrogates 






1.13 Rationale for the use of relaxin in cirrhosis and HRS 
 
RLN has been shown to have promising anti-fibrotic effects in rodent models of cirrhosis (Williams, 
Benyon et al. 2001) as well as with fibrosis in the lung (Huang, Gai et al. 2011), heart (Samuel 2005) 
and kidney (Chow, Kocan et al. 2014) .  However, the haemodynamic (particularly renal) effects of 
RLN in cirrhosis have not been fully explored.   
 
As discussed previously, central to HRS pathogenesis is profound renal vasoconstriction (Epstein, 
Berk et al. 1970).  The fact that RLN has been shown to increase RBF and GFR in vivo, to reduce 
myogenic reactivity in isolated vessels in vitro, and to preferentially dilate pre-constricted vessels (so 
called ‘anti-vasoconstrictor’ effect) makes it a potentially useful therapeutic agent in HRS (Debrah, 
Conrad et al. 2005; Teichman, Unemori et al. 2009).  Furthermore, RXFP1 has been shown to be 
expressed in the renal circulation, with rapid vasodilatory effects seen in isolated arteries suggesting 
that a targeted effect on the renal circulation is possible (Fisher, MacLean et al. 2002; McGuane, 
Debrah et al. 2011).  This contrasts with current therapy for HRS which works indirectly through 
splanchnic vasoconstriction.  Furthermore RLN has been shown to have anti-inflammatory effects 
suggesting that it may also have therapeutic benefit via other relevant mechanisms in the 
development of renal dysfunction in cirrhosis (Dschietzig, Brecht et al. 2012).  Finally, in both pre-
clinical studies and human trials with RLN, no significant drop in systemic blood pressure was 
observed, which is critical for the translation of RLN as a therapy in the cirrhosis/HRS population 









Relaxin can modulate renal haemodynamic responses in experimental cirrhosis and be used to 
increase renal blood flow and improve renal function in HRS.  
 
1.15 Aims and Objectives  
 
The overall aim of this thesis is to answer the central research question ‘Can the peptide hormone 
RLN, by virtue of its vasoactive effects, ameliorate renal vasoconstriction and improve renal 
function in the context of HRS?’ 
 
I will address this aim through achieving the following objectives: 
 
 Establishing and characterising robust and reproducible models of cirrhosis with portal 
hypertension, renal vasoconstriction and renal dysfunction in rats 
 Defining the renal haemodynamic effects of RLN in these models 
 Evaluating non-invasive measures of RBF in these models  
 Determining the expression profile of RXFP1 in the liver, kidney and vascular tissue in rats 
with cirrhosis and renal dysfunction 
 Investigating the downstream signalling pathways activated by RLN in the renal vasculature 
in experimental models of cirrhosis and renal dysfunction  
 Elucidating the pathogenic mechanisms that underpin renal dysfunction in experimental 















Male Sprague-Dawley rats were used for all the experiments presented in this thesis and were 
purchased by the University of Edinburgh and bred under specific pathogen free conditions.  All 
procedures involving animals were conducted with approval from the University of Edinburgh 
Animal Welfare and Ethical Review Body and UK Home Office and in accordance with the Use of 
Animals in Scientific Procedures Act 1986.  
 
2.2 Human tissue 
 
Human tissue was used in accordance with the Human Tissue (Scotland) Act 2006.  Non lesional 
human kidney from nephrectomies was acquired through the Scottish Academic Health Sciences 
Collaboration (SAHSC) Annotated Human BioResource, ethical research committee reference 
10/S1402/33.   
 
2.3 Relaxin (Serelaxin) 
 
The investigational product serelaxin has been manufactured using both recombinant and synthetic 
processes and is identical in structure to the naturally occurring H2-RLN.  Serelaxin was kindly 
provided by Dennis Stewart of Corthera, Inc. (a Novartis company). 
 
2.4 Experimental design 
 
All in vivo experiments were designed and implemented according to the NC3R ARRIVE guidelines.  
A sample size of ≥5 rats per group was determined prospectively using the statistical power analysis 
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tool G*Power Version 3.1.2 (Faul, Erdfelder et al. 2007) to perform a power calculation given 
α=0.05, power (1-β)=0.9, effect size (d)=2.64 based on preliminary experiments.  Cage mates were 
randomized to treatment (serelaxin) and vehicle groups. Clinically relevant hemodynamic endpoints 
(portal pressure, RBF, GFR) were analyzed by reference standard invasive methods, in addition to 
non-invasive measures. All surviving rats at the designated endpoints were included in the data 
analyses. No animals or potential outliers were excluded from the data sets presented. All 
biochemical and histological assessments were performed in a blinded manner.  
 
2.5 Rat carbon tetrachloride (CCl4) model  
 
Cirrhosis and portal hypertension was induced in 6-8 week old Sprague-Dawley rats by up to 16 
weeks administration of CCl4 through twice-weekly intraperitoneal (i.p.) injection (Sigma-Aldrich, 
UK).   A dose of 0.1mL/100g for the first 2 weeks and then 0.05mL/100g, thereafter, diluted 1:1 in 
olive oil (Sigma-Aldrich, UK) making a total of volume of 0.2mL/100g for the first 2 weeks and 
thereafter 0.1mL/100g.  A subset of rats was given twice-weekly i.p. injections of olive oil vehicle 
for 16 weeks to serve as a control group.  To characterize this model after 8, 12 and 16 weeks of 
CCl4 or olive oil (24 hrs following the final injection) subgroups of anesthetized rats (n=6-8) 
underwent hemodynamic monitoring without recovery.  
 
2.6 Rat bile duct ligation (BDL) model 
 
Biliary cirrhosis and portal hypertension was induced in 6-8 week Sprague-Dawley rats by BDL 
under isoflurane anaesthesia.  A 1cm upper midline incision was made, the common bile duct was 
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exposed and tied three times with 7-0 silk then ligated, leaving two proximal sutures to the ligation 
and one distal suture. The abdominal muscle was closed with 5-0 silk and the skin was closed using 
subcuticular 3-0 silk sutures. Rats were given 0.01mL/100g of Buprenorphine analgesia intra-
operatively along with 5mL of subcutaneous (s.c.) 0.9% normal saline (NaCl), both of which were 
repeated at 12 hr intervals for the first 2 days of the post-operative period if needed based on pain 
and dehydration scoring systems. Cage mates were randomly allocated to either BDL or sham 
procedure (controls), where the common bile duct was exposed but not ligated. To characterize this 
model subgroups of rats underwent haemodynamic monitoring at 14, 21 and 28 days post BDL and 
28 days post sham procedure.   
 
2.7 Haemodynamic measurements  
 
Haemodynamic monitoring was performed using aseptic technique in rats anesthetized with Inactin 
(Sigma-Aldrich) 0.1mL/100g (125mg/mL) unless specified.  A tracheostomy was performed to allow 
secretions to be aspirated and a right internal jugular vein was cannulated with PE50 tubing (Smiths 
Medical, UK). 0.9% NaCl, pre-warmed to 37
o 
C was instilled at a rate of 0.05mL/100g/mins 
throughout surgery and then 0.03mL/100g/mins during stabilization and monitoring (Menzies, 
Unwin et al. 2013).  To determine the GFR rats received 5% inulin-FITC (Sigma-Aldrich) instead of 
0.9% NaCl at the same rate as above.  Core body temperature was measured by rectal probe and 
maintained at 37
o
C using a heat mat. Mean arterial pressure (MAP) and heart rate (HR) were 
measured via a pre-heparinized (heparin 100U/mL in 0.9% NaCl) right femoral artery PE50 catheter 
(Smiths Medical). Portal pressure was measured using a 24G cannula inserted into the portal vein, 
and RBF was measured using a perivascular flow probe (MA2PSB, Transonic systems, 
ADInstruments, UK) sited around the left renal artery proximal to the bifurcation, all connected to a 
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Powerlab 4/35 system and analyzed using LabChart 7 Pro software (ADInstruments).  The urinary 
bladder was catheterized with PE90 tubing (Smiths Medical) and secured with a purse-string suture.  
All rats were stabilized for 20 mins prior to starting data recording, based on observations of 
fluctuations in haemodynamic parameters immediately following surgery. Urine and blood 
collections were performed for calculation of GFR as described in section 2.25. At the end of the 
experiment blood was collected, tissues were weighed and then either fixed in 10% buffered 
formalin or methyl Carnoy’s solution or snap frozen. 
 
2.8 Acute serelaxin in vivo hemodynamic study 
 
Groups of control rats (n=10) or 16 week CCl4 rats (n=14) were randomly allocated to treatment with 
serelaxin (4µg in 200µL i.v.) or equivalent volume of vehicle (24 hrs following the final injection of 
CCl4 or vehicle), then anesthetized for continuous hemodynamic monitoring over 60 mins, as 
described above.  
 
2.9 Acute serelaxin in vivo ultrasound study 
 
After determining the feasibility of this non-invasive imaging modality in a small pilot study in 
normal rats with regards to signal obtained and optimal monitoring conditions, groups of 16 week 
CCl4 rats (n=16) were randomized to treatment with serelaxin (4µg in 1.5mL i.v.) or equivalent 
volume of vehicle (24 hrs following the final injection of CCl4) prior to ultrasound assessment. A 
group of olive oil control rats (n=6) were scanned first to acquire baseline non-cirrhotic data. All rats 
were anaesthetized using 1.5-2% isoflurane in oxygen-enriched air (0.5L/mins air and 0.5L/mins 
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oxygen) for ultrasound assessment (Vevo 770, Visualsonics). Animals were placed in a supine 
position on a heated table (Visualsonics, Fujifilm), then cannulated via tail vein using a 24G cannula 
attached to pre-heparinized catheter tubing (Vygon, UK). Heart rate was monitored continuously 
using an electrocardiogram (ECG), core body temperature maintained at 37
o
C using a heated table 
and a heat lamp as required. The chest and abdominal regions were shaved and remaining hair 
removed with depilatory cream. Parasternal, long-axis B-mode and M-mode images were taken of 
the heart at the level of the papillary muscle for quantitative assessment of cardiac function at 
baseline and at 60 mins post injection of serelaxin or vehicle.  Parameters calculated included stroke 
volume (SV), cardiac output (CO) and ejection fraction (EF).  A short-axis image of the right kidney 
was then obtained and, using pulse-wave Doppler, measurements of RBF were taken from the 
superior branch of the renal artery distal to the point of renal artery bifurcation at the hilum.  
Measurement of Doppler blood flow was taken at baseline and every 10 mins for 60 mins after 
serelaxin or vehicle injection. The renal parameters calculated from the Doppler trace included 




Figure 2. 1 Velocity Time Integral Measurement 
The area under the curve/Doppler wave form is the velocity time integral (VTI) and represents, in 
our models, the amount of blood passing through the superior branch of the renal artery distal to the 






Figure 2. 2 Peak Pourcelot Resistance Index Measurement 
Schematic of how the Peak Pourcelot Resistance Index is calculated. The RI is calculated as shown 
in the equation above. 3 measurements were taken at each time point and averaged. 
 
 
2.10 Acute serelaxin BOLD MRI study 
 
Measurements were performed using a 7 Tesla preclinical MRI scanner (Agilent Technologies). 
Control (n=10), 8 week CCl4  (n=16) and 16 week CCl4 rats (n=12) were randomized to treatment 
with serelaxin (4µg in 1.5mL i.v.) or equivalent volume of vehicle (24 hrs after the final injection of 
CCl4) then anesthetized with 1.5-2% isoflurane in oxygen-enriched air (0.5L/mins air and 0.5L/mins 
oxygen). The tail vein was cannulated using a 24G cannula attached to pre-heparinized catheter 
(Vygon, UK). Rectal temperature was maintained at 37°C, and respiration rate was monitored 
throughout the scanning protocol.  A birdcage volume coil (72-mm diameter) and a 4-channel phased 
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array surface coil (Rapid Biomedical) were used for radio frequency transmission and signal 
reception, respectively. BOLD image acquisition used a multiple echo gradient-recalled MRI pulse 
sequence of ten images weighted in T2*; TE = 4, 8, 12, 16, 20, 24, 28, 32, 36, and 40 ms; TR = 100 
ms and flip angle of 30°. An axial slice through the center of the right kidney was selected with 
50×40 mm field of view containing a 192×128 acquisition matrix (in-plane resolution = 0.26×0.31 
mm). A single axial slice, aligned parallel with the renal artery identified by rapid scout scanning 
(fast gradient echo, 3 slices in coronal orientation), ensured slice position encompassed the most 
representative section of the kidney regions.  Slice thickness was 2 mm with 14 signal averages. The 
scan time was 3 mins for each BOLD scan. Three baseline scan were performed and then scans were 
performed every 3 mins for 60 mins after serelaxin or vehicle injection, with 30 and 60 mins being 
chosen as analysis points. T2* maps were generated using the scanner software.   
Regions of interest (ROI) (Fig 2.3) were selected on the T2* maps using ImageJ (NIH, USA) in the 
kidney cortex and medulla, avoiding regions containing large vessels. The same regions were 
selected in all animals and all conditions.  ROIs were drawn on baseline and subsequent images 
acquired after treatment to determine the signal intensity of each ROI.  T2* values were converted to 





Figure 2.3 BOLD image of kidney 
Example of images obtained through kidney with regions of interest (ROI) shown (cortex, outer and 
inner medulla). 
 
2.11 Acute nitrovasodilator in vivo hemodynamic study 
 
To establish the effect of a non-selective vasodilator on MAP and RBF in cirrhosis I chose to use 
sodium nitroprusside (SNP).  SNP is an endothelium independent vasodilator and works through 
release of NO and has been shown when instilled directly into the hind limb to increase hind limb 
blood flow at 0.09 and 0.9µg doses (Robertson, Gray et al. 2012).  To establish the effect of this drug 
systemically a groups of 16 week CCl4 rats (n=6), 24hrs following the final injection of CCl4 were 
anesthetized and treated with a range of doses of sodium nitroprusside (SNP; 0.09, 0.9 and 9µg in 
200µL i.v.; Sigma Aldrich) or an equivalent volume of vehicle.  Between each dose MAP and RBF 
was allowed to return to baseline.  Continuous hemodynamic monitoring was undertaken for 10 mins 
after each dose, as described above.  
 
2.12 Sustained (72hr) serelaxin in vivo hemodynamic study 
 
Both 16 week CCl4 (n=16) and 21 day post BDL (n=14) rats were randomized to receive continuous 
treatment for 72 hrs with either serelaxin (4µg/hr) or vehicle via s.c. osmotic minipumps (2ML1 
Alzet; Durect, USA). I chose 72 hrs as this is around the time-point in humans when response to 
current pharmacological therapy is assessed making it a suitable time-point to assess response to 
RLN (Salerno, Gerbes et al. 2007).  Secondly I wanted a time-point that allowed the rats time to 
recover from insertion of the minipump.  Finally, in non-cirrhotic rats sustained infusion of RLN for 
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24 hours to as long as 5 days have  been shown to have effects on RBF and GFR so I chose a mid-
point (Danielson and Conrad 2003) .  
 
Groups of CCl4 rats (n=12) were also randomly allocated to treatment with serelaxin or vehicle plus 
co-administration of  L-NAME (Sigma-Aldrich) 250 mg/mL in drinking water, starting 24 hrs before 
osmotic minipump insertion and continuing for the 72 hrs study period.  After 72 hrs rats had 
hemodynamic and renal functional measurements performed under terminal anesthesia using 
isoflurane anaesthetic and monitored as described above. 
 
2.13 Wire myography studies 
 
Wire myography was performed on isolated blood vessels.  Groups of rats (normal uninjured n= 6, 
Sham BDL n=8 , 28 day BDL n=8, 16 weeks n=12,  olive oil n=8 and 16 weeks CCl4 + 72 h 
serelaxin or vehicle n=14) were killed by cervical dislocation and vessels (mesenteric, extra-renal 
and intra-renal renal arteries-segmental, interlobar and arcuate) were harvested and placed in 4
o
C 
physiological salt solution (PSS) freshly prepared as follows: NaCl 119mM, KCl 4.7mM, CaCl2 
2.5mM, MgSO4 1.17mM,NaHCO3 25mM, KH2PO4 1.18mM, ethylenediaminetetra-acetic acid di-
potassium salt (K2EDTA) 0.026mM and D-glucose 5.5mM and used the same day.  Second order 
mesenteric arteries and the extra-renal, segmental and inter-lobar and arcuate renal arteries were 
dissected and cleaned of connective tissue. 2mm rings were mounted from each vessel segment onto 
40 µm stainless steel wires, one end of which was attached to a force transducer and the other to a 
micrometer (Fig 2.4A-B). The vessel ring was bathed in PSS at 37
o
C, bubbled with 95% O2 and 5% 
CO2 and stepwise radial stretching was performed to determine the lumen diameter necessary for 
optimal force generation.  Vessel rings were then stretched to achieve 90% of the diameter expected 
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if it had been fully relaxed and exposed to a transmural pressure of 13.3 kPa (100 mmHg).  The 
vessel ring was allowed to equilibrate for 30 mins before viability was assessed using three 
stimulations with a high potassium physiological salt solution( KPSS, 125 mM, made by equimolar 
substitution of KCl for NaCl in PSS), activated for 2 mins with each solution followed by a 5 mins 
washout period in PSS to allow full relaxation. Measurement of viability was performed in these 
vessels to confirm that isolation and mounting of the vessel did not damage the arterial wall. Isolated 
rings had their endothelium denuded by insertion of a wire into the lumen and the endothelium 
rubbed circumferentially.  The ability of the vessel to respond to contractile and relaxant agents was 





 M, Sigma-Aldrich), and a concentration that produced 70-80% 
maximum contraction (EC80) was chosen for each individual rat vessel ring.  Following contraction, 










Aldrich).  To establish the endothelial mechanisms responsible for vasodilation in the renal 
circulation a group of normal and CCl4  (n=6/group) vessel rings were co-treated for 45 mins with 
the NOS inhibitor L-NAME (1x10
-4
 M), cyclo-oxygenase inhibitor indomethacin (1x10
-5
M) or the 
endothelium derived hyperpolarising factor (EDHF) inhibitors apamin (1x10
-4
 M) and charybdotoxin 
(1x10
-5










Figure 2.4 Wire Myography 
Photograph of wire myography. (A) showing the water baths and connections, (B) the individual 




Following harvest, liver tissue was fixed overnight in 10% neutral buffered formalin (Sigma) or 
methyl Carnoy’s (60% Methanol: 30% Chloroform: 10% Glacial Acetic acid) solution, followed by 
paraffin embedding.  Detection of selected proteins was undertaken in 3µm formalin fixed tissue 
sections, unless otherwise stated, using either standard avidin-biotin staining or single and dual 
immunofluorescence staining methods. Sections were dewaxed and rehydrated in decreasing 
concentrations of ethanol (100%, 75%,  65%) .  Unless stated, antigen retrieval was performed by 
boiling for 15 mins in 10mM Sodium Citrate buffer, pH6. 
 
Following the above, endogenous peroxidise activity was inhibited with 3% hydrogen peroxide 
followed by avidin/biotin block (Vector Labs) and then non-specific binding minimised using 
appropriate serum block. All primary antibodies were incubated overnight at 4
o
C in species 
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appropriate serum.  For control sections no primary antibody was added.  Species appropriate anti-
IgG biotinylated secondary antibodies (Vector) were used at 1/400 dilution, at room temperature for 
1 hr.  Immunostaining was developed using 3,3’-diaminobenzidine (DAB; Dako, UK).  Picrosirius 
red and haematoxylin and eosin staining were performed according to standard performed by the 
histology department staff. Antibodies used in immunohistochemistry are shown in Table 2.1. 
 
Antibody Dilution Antigen retrieval 
Arginase II H64 (Santa 
Cruz, USA, 20151) 
1:200 15 mins 
Relaxin receptor 1 H160 
(Santa Cruz, USA, 50328) 
1:50 20 mins 
LGR7 (735-757) (Human) 
Antibody Phoenix 
Pharmaceuticals 
1:200 15 mins 
 
 
Table 2.1 Antibiotics used in Immunohistochemistry 
Antibodies with their dilution and necessary antigen retrieval condition used in 
immunohistochemistry. 
 
2.15 Single Immunofluorescence 
 
For single immunofluorescence initial preparation of sections was as above including blocking 
endogenous hydrogen peroxide however non-specific binding was minimised using protein block 
(DAKO) and the primary antibody was incubated overnight at 4
o
C in antibody diluent (DAKO).  
Control sections had no primary antibody added. Goat anti-rabbit HRP (Vector, 1:500) was then 
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added to sections for 30 mins at room temperature and TSAT Plus Cyanine 3 System (PerkinElmer 
NEL744B001KT) applied to amplify the signal for 10 mins at room temperature.  All sections were 
then blocked with 0.1% Sudan Black B (Sigma) and mounted with Dapi (4’, 6’-diamidino-2-
phenylindole) hard set mounting medium (Vector Labs H1500). All antibodies used in 






















Antibody Dilution Antigen retrieval 
Arginase II H64 (Santa 
Cruz, USA, 20151) 
1:200 15 mins 
PDGFβ (Abcam; ab32570) 
 
1:100 15 mins 
Caveolin I (Cell Signaling, 
#3238) 
1:125 10 mins 
 anti-endothelial cell 
(RECA-1) (Abcam, UK; 
ab9774) 
1:25 10 mins 
 anti-CD31 (Abcam; 
ab28364) 
1:100 10 mins 
Relaxin receptor 1 H160 
(Santa Cruz, USA; 50328) 





12µg/mL 10 mins 
Anti-Actin, alpha smooth 
muscle (Sigma-Aldrich) 
1:500 5 mins 
Wilms Tumor 1 antibody 
(GTX15249, GeneTex, 
USA) 
1:100 15 mins (TRIS EDTA) 
 
Table 2.2 Antibodies used in Immunofluorescence 




2.16 Dual Immunofluorescence 
 
To co-localise the cellular origin of the RXFP1 receptor dual immunofluorescence was undertaken. 
Sections were dewaxed and rehydrated with decreasing concentrations of ethanol. Antigen retrieval 
was undertaken as stated above, endogenous peroxidise activity was inhibited with 3% hydrogen 
peroxide peroxidase and primary antibodies PDGFβ or RECA or CD31 (rat or human sections, 
respectively) or WT1 applied to formalin fixed sections at concentrations shown above, overnight at 
4
o
C.  Goat and rabbit HRP (Vector, 1:500) was added to sections and TSAT Plus Cyanine 3 System 
(PerkinElmer NEL744B001KT) applied for 10 mins to amplify the signal.  After washing, further 
antigen retrieval was undertaken for 5 mins and protein block applied followed by incubation with 
either relaxin receptor 1 in rat or Anti-GPCR LGR7 antibody - C-terminal in human sections at 4
o
C 
overnight.  Goat anti rabbit HRP was added followed by TSAT Plus Cyanine 3 System (PerkinElmer 
NEL744B001KT).  All sections were then blocked with 0.1% Sudan Black B (Sigma) and mounted 
with DAPI hard set mounting medium (Vector Labs H1500).  For dual immunostaining with the 
Anti-Actin, alpha smooth muscle antibody, this was applied for 1 hr at room temperature and 
secondary donkey anti mouse Alexa 555 (Invitrogen A31570), followed by protein block, 
appropriate RXFP1 antibody overnight at 4
o
C, followed by the Goat anti rabbit HRP and TSAT Plus 
Cyanine 3 System. Relevant controls were undertaken with either no first primary, no second 
primary or without both. For all, sections were then blocked with 0.1% Sudan Black B (Sigma) and 
mounted with Dapi hard set mounting medium (Vector Labs H1500).  All photographs were taken 
using a Nikon Eclipse e600 microscope and camera (DXM1200F) and acquired using NIS–Elements 
D software (Nikon). 
 




For each animal, liver tissue was harvested from 4 separate lobes, sections cut at 3 µm and stained 
with picrosirius red.  Thirty non overlapping brightfield RGB digital images were captured per liver 
at a single magnification (x50) using a Zeiss Axiovert 200 microscope and AxioCam MRc camera 
by a blinded observer. Morphometric pixel analysis was undertaken using Adobe Photoshop CS2. 
Pixel counts of positive staining were shown as a percentage of total pixel count and hence % area.  
For picrosirius red staining, this was referred to as collagen proportionate area (CPA). Where stated 
‘relative % area’ was calculated by normalising to the mean % area of one group (Control) which 
was assigned a value of 1. 
 
2.18 Quantification of renal acute tubular necrosis (ATN) 
 
Renal ATN was measured on H&E stained kidney sections by a blinded pathologist as previously 
described (Melnikov, Faubel et al. 2002). Histological changes of ATN were evaluated by 
calculation of the percentage of tubules that displayed cell necrosis, loss of brush border, cast 
formation, and tubule dilatation as follows: 0, none; 1, ≤10%; 2,11–25%; 3, 26–45%; 4, 46–75%; 
and 5, >76%. At least ten fields (×40 magnification) were assessed. 
 
2.19 RNA extraction and quantitative RT-PCR 
 
RNA was extracted from rat kidneys, liver, heart, mesentery and renal artery, snap frozen and stored 
at -80
o
C, using Trizol reagent (Invitrogen) and RNeasy mini columns (Qiagen) according to the 
manufacturer’s protocol, followed by quantification using Nanodrop Spectrophotometer (Thermo 
Scientific). 2μg of RNA was reversed transcribed using Superscript III (Invitrogen) according to the 
manufacturer’s protocol.  Validated primer/probe sets for rat RXFP1 (Rn01495351_m1) and 
eukaryotic 18S were purchased from Applied Biosystems (UK).  qPCR was performed using an ABI 
61 
 
7500 Fast Realtime system with TaqMan Express qPCR master mix (Applied Biosystems, UK). 
Gene expression was calculated by 2
-ΔΔ
Ct method relative to the housekeeping gene 18S.  Where 
stated ‘relative gene expression’ was calculated by normalizing to the mean expression of one group 
which was assigned a value of 1. 
 
RT2 Profiler Rat Hypertension PCR array (SA Biosciences, Qiagen; PARN-037Z) was performed 
using RT2 First Strand Kit and RT2 SYBR Green/ROX PCR Master Mix according to 
manufacturer’s instructions.  Relative gene expression was analyzed against a panel of 5 
housekeeping genes using the RT2 Profiler PCR Array data analysis tool. 
 
2.20 Nitric oxide synthase activity assay 
 
Whole kidney tissue was homogenized in phosphate buffered saline (pH 7.4), centrifuged at 10,000g 
for 10 mins and the supernatant collected.  Protein determination was performed using the Bradford 
assay and 150µg of protein was used to measure NOS activity using an EnzyChrom TM kit 
(Bioassay Systems, USA).   
 
2.21 Serum analysis 
 
At the time of harvest, whole blood was collected from the femoral artery allowed to clot and serum 
isolated by centrifugation at 8000g for 5 mins.  Serum samples were stored at -80
o
C and analysed for 
Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), 




2.22 Nitric oxide measurement 
 
Rat urine and serum were filtered using a 10,000Da molecular weight cut-off filter (Millipore, UK). 
As NO has a short half-life in vivo of a few second or less, the levels of its more stable metabolites 
nitrite (NO2) and nitrate (NO3) can be used as indirect measurements of NO. Determination of these 
was performed using a Total Nitric Oxide and Nitrate/Nitrate Assay parameter Kit (R&D Systems, 
UK). Serum samples required a 2 fold dilution.  This assay determined the total nitrite concentration 
by measuring endogenous nitrite using the modified Griess Reaction and then the concentration 
following enzymatic conversion of nitrate to nitrite by nitrate reductase followed by the modified 
Griess Reaction. Samples were assayed in duplicate. The reaction was follow by colorimetric 
detection (with the optical density measured at 540nm with wavelength correction at 690 nm) of 
nitrite as an azo dye product of the Griess Reaction. Nitrite positive standards were assayed 
alongside samples in duplicate and a concentration curve constructed of decreasing dilutions of 
nitrite to allow a standard curve of nitrite concentration versus optical density to be constructed.   
Sample nitrite concentrations were then interpolated from the curve 
 
2.23 Relaxin measurement 
 
Rat serum was prepared as described in 2.21 and diluted 4 fold and relaxin levels measured by 
Human Relaxin-2 Immunoassay kit (R&D Systems, UK). 
 
2.24 TNFα measurement 
 
Rat serum was prepared as described in 2.21 and diluted 3 fold and TNFα measured by Quantikine 
ELISA kit (R&D Systems, UK). 
63 
 
2.25 GFR measurement 
 
Two 20 minute urine samples with midpoint plasma collections were collected for each rat.  Samples 
were thawed overnight and spun down. Urine samples were diluted 1:100 in HEPES buffer (HEPES 
1.19g, 450 mL distilled water, pH to 7.4 with 5M NaOH and autoclaved).  A 9 point 2 fold dilution 
series was constructed starting with 1 mg/mL in HEPES buffer (20 µL in 980 µL buffer). All 
samples were further diluted 1:100 in HEPES buffer and were performed in duplicate. 190µL was 
loaded per well and fluorescence read at 485nm (excitation) and 538nm (emission). Concentrations 
of inulin were calculated from the standard curve.  The GFR was calculated as follows: [(urine inulin 
x urine volume/min)/plasma inulin].  
 
2.26 Western blotting 
 
Western blot was performed on whole kidney lysates prepared by homogenization in T-PER protein 
extraction reagent (Thermo Scientific, Hemel Hempstead, UK) containing Halt protease and 
phosphatase inhibitor cocktail (Thermo Scientific). Protein concentration in kidney homogenates was 
determined by Bradford Assay (Bio-Rad, UK). 30 µg of protein was loaded per well of pre-cast gels 
(Biorad, UK) and separated by electrophoresis initially at 60V, increased to 80V when the proteins 
were into the gel.  They were then transferred, using wet transfer, onto nitrocellulose membranes 
(Whatman, GE, USA) using 240mA for 90 mins in standard buffer with 10% methanol.  Successful 
transfer was assessed by immersing the membrane in 1:10 diluted Ponceau Red which allowed 
visualizing of proteins.  Membranes were then cut so multiple proteins could be assessed. The 
membranes were blocked in either 5% non-fat dry milk powder/ Tris buffered saline (TBS)-Tween20 
(non-phosphorylated proteins) or 5% Bovine Serum Albumin/TBS-Tween20 (phosphorylated 
proteins) for 1 hr at room temperature and then the primary antibodies were diluted in 5% non-fat 
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dry milk powder/ TBS-Tween20 (non-phosphorylated proteins) or 5% Bovine Serum Albumin/TBS-
Tween20 (phosphorylated proteins) and incubated over night at 4
o
C.  The membranes were washed 
x3 (15 mins) in TBS-T and the secondary antibody: Anti-rabbit IgG, HRP-linked Antibody (Cell 
Signaling, #7074) was added and incubated with the membrane for 1 h at room temperature.  After 
further washing x3, detection was performed using enhanced chemiluminescence (Millipore, 
Livingstone, UK) and bands were visualized by X-ray films (Fuji, Bedfordshire, UK).  Selected 
membranes were stripped using western blot stripping buffer (Thermo scientific, UK) to allow the 
membranes to be re-probed to allow assessment of relative expression of phosphorylated to non-
phosphorylated proteins.  GAPDH loading control blot was performed for all experiments to ensure 
even loading.  Densitometry analysis was performed using ImageJ (NIH, USA). See Table 2.3 for 














panAKT (#4685) Cell signalling 1:1000 
PhosphoAKT Thr308(#C31E5E) Cell 
signalling 
1:1000 
eNOS (9572) Cell signalling 1:1000 
Phospho-eNOS Ser117 (#9671) Cell 
signalling 
1:1000 
Relaxin receptor 1 H160(Santa Cruz, 
50328) 
1: 1000 
Arginase II H64 (Santa Cruz 20151)  1:200 
Caveolin I (#3238) Cell Signalling 1:1000 
 
Table 2.3 Antibodies used for Western Blot 
Table showing antibodies with their dilutions used for Western blot. 
 
2.27 Statistical analysis 
 
Primary data are expressed as mean ± standard error of the mean (SEM).  GraphPad Prism Version 
5.03 (GraphPad Software Inc., USA) was used to perform statistical calculations. Differences among 
multiple groups were assessed with one-way ANOVA, or repeated measures ANOVA with post-hoc 
Bonferroni test. Statistical evaluation of two groups was with unpaired two-tailed Student’s t-test.  
Concentration response curves (CRC) were constructed as a percentage (%) dilation relative to the 
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pre-constricted PE dilation. Comparison of both cirrhosis/treatment and concentration between 
groups was assessed using two-way ANOVA with post-hoc Bonferroni test.  Non-linear regression 
analysis was used to assess differences in sensitivity of vessels (IC50 or EC50) to vasodilators and 
























CHAPTER 3 – RESULTS -



























3.1 Overview of Chapter: 
 
To provide proof of concept of RLN’s effect in cirrhosis, I needed to define suitable robust models of 
cirrhosis with sinusoidal portal hypertension, renal vasoconstriction and renal dysfunction.  In this 
chapter I fully characterised two distinct rat models of cirrhosis in terms of histological, biochemical, 
systemic and renal haemodynamic parameters.  I used CCl4 and BDL models and monitored the rats 
using invasive monitoring at time points throughout their evolution, with suitable controls, focussing 
particularly on the effect on renal blood flow and renal function (GFR).  
 
3.2 Author contribution: 
 
I performed BDL and all the microsurgical invasive monitoring. Will Mungall did the twice weekly 
CCl4 injections and also latterly assisted with the BDL surgery. Picrosirius red (PSR), periodic acid-
Schiff (PAS) and haematoxylin and eosin (H+E) staining was undertaken by the histology 
department. Dr Tim Kendall (Consultant Histopathologist, University of Edinburgh) reported all the 





HRS in humans, as previously described in the Introduction, is diagnosed according to strict 
criteria, which have recently been updated (Angeli, Gines et al. 2015).  However, faithfully 
recapitulating these diagnostic criteria in preclinical models, as a platform for testing potential novel 
interventions, is a challenge.  The key features are ‘functional’ (and therefore potentially reversible) 
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AKI rather than structural kidney disease, and the absence of septic shock, hypovolaemia, or 
nephrotoxic drugs (Angeli, Gines et al. 2015).  Although bile duct ligation (BDL) (Pereira, dos 
Santos et al. 2008) or galactosamine (Anand, Harry et al. 2002) in rodents have been shown to 
induce renal failure without obvious intrinsic renal damage,  in the presence of cirrhosis and acute 
liver failure respectively, there are currently no well validated models of HRS.  This is largely due to 
the complexity of this condition, with activation of many signalling pathways meaning that a model 
of genetic manipulation is unlikely to be successful.  Furthermore as our current understanding of 
HRS pathogenesis is incomplete it is difficult to know how best to approach an animal model 
system. 
 
Functional renal arterial vasoconstriction is the central mechanism underlying HRS pathogenesis and 
therefore it is crucial for any model of HRS that this is a reproducible feature (Epstein, Berk et al. 
1970; Platt, Ellis et al. 1994; Dagher and Moore 2001). Historically, HRS in humans has been 
classified into Type 1 and Type 2.  Type 1 HRS is defined by doubling of the creatinine over 2 
weeks, often precipitated by an event such as sepsis/bleeding/untreated dehydration, whilst Type 2 
occurs in a more indolent way with a gradual increase in creatinine often seen in patients with 
refractory ascites (Arroyo, Guevara et al. 2002).  The recent change in definition of AKI has led to a 
change in the definition of HRS-AKI surpassing the above with the criteria needing to be fulfilled to 
allow diagnosis in humans shown in Introduction 1.6. (Angeli, Gines et al. 2015).  It has been shown 
that renal vasoconstriction worsens throughout advancing cirrhosis until it reaches a critical 
perfusion threshold and then AKI occurs and HRS, according to the above criteria, can be diagnosed 
(Ring-Larsen 1977).  I was keen to establish models that were representative of this progression, i.e. 




The first model I studied for haemodynamic characterisation was chronic carbon tetrachloride (CCl4) 
intoxication.  CCl4 is the most widely used hepatotoxin in experimental models of fibrogenesis and 
its resolution.  When administered in vivo it is metabolised by the Cyp2E1 enzyme system forming 
trichloromethyl peroxy free radicals which result in lipid peroxidation, subsequently affecting the 
integrity of the cell membrane and allowing activation of intracellular calcium-dependent proteases, 
ultimately resulting in hepatocyte death through both apoptosis and necrosis (Shi, Aisaki et al. 1998; 
Manibusan, Odin et al. 2007).  As Cyp2E1 is predominantly expressed in the centrilobular (Zone 3) 
hepatocytes, the majority of cell death occurs in these areas. This model shares a similar 
pathogenesis with human alcohol related liver damage and non-alcoholic steatohepatitis which also 
affect Cyp2E1, inducing lipid peroxidation causing Zone 3 liver damage (Lieber 2004).  Chronic 
iterative administration results in recurrent hepatic necrosis with wound healing and ultimately 
fibrosis and cirrhosis,  in many respects mimicking human disease in pathological evolution (Perez 
Tamayo 1983).  Through this pattern of progressive fibrosis, sinusoidal portal hypertension develops 
and as a result this model has been used to study potential therapies for this complication of cirrhosis 
(Abraldes, Rodriguez-Vilarrupla et al. 2007).   However, there has been very little published 
literature on the renal manifestations of CCl4 cirrhosis.  
 
The second model I characterised was the bile duct ligation (BDL) model of cirrhosis, which is 
induced by preventing bile outflow leading to progressive cholestasis, biliary inflammation and 
intense fibrosis.  This model has been suggested to have analogous features to human HRS.  BDL in 
rats has been shown to produce a rapid deterioration in renal function, within days (Rivera-Huizar, 
Rincon-Sanchez et al. 2006) with no signs of acute tubular damage.  Pereira et al (2008) showed 
progressive renal dysfunction over weeks, with rats developing renal impairment evidenced by 
reduced creatinine clearance and ascites by 4-6 weeks, with no signs on electron microscopy of 
tubular damage (Pereira, dos Santos et al. 2008).  However, unlike humans with HRS they witnessed 
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increasing urinary sodium excretion and the rats did not become oliguric.  Noticeably they did not 
look at changes to renal blood flow itself.  Other groups have observed renal dysfunction by 4 weeks 
after BDL and used lipopolysaccharide (LPS) as a ‘second hit’ (Harry, Anand et al. 1999; Shah, 
Dhar et al. 2012).  A possible criticism of this approach is that this second hit, although theoretically 
akin to a superadded infection in humans, renders the animals moribund and cardiovascularly 
unstable such that subsequent physiological observations are unpredictable and rather heterogeneous. 
In BDL and BDL-LPS rats with this more severe phenotype, histological changes are apparent in the 
tubules that indicate a degree of ATN (Shah, Dhar et al. 2012). However, this may not be a major 
concern given recent evidence from kidney biopsy series in ‘HRS’ patients which suggests that 
tubular damage may occur more frequently than previously thought (Trawale, Paradis et al. 2010; 
Fagundes, Pepin et al. 2012).  Taken together, there is considerable evidence to support BDL in rats 
as a suitable model in which to study HRS.   
 
I chose to use rats as my rodent species in both models for several reasons.  Firstly, our laboratory 
has extensive experience with CCl4 models of fibrosis in rats (Issa, Zhou et al. 2004).  Chronic 
dosing with CCl4 or BDL in outbred rats leads to a reproducible fibrotic lesion and the development 
of cirrhosis (Constandinou, Henderson et al. 2005) .  Secondly, rats are much more amenable to 
microsurgical procedures such as BDL and vascular cannulation, which is technically challenging in 








3.4 Aims of this Chapter:  
 
 To define the phenotype of CCl4 treated rats in terms of: 
 Liver fibrosis and liver function 
 Portal hypertension 
 Systemic and renal haemodynamics  
 Kidney function 
 Kidney histology 
 
 To define the phenotype of BDL treated  rats in terms of: 
 Liver fibrosis and liver function 
 Portal hypertension 
 Systemic and renal haemodynamics  
 Kidney function 




3.5 Chronic CCl4 intoxication generates hepatic necro-inflammation with progressive collagen 
deposition and synthetic dysfunction  
 
I wanted to determine the histological, biochemical and haemodynamic changes that occur in the 
CCl4 model of fibrosis in rats to enable me to choose appropriate time-points to investigate 
therapeutic modulation of renal vasoconstriction and renal function with RLN.  To do this, 6-8 week 
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male Sprague-Dawley (SD) rats had intraperitoneal (i.p.) injections of CCl4 or olive oil (vehicle 
controls) administered twice weekly for up to 16 weeks.  The rats underwent haemodynamic 
monitoring under terminal general anaesthetic after 8, 12 and 16 weeks of CCl4, 24 hrs following the 
final dose of CCl4 (n= 6-11/ time-point).  After haemodynamic monitoring, blood and tissues were 
harvested.  The results expressed below are from two separate CCl4 models run two weeks apart with 
3-4 rats analysed at each time-point to ensure reliability and robustness of findings. 
 
In figure 3.1A-C, liver tissue at each time-point was stained with haematoxylin and eosin (H+E) to 
visualise lobular architecture and picrosirius red (PSR) to visualise collagen deposition. Hepatic 
fibrosis was quantified by morphometric pixel analysis (n=5-8/time-point) and expressed as % of 
total pixels relative to controls, termed relative collagen proportionate area (relative CPA; %).  With 
chronic administration of CCl4 there was progressive hepatic necro-inflammation with loss of the 
normal lobular liver architecture (Fig 3.1A). There were no differences in fibrosis seen in either olive 
oil or normal controls. Hepatic fibrosis (CPA) increased progressively with duration of CCl4 
administration leading to cirrhosis (Fig 3.1B and C).  Biochemically, I measured serum alanine 
aminotransferase (ALT) levels, a marker of hepatic injury routinely used in clinical practice, and this 
was progressively elevated with increased duration of CCl4 (Fig 3.2A). I measured hepatic functional 
impairment using serum albumin, routinely used in clinical practice as a marker of hepatic synthetic 
function and this was significantly reduced after 16 weeks (Fig 3.2B) at a time when liver histology 









Figure 3.1 CCl4 Model of Cirrhosis 
CCl4 model of cirrhosis with representative liver sections stained with H+E (A), PSR (B). (A). 
hepatic necro-inflammatory changes (triangle) (B). PSR staining for total collagen (arrow). (C). 
Hepatic fibrosis was assessed by PSR staining and morphometric pixel analysis (Expressed relative 
to mean % area of  controls; n=4-8 per time point). Data expressed as mean±SEM and analysed by 







Figure 3.2 Serum Biochemistry changes in CCl4 model of cirrhosis 
(A). Serum Alanine Transaminase (ALT), a marker of hepatic injury, (B). Serum Albumin, a marker 
of hepatocyte synthetic function were measured in normal, olive oil and 8,12 and 16 week CCl4 rats. 
Data expressed as mean±SEM and analysed by one-way ANOVA with post hoc Bonferroni test. 






3.6 Chronic CCl4 treated rats do not develop ascites despite significant portal hypertension 
 
No CCl4 treated rats developed jaundice or detectable ascites. I measured portal pressure at each 
time-point, by cannulation of the hepatic portal vein, (Fig. 3.3) and this showed elevation at 8 weeks 
(12.8±0.9 mmHg, p<0.001), 12 weeks (12.64±0.9mmHg; p<0.001) and 16 weeks CCl4 (11.1±0.7 
mmHg, p<0.05) compared to normal (7.4±0.4mmHg) and olive oil control rats (7.4±0.7 mmHg).  
 
 
Figure 3.3 Portal Pressure changes in CCl4 Cirrhosis 
Portal pressure, measured by cannulation of the portal vein.  Data expressed as mean±SEM and 






3.7 Chronic CCl4 treated rats exhibit renal vasoconstriction and renal dysfunction with no 
reduction in mean arterial pressure 
 
RBF was measured invasively using a perivascular flow probe attached around the left renal artery 
immediately proximal to the bifurcation.  After 16 weeks of CCl4, RBF (Fig.3.4A) was markedly 
reduced (2.4±0.2 mL/min) compared to normal (6.5±0.5 mL/min; p<0.05), olive oil (7.3±1.0 
mL/min; p<0.01) and 8 week CCl4 treated rats (6.3±0.9 mL/min; p<0.01). This was accompanied by 
a substantial decline in GFR, measured by inulin clearance, (Fig. 3.4B) after 16 weeks CCl4 (0.8±0.2 
mL/min, p<0.01) compared to olive oil controls (2.4±0.4 mL/min). To establish whether this 
reduction in RBF and GFR was secondary to a reduction in systemic blood pressure, MAP was 







Figure 3.4 Renal Blood Flow, Glomerular Filtration Rate and Mean 
Arterial Pressure Changes in the CCl4 Model of Cirrhosis 
(A). RBF, measured by a flow probe. (B). GFR, measured by inulin clearance. (C). MAP, measured 
by a femoral line were measured in normal, olive oil, 8,12 and 16 week CCl4 rats. Data expressed as 
mean±SEM and analysed by one-way ANOVA with post hoc Bonferroni test. *p<0.05 **p<0.01 
***p<0.001. 
  
3.8 Chronic CCl4 intoxication does not induce histological changes in the kidneys 
 
Despite renal functional impairment, kidney tissues from 16 week CCl4 treated rats stained with H+E 
and reviewed by a pathologist blinded to the slides, showed no structural damage compared with 
olive oil controls, and in particular no evidence of acute tubular necrosis (ATN).  Fig 3.5 shows 








Figure 3.5 CCl4 Kidney Histology 
Representative images of olive oil (A) and 16 week CCl4 (B) kidneys sections. Original 
magnification x20.  Arrow-Glomerulus, triangle-tubular cells. 
 
3.9 Bile duct ligated rats exhibit rapidly progressive biliary fibrosis and development of 
decompensated cirrhosis 
 
I went on to determine whether I could model HRS using BDL injury. To do this I performed 
surgical ligation of the common bile duct under general anaesthetic in 6-8 week old S-D rats and 
subsequently performed haemodynamic monitoring under terminal general anaesthesia with tissue, 
urine and serum collection every 7 days until 28 days to evaluate changes in these parameters.  As a 
control group I performed a ‘sham’ operation, exposing the common bile duct but not ligating it and 
then monitored the rats until 28 days when I undertook identical assessment as for the BDL animals. 
The sham procedure controls for the potential confounding effects of surgery and anaesthesia in the 
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BDL model. The results below are pooled from 3 separate cohorts of BDL treated rats that I 
generated over time, to ensure that the findings were reproducible (n=5-6/ time-point).  
 
Following BDL, rats were jaundiced after 14 days and all had ascites by 28 days. From 14 days post 
BDL, liver tissue stained with H+E showed florid inflammation (Fig 3.6A) and staining with PSR 
showed progressive deposition of collagen with  loss of normal lobular liver architecture (cirrhosis) 
(Fig. 3.6B, C).  Serum alkaline phosphatase (ALP, a marker of biliary obstruction) rapidly increased 
after BDL (Fig 3.7A; p<0.05).  Serum albumin was reduced at 28 days after BDL compared with 





Figure 3.6 BDL Model of Biliary Cirrhosis 
BDL Model of Cirrhosis with representative liver sections stained with H+E (A), PSR (B) in sham, 
14, 21 and 28 days post BDL. (A). Hepatic necro-inflammatory changes (triangle) (B). PSR staining 
for total collagen (arrow). (C). Quantification of PSR by morphometric pixel analysis (Expressed 
relative to mean % area of sham controls; n=4 per time point). Data expressed as mean±SEM and 




Figure 3. 7 Serum Biochemistry Changes in BDL model of Cirrhosis 
 
(A). Serum alkaline phosphatase (ALP), a marker of biliary injury and (B). Serum Albumin, a 
hepatic synthetic marker were measured in shams, 14,21 and 28 day BDL rats. Data expressed as 





3.10 Bile duct ligated rats rapidly develop portal hypertension, renal arterial vasoconstriction 
and renal functional impairment 
 
Following BDL, portal pressure (Fig. 3.8) was increased after 14 days (12.0±2.0 mmHg; p<0.01), 21 
days (16.4±0.4 mmHg; p<0.001) and 28 days (14.8±1.5 mmHg; p<0.001) compared to sham 
operated controls (5.2±0.8 mmHg).  In addition, RBF (Fig. 3.9A) was decreased following BDL 
(1.9±0.4 mL/min after 14 days, p<0.01; 1.6±0.3 mL/min after 21 days, p<0.01; 1.5±0.4 mL/min after 
28 days, p<0.01) compared to sham controls (6.5±1.5 mL/min). Furthermore, there was a parallel 
reduction in GFR (Fig. 3.9B) (1.1±0.3 mL/min after 14 days, p<0.05; 0.9±0.2 mL/min after 21 days, 
p<0.01; 0.7±0.3 mL/min after 28 days post BDL, p<0.01) compared to sham controls (2.4±0.2 
mL/min).  Although there was a reduction in MAP  (Fig. 3.9C)  after 21 days 
(69.4±7.1mmHg;p<0.05) compared with sham controls (96.4±7.9mmHg), there was no significant 









Figure 3.8 Portal Pressure Changes in BDL Model of Cirrhosis 
Portal pressure was measured by cannulation of portal vein in sham, 14, 21 and 28 day BDL rats. 
Data expressed as mean±SEM and  analysed by one-way ANOVA with post hoc Bonferroni test. 







Figure 3.9 Renal Blood Flow, Glomerular Filtration Rate and Mean 
Arterial Pressure Changes in BDL Cirrhosis 
(A). RBF, measured by a flow probe, (B). GFR measured by inulin clearance and (C). MAP 
measured by a femoral line were measured in sham, 14, 21 and 28 day rats. Data expressed as 
mean±SEM and analysed by one-way ANOVA with post hoc Bonferroni test. *p<0.05 **p<0.01 
***p<0.001. 
 
3.11 BDL kidneys show signs of ischaemic glomerular and tubular damage 
 
To establish whether there was any histological damage to the kidneys, tissue sections from 21 and 
28 day BDL rats and sham controls were stained with H+E and periodic acid shiff (PAS), and 
examined by a blinded pathologist.  In contrast to the CCl4 model, extensive acute tubular injury and 
necrosis (short arrows) were seen on H+E staining (Fig.3.10A).  PAS staining showed variable 
glomerular abnormalities with mesangial hypercellularity and podocyte proliferation, in keeping with 
glomerular ischaemic injury (long arrow: podocyte proliferation, triangle: mesangial 
hypercellularity).  Using a validated histological ATN score (Melnikov, Faubel et al. 2002), an 





Figure 3.10 Kidney Histology in BDL Cirrhosis 
(A). Representative images of sham and 28 day BDL kidneys sections, stained with PAS and H+E. 
Original magnification x50.  Reviewed by a blinded histopathologist. (long arrow: podocyte 
proliferation, triangle: mesangial hypercellularity).  Acute tubular injury and necrosis (short arrows) 
(B). Validated histological ATN score (Melnikov, Faubel et al. 2002) used to analyse degree of ATN 
90 
 
(n=4/group). Data expressed as mean±SEM, analysed by one way ANOVA with post hoc Bonferroni 




I have characterised two distinct rat cirrhosis models, one a model of repetitive hepatic necro-
inflammation that evolves to compensated (pre-ascitic) cirrhosis, the other a model of rapid onset 
biliary fibrosis that evolves to decompensated cirrhosis and ascites.  My aim was to establish two 
independent models that were suitable for use to investigate the pathophysiology and treatment of 
renal dysfunction/HRS in cirrhosis. Critically, a central feature of both models is progressive and 
significant portal hypertension, renal arterial vasoconstriction (demonstrated by a reduction in RBF) 
and a parallel decline in GFR (Fig.3.4A and B, Fig 3.9A and B).  The relevance of these models to 
human liver disease is highlighted further, firstly, by common biochemical markers of hepatic injury 
(ALT; Fig 3.2A) and biliary injury (ALP; Fig 3.7A) showing marked abnormalities with increasing 
hepatic/biliary injury, respectively.  Secondly, with portal hypertension developing in both, 
consistent with what is seen in advancing human cirrhosis (Fig 3.3 and Fig 3.8). Taken together, the 
haemodynamic phenotype shared in these models in many respects resembles human HRS in 
cirrhosis, although all animal studies are subject to the legitimate criticism that they cannot be 
considered to truly reflect events in the human condition. 
 
In characterising two pathologically distinct cirrhosis models, it is clear that the key observations are 
not model dependent, rather they reflect the inevitable consequence of severe portal hypertension 
regardless of the initial insult. Furthermore, the magnitude of RBF and GFR reduction in these 




There are some variances in these models that mean under the strict diagnostic criteria (Angeli, 
Gines et al. 2015) these rats would not necessarily be classified as having ‘true’ HRS.  Specifically, 
the BDL kidneys showed changes consistent with ATN (Fig 3.9B). But does this matter?  Although 
it was previously held that HRS kidneys were structurally ‘normal’, current evidence derived from 
human biopsies and urinary markers of structural kidney injury suggests that in many cases some 
degree of tubular damage in HRS is present (Trawale, Paradis et al. 2010; Fagundes, Pepin et al. 
2012).  In addition, HRS that does not respond to treatment with vasoconstrictors and albumin will 
inevitably progress to ATN in time.  This suggests that the BDL model might reflect a severe 
intractable form of human HRS.  There has also been debate as to whether the renal dysfunction seen 
in BDL is actually due to hyperbilirubinaemia distorting the tubules rather than being a reflection of 
true HRS (Assimakopoulos and Vagianos 2009).  This criticism is valid, but it is worth remembering 
that,  in humans, HRS is often precipitated by decompensation (including jaundice) and that this in 
itself can induce oxidative stress and HRS (Bomzon, Holt et al. 1997). It seems unlikely that the 
significant reduction in RBF that was observed with BDL (and CCl4) can be accounted for purely by 
tubular damage from hyperbilirubinaemia.   
 
A criticism of the CCl4 model is that the rats are well compensated and do not have ascites.  In 
humans HRS is predominantly seen in patients with decompensated cirrhosis and ascites or in 
patients with fulminant liver failure or severe acute alcoholic hepatitis (Moore 1999; Gines, Guevara 
et al. 2003; Verma, Ajudia et al. 2006). Renal dysfunction (demonstrated by a low GFR) (Fig 3.4A 
and B) was only evident at the extreme end of the CCl4 model (16 weeks).  There is some evidence 
that CCl4 is nephrotoxic (Jaramillo-Juarez, Rodriguez-Vazquez et al. 2008) and that this could 
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underlie any associated renal phenotype, although this was described in a different strain of rat 
(Wistar).  In my CCl4 model, using SD rats, there was no evidence of nephrotoxicity.  
 
To assess the effect of RLN on RBF and GFR in cirrhosis, I decided that the optimal time-point 
(associated with portal hypertension, renal vasoconstriction and renal dysfunction) was 16 weeks of 
CCl4.  For the BDL model, identifying the optimal time-point was more complicated.  After 14 days 
the rats exhibit a reduction in RBF and GFR, but they are not yet cirrhotic and do not have ascites. 
After 28 days the rats have ascites and are deeply jaundiced, but are too unstable to undergo 
prolonged general anaesthetic and microsurgery. Therefore for future in vivo experiments requiring 
prolonged general anaesthetic I decided to use 21 day BDL rats that showed a significant and 
reproducible reduction in RBF and GFR, but had better health status/body condition score than 28 
day rats. In contrast, for some experiments where general anaesthetic was not required I analysed 28 
day BDL rats.  
 
Summary of important findings: 
 
 Chronic CCl4 intoxication generates progressive hepatic fibrosis, culminating in cirrhosis 
with hepatic functional decline and an increase in portal hypertension 
 16 week CCl4 treated rats exhibit renal functional impairment with a reduction in renal blood 
flow, but no evidence of structural renal injury  
 BDL induces an intense biliary cirrhosis with rapid hepatic decompensation  
 BDL induces a more rapid (by 14 days) decline in renal blood flow and renal function 





Having characterised two pathologically distinct models of rat cirrhosis with a significant and 
reproducible reduction in renal blood flow and renal function, that were suitable for future use as a 
platform for evaluating the effects of RLN, the next step was to determine the extent and the 
















CHAPTER 4 - RESULTS - 
EXPRESSION AND DISTRIBUTION OF RXFP1 
















4.1 Overview of Chapter: 
 
In the previous chapter I fully characterised two distinct models of cirrhosis with sinusoidal 
hypertension and renal dysfunction.  I subsequently needed to confirm that the chief target for RLN, 
its G-protein coupled receptor, RXFP1, was present in these models and to determine its’ cellular 
location.  I used qPCR to monitor transcript expression and immunohistochemistry and western blot 
to measure protein expression of the RXFP1 receptor. Additionally, I utilised dual 
immunofluorescence to try to establish cellular location and I validated these findings in both rat and 
human tissue.  
4.2 Author contribution: 
 




The vasoactive actions of RLN are transduced by binding to its cognate receptor LGR7 or RXFP1.  
LGR7 is a member of the leucine-rich-repeats containing G-protein coupled receptor family (LGR) 
which are also known as the RLN family peptide (RXFP) receptors.  RXFP1 has been shown to be 
widely expressed in both rodent and human tissues outside the reproductive organs, importantly 
including the kidney (Hsu, Nakabayashi et al. 2002).  As previously described, H2-RLN binds to 
both RXFP1 and RXFP2, with the former suggested  from knockout murine models to be the 
predominant receptor through which RLN mediates its vascular effects (Novak, Parry et al. 2006; 




In HRS renal arterial vasoconstriction is central to its pathogenesis (Epstein, Berk et al. 1970).  I 
therefore wanted to focus my investigation on vascular expression of RXFP1. The current literature 
has evolved during my time undertaking this PhD and is significantly further on than when I started 
this body of work.  The majority of work has been done in rodents. The Rxfp1 transcript and its’ 
protein determined by Western blot, was initially localized in male and female rats to the small renal, 
mesenteric arteries and the thoracic aorta (Novak, Parry et al. 2006).  At a cellular level, Conrad and 
colleagues (2010) found that Rxfp1 transcripts were in greatest abundance in the vascular smooth 
muscle of arteries rather than the endothelium, although the relative contribution of receptors in each 
location in mediating the vasoactive effects of RLN remained unknown.  It had also been shown, 
from myogenic studies of isolated rat renal arteries, that removal of the endothelium obliterated the 
vascular response to RLN, suggesting that the endothelium is critical either through expression of the 
receptor or for the post binding signalling pathway (Novak, Ramirez et al. 2002).  Further evidence 
for the presence and importance of endothelial RXFP1 comes from a recent abstract showing that 
vascular reactivity is altered in mice with a conditional knockout of Rxfp1 in endothelial cells 
(Woodward W, Rusnak M et al. 2014). 
 
Much of the debate over RXFP1 expression comes from literature that has studied levels of 
transcription, with much less data on protein expression.  Based on the following chapter of work 
and through personal discussion with different laboratories, also searching for this receptor in other 
disease states, the reason for this is likely to be secondary to the quality of the antibodies available 
for this receptor.  Recent work from detailed immunohistochemistry in rodents has suggested that 
RXFP1 is expressed on both endothelial and smooth muscle cells in small renal arteries, mesenteric 
arteries and veins, aorta, femoral arteries and veins with differing abundance of endothelial versus 
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smooth muscle expression seen depending on the vessel type (Jelinic, Leo et al. 2014).  This appears 
to affect the myogenic response to RLN in individual vessels.  There is still limited expression data 
reported in human tissues. 
 
RXFP1 is widely expressed outside the vasculature.  In the liver we have shown that RXFP1 is 
expressed on activated myofibroblasts in fibrosis in both rats and humans (Fallowfield, Hayden et al. 
2014) and this has also been shown to be the case in the lung (Huang, Gai et al. 2011).  It has 
additionally been found to be expressed on cardiomyocytes in the heart  (Moore, Su et al. 2014).  
None of the work summarised above, apart from our recent paper (Fallowfield, Hayden et al. 2014) 
based on some of the following work, has been undertaken in cirrhosis.  Given what is known about 
the expression of this receptor and the differing cellular origin in different vascular beds and tissues, 
it is likely that disease states may also affect RXFP1 expression profile.   
 
4.4 Aims of this chapter: 
 
 To determine Rxfp1 mRNA transcript expression in in the liver, kidney and renal artery of 
CCl4 and BDL treated  cirrhotic rats 
 To determine RXFP1 protein expression in the liver, kidney and renal artery of CCl4 and 
BDL treated cirrhotic rats 








4.5 Kidney and liver Rfxp1 mRNA transcript expression increases in cirrhosis 
 
To determine Rxfp1 mRNA expression I used a pre-made and validated primer/probe set for rat 
Rxfp1 (Rn01495351_m1).  In normal/uninjured control rat liver the Rxfp1 transcript is expressed at 
very low levels. I used tissue from 16 week CCl4 and 28 day BDL rats (n=3-5/group) and compared 
individual organ expression to their respective control liver (given a value of 1) to view overall Rxfp1 
expression in these models. In Fig 4.1A  Rxfp1 mRNA transcript is most highly expressed in the 
heart in CCl4 cirrhosis compared to other organs (*p<0.05).  This was also seen in the BDL model 




Figure 4. 1 Rxfp1 mRNA expression in cirrhosis models 
(A) Relative Rxfp1 mRNA transcript expression in 16 week CCl4 cirrhosis (B) Relative Rxfp1 
mRNA transcript expression in 28 day BDL cirrhosis. n=3-5/group. Data expressed as mean ±SEM, 
analysed relative to uninjured liver expression, given value of 1. Analysed by 1 way ANOVA with 




To observe the effect of cirrhosis on individual organ Rxfp1 expression, I compared expression in 
that organ to expression in their respective control tissue (n=4-5/group).  In Fig 4.2A and B the 
hepatic expression of Rxfp1 was increased 40-fold in CCl4 and 70-fold in BDL cirrhosis.  This was 
also seen in the kidney (Fig 4.2C and D) with a 5- and 19-fold increase in CCl4 and BDL cirrhosis, 
respectively. Focussing on the renal artery (Fig 4.2E and F) there was a 2-fold increase in CCl4 





Figure 4. 2 Rxfp1 mRNA expression in cirrhosis in the Liver, Kidney 
and Renal artery 
Rxfp1 transcript expression in in the liver (A-B), kidney (C-D) renal artery (E-F) in 16 week CCl4 
and 28 day BDL relative to control tissue.  n=4-5/group. Expressed as mean±SEM and analysed 




4.6 RXFP1 receptor protein expression increases in cirrhosis 
 
To establish if mRNA transcript levels translated into increased protein expression I performed DAB 
immunohistochemistry (IHC).  I stained sections of liver tissue from the CCl4 model (n=4 per group) 
and using ImageJ (NIH, USA) counted the number of stained cells per field (x50 magnification) 
averaged over 30 non-overlapping fields. Hepatic expression of RXFP1 increased in CCl4 cirrhosis 









Figure 4.3 Hepatic RXFP1 protein expression in CCl4 cirrhosis 
(A) Representative images of RXFP1 staining in the liver by immunohistochemistry in olive oil, 8, 
12 and 16 week time-points. Original magnification x50. Arrow shows staining. Quantified in B 
(n=4) per time point by image J analysis, expressed as number of positive cells stained per x50 
magnification. Analysed by one way ANOVA with post hoc Bonferroni correction, *p<0.05 
**p<0.01. 
 
I also stained kidney sections at the same time-points but the pattern of staining, despite optimisation 
was not such that I could establish a way to reliably count receptor expression, or use morphometric 
pixel analysis.  I therefore proceeded to analyse RXFP1 protein expression levels quantitatively 
using Western blot analysis. Western blotting of whole kidney (n=4/group) with densitometry 
analysis from the CCl4 kidney showed increased expression of RXFP1 (Fig 4.4A and B;*p<0.05). 
Whereas with BDL kidneys, although suggesting a similar expression trend (Fig 4.4C and D; 
p=0.0755), it did not reach statistical significance with the sample size (n=4) used. Finally, I stained 
renal arteries from CCl4 rats, with their respective controls (n=4 per group) and there was 




Figure 4.4 Kidney RXFP1 protein expression in cirrhosis 
(A) Representative Western Blots of RXFP1 in Olive oil and CCl4 kidney with densitometry 
analysis, (B). (C) Representative Western blots of RXFP1 in sham and 28 day BDL kidneys, with 








Figure 4.5 Renal artery RXFP1 expression in cirrhosis 
Representative images of renal arteries isolated from olive oil and 16 week CCl4 rats with negative 
control (no primary RXFP1 antibody). Staining in smooth muscle (triangle) and endothelium 
(arrow). Magnification as shown. 
 
4.7 RXFP1 is expressed abundantly in kidneys from cirrhotic rats 
 
To delineate where RXFP1 is expressed in the kidney and its vasculature I used immunofluorescence 
(IF) with tyramide enhancement. Optimising this technique over DAB IHC meant that once I had 
established adequate staining with the single RXFP1 antibody I could then move on to dual IF . I 
firstly stained mouse uterus as a positive control to show validity of the antibody in IF compared to 
DAB staining (Fig 4.6A DAB staining original magnification x80, 4.6B IF, original magnification 
x100). In 16 week CCl4 kidneys RXFP1 expression was seen throughout the kidney, with expression 
seen in extra and intra renal arteries, glomerular and peri-tubular capillaries, medullary rays and the 
renal papilla (Fig 4.6B). This pattern of staining appeared consistent with sections from BDL kidney 
(Fig 4.6C).  The distribution of staining suggested that RXFP1 could be expressed in podocytes, 








Figure 4.6 Distribution of RXFP1 expression in cirrhosis 
(A). Representative images of RXFP1 DAB and IF staining in mouse uterus which was used as a 
positive control. (B). 16 week CCl4 kidney sections showing RXFP1(green) expression throughout 
the kidney, in extra and intra renal arteries, glomerulus and peri-tubular region, medullary rays and 
the renal papilla. (C) 28 day BDL kidney sections stained for RXFP1. Magnification as shown. 
 
4.8 RXFP1 is expressed in the kidney on endothelial cells, smooth muscle cells and renal 
pericytes 
 
To establish the key cells expressing RXFP1 in these models I utilised both dual IF and serial section 
staining. For these co-localisation stains I focussed on the CCl4 tissue as I had shown a consistent 
expression profile (Fig 4.6) between models. Fig 4.7A and B shows that there did not appear to be 
any co-localisation with WT1 expressing podocytes. There was convincing co-localisation with rat 
endothelial cell antibody (RECA) stained endothelial cells in renal arteries (Fig 4.8).  Again there 
was consistent overlap with αSMA positive cells in renal arteries (Fig 4.9). Finally, there was 






Figure 4.7 Serial sections and Dual Immunofluorescence of RXFP1 and 
WT1 expressing podocytes 
(A) Serial sections of 16 week CCl4 kidney were stained for RXFP1(green) and WT1(red) and DAPI 







Figure 4.8 Dual Immunofluorescence of RXFP1 and RECA 
16 week CCl4 renal artery sections were stained using dual immunofluorescence for rat endothelial 
cell marker (RECA;red) and RXFP1(green) with DAPI(blue) for nuclear stain. Co-localisation was 
seen on the endothelial cells (arrow). Original magnification x 200. Area of co-localisation 






Figure 4.9 Dual Immunofluorescence of RXFP1 and ASMA 
16 week CCl4 renal artery sections were stained using dual immunofluorescence for ASMA and 







Figure 4.10 Serial Section and Dual Immunofluorescence of RXFP1 
and PBGFβ 
16 week CCl4 kidney serial sections were stained for PDGFβ (red) and RXFP1(green) (A). Dual 
immunofluorescence with PDGFβ and RXFP1 in 16 week kidney tissue (B). Possible co-localisation is seen, 
arrow. Original magnification x 200 and x 360. 
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4.9 RXFP1 is expressed in human kidney on endothelial cells, smooth muscle cells and 
pericytes 
 
Kidneys are rarely biopsied from cirrhotic patients, even with AKI. Therefore to establish cellular 
expression of RXFP1 in human HRS remains difficult.  I obtained normal human kidney tissue, 
harvested from organs that had been surgically removed due to cancer.  I analysed these tissues 
firstly, using single stain RXFP1 IF (Fig 4.11A), which confirmed a similar staining pattern to both 
cirrhosis models.  Secondly I undertook dual IF with an endothelial marker (CD31), a smooth muscle 
cell marker (αSMA) and a pericyte marker (PDGFβ).  Fig 4.11 B,C and D show respective co-







Figure 4.11 RXFP1 staining in the Human Kidney 
Human kidney, stained with single IF for RXFP1 (green) (A). Dual IF with CD31 (endothelial 
marker;red; arrow showing co-localistation;B), ASMA (smooth muscle marker;red; triangle showing 





I have shown that Rxfp1 mRNA transcript levels are increased in the CCl4 and BDL models in the 
liver and kidney with an increase in the renal artery expression in the CCl4 model of cirrhosis and a 
trend in the BDL model.  With regards the renal artery results in BDL, the non-significant results are 
likely due to the small sample size as I analysed n=4 and the expression was variable.  This could be 
in part due to differences in the relative area of the renal artery that was used in RNA extraction.  My 
aim was to cut across the artery to achieve a cross sectional piece incorporating smooth muscle and 
endothelium. However, given the small nature of this sample, this may have not been consistent, 
resulting in greater variation in the renal artery results.    Additionally, I have shown that these 
expression changes are not limited to transcript changes with increasing RXFP1 protein expression 
in the liver and kidney in CCl4 cirrhosis and a trend to increase in the BDL model.  This latter 
finding may reflect an issue with technique.  Using Western blot for measuring expression relies on 
incorporating an equal amount of cortex/medulla/renal vasculature into the sample, therefore for a set 
protein amount you may get differing levels of expression depending on what makes up that 




Although detailed investigation of the mechanism of RXFP1 gene regulation in rat cirrhosis models 
was beyond the scope of this thesis, recent data in  myocardium suggested that RXFP1 expression is 
regulated by α1 and β1 adrenoceptors (Moore, Su et al. 2014).  In the liver it is tempting to speculate, 
given that RXFP1 is known to be expressed on myofibroblasts (Fallowfield, Hayden et al. 2014) that 
increasing expression of this cell type in fibrogenesis leads to increasing expression of RXFP1.  
However, this hypothesis cannot explain why it is increased in the renal vasculature and kidney as 
there is no evidence that either CCl4 or BDL induce fibrosis in the kidney or vasculature. It may well 
be unique to different organs and vascular beds. To attempt to answer this question I needed to know 
which cells expressed RXFP1 in the kidney.   
 
From co-localisation staining I have shown expression of RXFP1 on endothelial cells, smooth 
muscle cells and pericytes (Fig 4.9 and 4.10). This is in agreement with previous literature in healthy 
rodents (Jelinic, Leo et al. 2014).  These are all cells integral to renal blood flow regulation and 
vascular reactivity, making them promising targets for therapeutic modulation.  Despite thorough 
optimisation and the use of tyramide, I had many problems with the secondary antibodies cross 
reacting with the primary antibodies as my antibodies were all raised in Rabbit.  Most of my issues 
with the methodology in this current chapter of work were due to the quality of RXFP1 antibodies 
available.  I consistently used the Santa Cruz one for all rat IF work to prevent additional variables, 
such as antibody affinity, compromising my findings. Additionally, despite promising results with 
the Phoenix antibody in the liver I was unable to get this antibody to work using IF thereby limiting 
its use in establishing co-localisation.  Commercially available RXFP1 antibodies appear to lack 
specificity, and despite extensive troubleshooting, I did not manage to obtain a completely clear 
answer to my questions.  In situ hybridisation is an alternative technique that could be used in the 




Finally, I have shown that RXFP1 cellular expression in human kidney tissue appears analogous to 
that in the rodent. This represents an important finding.  By sharing a similar expression profile one 
can postulate that RLN may work in a mechanistically similar way between species. 
 
Summary of important findings: 
 
 Rxfp1 mRNA transcripts are increased in the liver and kidney in both rat cirrhosis models 
 RXFP1 protein is detectable in both models of cirrhosis in the kidney and its expression 
appears to increase in cirrhosis 
 RXFP1 co-localised to endothelial cells, smooth muscle cells and pericytes in rat and human 




Having established the presence of RXFP1 in the renal vasculature and kidneys in both CCl4 and 







CHAPTER 5 - RESULTS - 
THE EFFECTS OF EXOGENOUS RLN IN VIVO 




















5.1 Overview of Chapter: 
 
In this chapter I used both models of cirrhosis with renal vasoconstriction and renal dysfunction to 
determine the effect of exogenous RLN on renal and systemic haemodynamics.  I firstly investigated 
the pharmacodynamic effects of a single acute bolus of RLN on renal and systemic haemodynamics 
and then proceeded to study the effect of an extended subcutaneous (s.c.) RLN infusion on renal 
function, which is the pivotal end point of interest in human HRS.  I utilised not only invasive 
monitoring to study changes in renal and systemic haemodynamics in response to exogenous RLN, 
but also evaluated the use of non-invasive imaging tools - USS and BOLD MRI - to measure 
changes in velocity time integral and resistive index and renal oxygenation, respectively.  
 
5.2 Author Contribution: 
 
I designed, performed all the invasive experiments in this chapter and did all the analysis. Adrian 
Thomson operated and optimised the USS technique and Ross Lennen operated and optimised the 
BOLD MRI imaging. 
   
5.3 Background: 
 
Summarising briefly what I discussed in the Introduction, endogenous RLN has been shown to have 
pleiotropic effects in matrix and collagen turnover, vascular remodelling and haemodynamic 
adaptations to pregnancy (Conrad 2010).  It has been shown to be an important mediator of the 
maternal haemodynamic adaptations to pregnancy in both humans and rodents (Debrah, Novak et al. 
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2006; Smith, Murdoch et al. 2006).  RLN’s effects in the systemic circulation are increased cardiac 
output, increased global arterial compliance, reduced systemic vascular resistance and in the renal 
circulation, increased RBF, increased GFR and reduced renal vascular resistance. All these vascular 
effects have been recapitulated using exogenous H2-RLN in both male and non-pregnant female 
rodents and importantly no decrease was seen MAP due to the increased cardiac output through 
increased stroke volume (Conrad, Debrah et al. 2004; Debrah, Conrad et al. 2005; Debrah, Conrad et 
al. 2005).  Arteries from RLN deficient mice show increased myogenic reactivity and reduced 
compliance (Novak, Parry et al. 2006).  Furthermore, a study in healthy human volunteers showed an 
increase in renal plasma flow as early as 30 minutes in response to exogenous RLN infusion with no 
drop in MAP (Smith, Danielson et al. 2006).  More recent studies in patients with acute and chronic 
heart failure and a study in patients with scleroderma have also shown that exogenous RLN 
improved renal function.  
 
Therefore, there is fairly compelling evidence that exogenous RLN may improve RBF and renal 
function in certain disease states.  Given the hypothesis that functional renal arterial vasoconstriction 
(Epstein, Berk et al. 1970; Gines, Guevara et al. 2003) is central to HRS development, a drug that 
can modulate this directly could be very beneficial.  Previous work has suggested that RLN 
preferentially vasodilates pre-constricted vessels, adding promise to my hypothesis of its potential 
beneficial effects in HRS (Debrah, Conrad et al. 2005; Teichman, Unemori et al. 2009).  
Furthermore, I have shown the presence of RXFP1, RLN’s major receptor in the kidneys and 
particularly the renal arteries of cirrhotic rats and that this expression profile is the same as human 




There has been significant work undertaken in normal rodents on dosing and duration of exogenous 
H2-RLN to recapitulate the endogenous effects seen in pregnancy, to summarise: 
 The first conclusion is that H2-RLN is the functional orthologue of rat and mouse RLN, 
though their amino acid sequence is not homologous (Halls, van der Westhuizen et al. 2007).  
 Second, all studies in these normal rats used H2-RLN and have shown robust effects 
suggesting that its effects are not limited to its species, summarised in (Conrad 2010). 
  Third, given it is also the drug given to humans, it stands to reason that for translational 
potential I should use the human recombinant form, given that it is also known to have effects 
in rodents.  
Exogenous RLN administration has been shown to produce a U-shaped, biphasic dose response 
curve (Danielson and Conrad 2003; Debrah, Conrad et al. 2005) with 4µg/hr producing peak renal 
and systemic effects with serum RLN levels of 10-20ng/mL, whereas 40µg/hr produced serum RLN 
levels of 80ng/mL with minimal renal effects.  I therefore chose 4µg/hr as the dose to work with in 
my rodent models. It is also known that duration of exposure to RLN also affects the downstream 
pathway activation (Section 1.12). Isolated vessels can rapidly dilate in minutes (Fisher, MacLean et 
al. 2002), with in vivo experiments suggesting that more sustained exposure resulted in an increase in 
RBF and GFR peaking at 24 hours and persisting with duration of exposure (Danielson, Kercher et 
al. 2000; Danielson and Conrad 2003).   
 
To date, no other groups have looked at the effect of H2-RLN on renal and systemic haemodynamics 





5.4 Aims of this Chapter:  
 
 To define the acute effect of a single i.v. bolus of H2-RLN on renal and systemic 
haemodynamics in control and cirrhotic rats 
 To establish non-invasive imaging techniques to monitor changes in renal and 
systemic haemodynamics in response to H2-RLN in these models 
 To assess the effect of sustained H2-RLN infusion on systemic and renal 
haemodynamics and renal function  
 
RESULTS 
5.5 Renal blood flow is augmented by a single bolus of recombinant human H2-RLN 
(serelaxin) 
 
In preliminary experiments of n=4 rats, I firstly established that a 200µL volume challenge did not 
cause a rapid change in RBF (Fig 5.1A) though a non-clinically relevant reduction was seen in MAP 
by 5 mins relative to baseline (0 mins: 105.6±7.5mmHg versus 5 mins: 102.4±7.9mmHg; p<0.05) 
(Fig 5.1B) when monitored invasively under general anaesthetic. The question I was trying to answer 
with this experiment was whether a bolus of 200µL caused relevant changes in these parameters, 




Figure 5.1 Effect of bolus of Vehicle on Renal Blood Flow and Mean 
Arterial Pressure 
Anaesthetised 16 week CCl4 rats were given an i.v bolus of 200 µL of normal saline and their RBF, 
measured by flow probe for 5 mins (A), MAP , measured by femoral arterial line, for 5 mins. (B). Data 
expressed as mean±SEM and analysed by one-way ANOVA with post hoc Bonferroni test. *p<0.05. 
 
Subsequently, I undertook a small feasibility study to establish that the dosing suggested by the 
literature was valid in my model.  I treated 16 week CCl4 rats, anaesthetised with Inactin, with an i.v. 
bolus of RLN of 1,4,10 or 20 µg in 200 µL via their jugular vein and monitored them for up to 80 
minutes. This was not a formal dose-response study, with only n=1 rat studied per dose.  My aim was 
firstly to establish that with my invasive monitoring, under general anaesthetic, I was able to detect 
changes in RBF and MAP and, secondly, to ensure that the 4µg dose was sufficient for this acute 
study.  My justification for this approach was that there are good publications on dosing of H2-RLN 
and, to try to abide by the 3R’s philosophy, I felt that the rats were better utilised in establishing 
novel results rather than repeating experiments.  If there had not been sufficient literature to base my 
dosing decision on, I would have planned a larger scale dose-response study.  In Fig 5.2A and B, 
there was an observed increase in RBF seen with 1, 4 and 10µg, with 4µg giving the most apparent 
change from baseline at 60 minutes. With 20µg a reduction in RBF was seen.  Furthermore, with 1 
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and 4µg there was no drop in MAP.  However this appeared more labile at higher doses (Fig 5.2C). 
The conclusion I drew from this limited experiment was that I would continue using 4µg of RLN for 








Figure 5.2 Effect of Different Doses of Relaxin on Renal Blood Flow 
and Mean Arterial Pressure in 16 week CCl4 cirrhotic rats 
16 week CCl4 rats, 24-48 hours after their last CCl4 injected, were anaesthetised and their RBF (A) 
and MAP (C) monitored invasively for 80 minutes in response to i.v. bolus of 1, 4, 10 or 20µg of 
RLN. (B) RBF at 0 compared to 60 mins. Data expressed as individual rat, n=1 per dose. 
 
 
I treated anaesthetized control (uninjured n=5/group) and 16 week CCl4 rats (n=6/group) with either 
a single i.v. bolus of RLN (4µg in 200 µL via jugular vein) or equivalent volume of vehicle and 
monitored their RBF, MAP and HR invasively for 60 mins.  The mean serum RLN level after 60 
mins was 6.0±0.3 ng/mL.  Fig.5.3 shows the relative change in RBF.  There was a progressive 
increase in RBF seen in both the 16 week CCl4 cirrhotic (Fig. 5.3A) and control rats (Fig. 5.3B) 
given RLN compared to vehicle.   Cirrhotic rats showed an increased relative rise in RBF compared 
with their uninjured counterparts, in response to RLN (Fig 5.3C).  Looking at absolute changes, after 
a single bolus of RLN RBF increased in the CCl4 model from 2.0±0.3mL/min at baseline to 
2.79±0.5mL/min at 30 minutes (p<0.01) to 3.1±0.5mL/min at 60 minutes (p<0.001) Fig 5.3D: a 50% 











Figure 5.3 Effect of Single Dose Relaxin on Renal Blood Flow in 16 
week CCl4 cirrhotic and normal uninjured rats 
Anaesthetized control (uninjured n=5/group) and 16 week CCl4 rats (n=6/group) were treated with a 
single i.v. bolus of RLN (4µg in 200 µL via jugular vein) or equivalent volume of vehicle and their 
RBF monitored invasively for 60 minutes.  (A) RBF change in 16 week CCl4 rats RLN versus 
vehicle (B) RBF in normal uninjured rats, RLN versus vehicle. (C)  RBF change in 16 week CCl4 
versus normal given RLN. Data was expressed relative to mean RBF pre-RLN, which was given the 
value of 1, and analysed by repeated measures ANOVA with post-hoc Bonferroni test. (D) Absolute 
RBF in CCl4 group given RLN (D).  Data expressed as individual values and analysed by one way 
ANOVA with post-hoc Bonferroni test. *p<0.05 **p<0.01 ***p<0.001. 
 
5.6 There was no drop in mean arterial pressure after a single bolus of RLN 
 
I monitored the MAP via a femoral arterial line for 60 mins after the i.v. bolus of RLN or vehicle.  A 
potential concern for using any vasodilator is the risk of inducing hypotension, which in cirrhotic 
patients, as they often have low MAPs, might induce a detrimental reduction.  My results show that 
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even at the extreme of the CCl4 model there was no drop in MAP in response to RLN (Fig 5.4A).  
Furthermore there was no difference in MAP in the rats given RLN versus vehicle (Fig 5.4B). The 
significant increase in RBF after RLN, with no change in MAP, indicates that RLN is acting as a 







Figure 5.4 Effect of Single Dose Serelaxin on Mean Arterial Pressure in 
16 week CCl4 cirrhotic rats 
16 week CCl4 rats. MAP was monitored invasively via the femoral arterial line for 60 mins after 
RLN or same volume vehicle. (A) MAP in rats given RLN. Analysed by repeated measures ANOVA 
with post-hoc Bonferroni test. (B) MAP in RLN versus vehicle, analysed by two way ANOVA with 
post hoc Bonferroni test. 
 
5.7 Non-invasive Doppler ultrasound confirms augmentation of renal blood flow after a single 
i.v. bolus of RLN 
 
Although invasively monitoring RBF using a renal flow probe wrapped around the renal artery is a 
well-established technique for monitoring real time changes in renal haemodynamics in rodents, it is 
not a technique that we would use in humans due to its invasive nature.  Additionally, the process of 
cannulating arteries and veins and performing a laparotomy to visualise the renal artery leads to fluid 
shifts, which is an additional potentially confounding variable.  Although I ensured the surgery was 
optimised with regards to fluid losses, criticisms still remained as to the validity of using this method 
to monitor real time changes in response to vasoactive drugs. With this in mind I went on to use 
Doppler ultrasound.  Doppler USS is used routinely in clinical practice and as such remains a 
potential technique with which to translate findings from murine models to humans more easily.  
Using this non-invasive technique allowed me to firstly corroborate my invasive findings and 
secondly to monitor parameters I had not been able to before, such as cardiac output.  
 
16 week CCl4 cirrhotic rats (n=14) were anaesthetised using isoflurane.  This inhalational agent was 
used as it allows the operator more control over the onset and depth of anaesthesia compared to 
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injectable inactin.  A baseline scan was performed and then the Doppler trace was measured 
continuously for 60 minutes. During this time I collected data every 10 minutes.  Fig. 5.5, I have 
shown results of the effect of RLN (4µg i.v.) or vehicle on Velocity Time Integral (VTI).  VTI is 
calculated by measuring the volume under the curve in time (schematic shown in METHODS Fig 
2.1).  An increase in renal arterial VTI (Baseline 2.6±0.3cm vs. 60 min 3.4±0.3cm, p<0.05) was seen 
with RLN (n=8), whereas no effect was seen with vehicle (n=6) (Fig. 5.5A, B and C). Examples of 









Figure 5. 5 Effect of Single Dose Relaxin on Velocity Time Integral 
measured by Ultrasound Doppler 
16 week CCl4 rats were anaesthetised and randomised to either vehicle (n=6) or RLN (n=8) and 
monitored for 60mins. VTI change in rats given vehicle (A), VTI change in rats given RLN (4µg i.v; 
B).  Data expressed as individual data with mean±SEM and analysed by one way ANOVA with 
post-hoc Bonferroni test. RLN versus vehicle (C). Data analysed by 2-way ANOVA with post-hoc 
Bonferroni test. Example of images obtained (D). *p<0.05 **p<0.01 ***p<0.001. 
 
5.8 Renal Resistive Index is reduced by a single i.v. bolus of RLN 
 
The renal resistive index or peak Pourcelot resistive index (RI) is a measure of renal arterial 
vasoconstriction. Platt et al were the first to show that RI was increased in HRS (Platt, Ellis et al. 
1994).  More recently RI has been shown in cirrhosis to correlate with MELD and Child-Pugh score, 
with higher scores seen in more decompensated patients (Culafic, Stulic et al. 2014) and a recent 
small study has shown increasing RI with reducing renal function in cirrhosis (Mindikoglu, Dowling 
et al. 2014).  Currently it is not used routinely in clinical practice.  A score of 0.6 is considered 
normal in a human intra-renal artery, with 0.7 the very upper limit of normal in native non-
transplanted kidneys. There is limited data in murine models although the suggestion is that it is a 
similar range to humans (Kong, Chen et al. 2013).  The RI is measured as shown in Fig 2.2.  In our 
model peak RI decreased following RLN (baseline 0.68±0.02 vs. 60 min 0.63±0.01, p<0.01), with no 
effect seen with vehicle (Fig.5.6 A, B).  Fig 5.6C shows the effect on RI, measured every 10 










Figure 5.6 Effect of Single Dose Relaxin on Resistive Index measured 
by Ultrasound Doppler 
16 week CCl4 rats were anaesthetised and randomised to either vehicle (n=6) or RLN (n=8) and 
monitored for 60mins. RI change in rats given vehicle (A), RI change in rats given RLN (4µg i.v; B).  
Data expressed as individual data with mean±SEM and analysed by one way ANOVA with post-hoc 
Bonferroni test. RLN versus vehicle (C). Data analysed by 2-way ANOVA with post-hoc Bonferroni 
test. Example of images obtained (D). *p<0.05 **p<0.01 ***p<0.001. 
 
5.9 Blood oxygen level dependent MRI showed reduced renal deoxygenated Haemoglobin in 
response to RLN 
 
To complement my ultrasound blood flow analyses, I also assessed kidney parenchymal oxygenation 
using blood oxygen level-dependent magnetic resonance imaging (BOLD MRI) in anesthetized CCl4 
cirrhotic rats.  BOLD MRI uses the paramagnetic properties of deoxyhaemoglobin to acquire images 
sensitive to local tissue oxygen concentration.  As the deoxyhaemoglobin in blood increases the T2* 
relaxation time decreases and this produces measurable signal loss in these areas.  The validity of 
this technique as a surrogate marker of oxygenation has been shown by studies that found 
comparable results between invasive measurements of oxygenation and BOLD MRI signal (Li, 
Halter et al. 2008).  The loss of phase coherence (T2*) maps were generated in the kidney and 
regions of interest (cortex, outer medulla and inner medulla) were selected and R2* values were 
calculated by 1/T2*. R2* (relaxation rate) correlates inversely with the oxygenation of the kidney 
and is proportional to the level of deoxyhaemoglobin.  As long as the temperature of the rat, sedation 
(respiration rate) and hydration remain constant so as to not increase R2*, any changes in this 
parameter should reflect changes to the blood supply of oxygenated blood, thereby making it a 




Three baseline 3 minute scans were performed and RLN or equivalent volume of vehicle given i.v. 
through a tail vein cannula and 3 minute scans were repeated for 60 minutes post injection.  In 8 
week CCl4 rats the R2*was reduced after 60 minutes in the renal cortex and outer medulla in 
response to acute i.v. RLN, which was not seen with same volume of vehicle (Fig 5.7A-D; 
n=7/group;*p<0.05).  In the inner medulla these results were not reproduced (Fig 5.7E-F).  In 16 
week CCl4 rats the R2* was reduced after 60 minutes in both the outer and inner medulla in response 
to RLN whereas no response was seen in the vehicle treated group (Fig 5.8A-D, n=4-












Figure 5.7 Effect of Single Dose Relaxin on R2* (Deoxygenated 
Haemoglobin) in 8 week CCl4 Fibrotic Rats 
8 week CCl4 rats were anaesthetized and three baseline 3 minute scans were performed and RLN 
(n=7) or equivalent volume of vehicle (n=7) given i.v. through a tail vein cannula and 3 minute scans 
were repeated for 60 minutes post injection.  (A-B) Cortex in response to vehicle or RLN, (C-D) 
Outer medulla in response to vehicle or RLN, (E-F) Inner medulla in response to vehicle or RLN. 
Data expressed as individual with mean ±SEM and analysed by one way ANOVA with post-hoc 







Figure 5.8 Effect of Single Dose Relaxin on R2* (Deoxygenated 
Haemoglobin) in 16 week CCl4 Cirrhotic Rats 
16 week CCl4 rats were anesthetized and three baseline 3 minute scans were performed and RLN 
(n=5) or equivalent volume of vehicle (n=4) given i.v. through a tail vein cannula and 3 minute scans 
were repeated for 60 minutes post injection.  (A-B) Cortex in response to vehicle or RLN, (C-D) 
Outer medulla in response to vehicle or RLN, (E-F) Inner medulla in response to vehicle or RLN. 
Data was expressed as individual with mean ±SEM and analysed by one way ANOVA with post-hoc 
Bonferroni test. *p<0.05 **p<0.01 ***p<0.001. 
 
Having shown results, using 3 modalities, of the dynamic renal vasodilator effects of acute bolus 
RLN in CCl4 cirrhosis I went on to define its effect on a more translatable and clinically relevant 
parameter (renal function). This is the parameter we currently monitor in the clinical setting and it is 
also used in clinical trials to determine the efficacy of drugs on HRS.  Previous work has shown it 
takes several hours to start seeing changes in the GFR in normal conscious rodents (Danielson and 
Conrad 2003).  I chose to give the infusion for 72 hours as this is around the time point that we use to 
establish whether a patient is responding to current pharmacological therapy for HRS (Salerno, 
Gerbes et al. 2007). 
 
5.10 Sustained RLN infusion elicits renal vasodilation and restores renal function in chronic 
carbon tetrachloride treated rats 
 
Sustained treatment with RLN (4µg/hr s.c.) for 72h in 16 week CCl4 rats resulted in mean serum 
RLN levels of 10.2±1.3 ng/mL. Rats treated with RLN had improved RBF compared with vehicle 
(RLN 3.8±0.3 mL/min vs. vehicle 2.5±0.2 mL/min, p<0.01; Fig. 5.9A). This was mirrored by a 
parallel improvement in GFR (RLN 2.6±0.3 mL/min vs. vehicle 0.7±0.3 mL/min, p=0.001; Fig. 
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5.9B). RLN therefore restored the RBF from 37% to 59 % of normal uninjured controls and the GFR 




Figure 5.9 Effect of Sustained 72 Hour Infusion of Relaxin on Renal 
Blood Flow and Glomerular Filtration Rate in 16 week CCl4 Cirrhotic 
Rats 
Sustained treatment with RLN (4µg/hr s.c.) or  vehicle for 72h in 16 week CCl4 rats. Rats were 
anaesthetised and RBF, measured by flow probe compared with vehicle (A). GFR by inulin 
clearance (B). Data expressed as individual data ±SEM and analysed by Students t test. *p<0.05 
**p<0.01 ***p<0.001. 
 
5.11 Sustained RLN treatment reduces portal pressure but does not affect mean arterial blood 
pressure or systemic nitric oxide levels in CCl4 cirrhotic rats 
 
There was no difference in MAP between RLN and vehicle treated 16 week CCl4 cirrhotic rats (RLN 
105±4 mmHg vs. vehicle 106±4 mmHg, p=0.85; Fig. 5.10A).  In contrast, there was a significant 
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reduction in PP in the RLN treated rats which was not seen with vehicle treated rats (RLN 
6.1±1.1mmHg vs. vehicle 9.5±0.8mmHg, p<0.01; Fig 5.10B).  I tested for changes in serum total 
nitrite as a surrogate for nitric oxide (NO).  Central to the ‘vasodilatation’ theory of HRS 
development is the concept that excessive circulating NO leads to worsening splanchnic 
vasodilatation.  Given that the results indicated that RLN was causing renal vasodilatation I 
investigated whether this was associated with increased circulating NO levels. This was not the case 
as total serum nitrite levels were not different between RLN and vehicle treated rats (RLN 18.6±1.7 






Figure 5.10 Effect of sustained 72 hour Infusion of Relaxin on Mean 
Arterial Pressure, Portal Pressure and Serum Nitric Oxide in 16 week 
CCl4 Rats 
MAP was measured by a femoral arterial line in 16 week CCl4 cirrhotic rats post 72 hrs of RLN or 
vehicle (A).  PP was measured by portal vein cannulation (B).  Serum nitrite levels (C). Data 
expressed as individual data ±SEM and analysed by Students t test. *p<0.05. 
 
5.12 72 hours sustained RLN does not affect hepatic injury or fibrosis but an increased serum 
albumin is observed 
 
Given that we know the underlying insult leading to HRS is cirrhosis and that RLN has anti-fibrotic 
effects and an anti-portal hypertensive effect (Fig 5.10B; (Fallowfield, Hayden et al. 2014)) , I 
wanted to investigate whether the effect on RBF could be attributed to improvements in hepatic 
fibrosis or injury.  I measured serum ALT in each group to determine whether there was a difference 
in the degree of liver injury, but ALT levels were similar (RLN 89±28µmol/L vs. vehicle 
80±21µmol/L, p=0.76; Fig. 5.11A). Serum albumin, a hepatocyte synthetic marker, was modestly 
increased with RLN treatment (RLN 27.4±0.7g/L vs vehicle 24.75±0.7g/L, p<0.05; Fig 5.11B).  I 
quantified PSR staining of liver sections (n=4/group) and found no difference between RLN and 
vehicle treated rats (collagen proportionate area (CPA); RLN 2.9±0.1% vs. vehicle 2.5±0.1%, 
p=0.43; Fig. 5.11C, representative images shown in Fig. 5.11D). In addition there were no 







Figure 5.11 Effect of Sustained 72 Hour Infusion of Relaxin on Hepatic 
Injury, Function and Fibrosis in CCl4 Cirrhosis 
Serum ALT, a marker of liver injury (A). Serum albumin, a hepatocyte synthetic marker, (B).  (C). 
Morphometric analysis of PSR stained liver sections (n=4/group) from RLN or vehicle treated rats 
(represented as collagen proportionate area (CPA)) (C).  Representative images shown-arrows 







5.13 Sustained RLN infusion elicits renal vasodilation and improves renal function in bile duct 
ligated rats 
 
To exclude a model dependent effect of RLN on RBF and GFR and to determine the effect of RLN 
in a preclinical setting more akin to human HRS, I repeated my analyses from the CCl4 cirrhosis 
model in decompensated 21 day BDL rats. Sustained treatment with RLN (4µg/hr s.c.) for 72hr in 
resulted in mean serum RLN levels of 10.6±1.8 ng/mL and elicited a significantly increased RBF 
compared with vehicle (RLN 2.3±0.2 mL/min vs. vehicle 1.5± 0.2 mL/min, p=0.01; Fig. 5.12A). 
GFR was also increased in RLN treated rats (RLN 2.1±0.5 mL/min vs. vehicle 0.8±0.3 mL/min, 
p=0.04; Fig 5.12B). Importantly this represents an increase in RBF from 22 % to 38% and GFR from 
25% to 86% of sham controls after 72 hrs infusion.   
 
 
Figure 5.12 Effect of Sustained 72 Hour Infusion of Relaxin on Renal 
Blood Flow and Glomerular Filtration Rate in 21 day BDL Rats 
Sustained treatment with RLN (4µg/hr s.c.) or vehicle for 72h in 21 day BDL rats. Rats were 
anaesthetised and RBF, measured by flow probe compared with vehicle (A). GFR by inulin 
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clearance (B). Data expressed as individual data ±SEM and analysed by Students t test. *p<0.05 
**p<0.01 ***p<0.001. 
 
5.14 Sustained RLN treatment reduces portal pressure but does not affect mean arterial blood 
pressure or systemic nitric oxide levels in BDL cirrhosis  
 
I invasively measured MAP via a femoral arterial line and found no difference between RLN and 
vehicle treated 21 day BDL treated rats  (RLN 81±8 mmHg after vs. vehicle 73±4 mmHg, p=0.39; 
Fig. 5.13A).  In contrast RLN treated rats exhibited a reduction in PP (RLN 8.8±0.7mmHg vs 
vehicle 14.1±1.3mmHg, p<0.01; Fig 15.13B).  Again, serum total nitrite levels were unaffected by 





Figure 5.13 Effect of Sustained 72 Hour Infusion of Serelaxin on Mean 
Arterial Pressure, Portal Pressure and Serum Nitric Oxide in 21 day 
BDL Rats 
MAP was measured by a femoral arterial line (A).  PP was measured via portal vein cannulation (B).  
Serum nitrite levels were measured in the blood (C) after 72hrs of RLN or vehicle treatment in 21 
day BDL cirrhotic rats.  Analysed by Students t test. *p<0.05 **p<0.01 ***p<0.001. 
 
5.15 72 hours sustained RLN does not affect biliary injury, hepatic fibrosis or function 
 
The haemodynamic effects of RLN appeared to be independent of biliary injury as serum ALP was 
unaffected (RLN 498±43 µmol/L vs. vehicle 509±69 µmol/L, p=0.8939; Fig. 5.14A).  Serum 
albumin was also similar in RLN and vehicle treated rats (RLN 21.5±1.9g/L vs vehicle 26.6±1.3g/L, 
p=0.062; Fig 5.14B).  Furthermore there was no difference in liver fibrosis (CPA; RLN 2.3±1.4% vs. 





Figure 5.14 Effect of Sustained 72 Hour Infusion of Relaxin on Hepatic 
Injury, Function and Fibrosis in BDL Cirrhosis 
149 
 
Serum ALP, a marker of biliary injury (A). Serum albumin, a hepatocyte synthetic marker, (B) were 
measured in blood from BDL rats exposed to 72hrs of either RLN or vehicle.  (C) Morphometric 
analysis of PSR stained liver sections (n=4/group) from RLN or vehicle treated rats (represented as 
collagen proportionate area (CPA)). (D) Representative images shown. Analysed by Students t test. 
*p<0.05 **p<0.01 ***p<0.001. 
 
5.16 Cardiac effects of RLN 
 
I measured cardiac output and stroke volume by M-mode Doppler ultrasound at baseline and then at 
60 min following either a single i.v. injection of RLN or vehicle but observed no effect on either 
parameter (Fig. 5.15A and B).  However, when heart rate was measured invasively through the 
femoral arterial line in response to RLN, I observed a positive chronotropic effect at 30 and 60 
minutes relative to baseline (Baseline 250, 30 mins 333, 60 mins 329;p<0.001; Fig 5.15C) which 
was not seen with vehicle.  In contrast, there was no difference in the heart rates of rats exposed to 72 
hours of RLN compared to vehicle in either cirrhosis model (Fig 5.15D and E).  This suggests that 







Figure 5.15 Effect of Relaxin on Cardiac Output, Stroke Volume and 
Heart Rate 
Cardiac output and stroke volume measured by M-mode Doppler ultrasound at baseline and then at 
60 min following either a single i.v. injection of RLN or vehicle. (A and B).  Shown as individual 
data and analysed by 2 way ANOVA with post hoc Bonferroni test. Heart rate, measured invasively, 
through the femoral arterial line in response to acute vehicle or RLN (C) shown as individual data 
with mean±SEM and analysed by one way ANOVA with post hoc Bonferroni test. Heart rates of rats 




5.17 Acute bolus of a non-selective vasodilator does not improve real blood flow 
 
As NO is pivotal to the mechanism of vasodilation proposed for RLN (McGuane, Debrah et al. 
2011), I also investigated the acute in vivo haemodynamic response to the NO-releasing drug SNP in 
the CCl4 rat cirrhosis model (n=6).   I used doses of SNP previously shown to increase hind-limb 
blood flow in rats (Robertson, Gray et al. 2012).  In contrast to the selective effects of systemically 
administered RLN on RBF with preservation of MAP, the vasodilatory agent SNP did not increase 
renal perfusion (Fig.5.16A-B).  This experiment adds further evidence that RLN is a selective 
vasodilator, as the effects seen with a normal vasodilator include hypotension.  These results 
correlate with previous trials of nitrates and vasodilators in HRS showing no success (Salmeron, 







Figure 5.16 Acute Bolus of the nitrovasodilator SNP on Renal Blood 
Flow and Mean Arterial Pressure in 16 week CCl4 Cirrhotic Rats 
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16 week CCl4 rats were given acute i.v. boluses of SNP and their RBF and MAP measured invasively 
for 10 minutes. (A) RBF . (B) MAP.  Data expressed as mean±SEM and analysed by 2 way ANOVA 





In this chapter I have shown for the first time the in vivo effects of H2-RLN in two rat models of 
cirrhosis. To date, work into the effect of exogenous RLN on RBF and GFR has been undertaken in 
normal and pregnant rats.  Acute i.v. bolus RLN rapidly augments RBF in 16 week CCl4 rats without 
affecting the MAP, suggesting its role as a selective renal vasodilator (Fig 5.3 and 5.4). Current 
pharmacological therapy for HRS in humans consists of an indirect treatment with 
systemic/splanchnic vasoconstrictors that have been shown to improve renal function in 40-50% of 
patients but have side effects related to their vasoconstrictor properties.  Using a selective vasodilator 
to target the vasoconstricted renal circulation makes sense therapeutically, but the concern with the 
use of vasodilators has always been their systemic vasodilatory effects causing deleterious effects on 
the already labile arterial pressure that is contributing to HRS and to date none have been successful 
in clinical trials (Salmeron, Ruiz del Arbol et al. 1993).  However, here I have also shown that 
extended RLN treatment in CCl4 cirrhosis increases RBF and GFR without any effect on MAP.  
Additionally, in the BDL model where the rat is decompensated and hypotensive, no further 
deleterious effect was observed on the MAP (Fig 5.13A). Therefore, the apparently selective renal 




I have shown that acute i.v. bolus RLN augments RBF more in cirrhotic rats than in normal rats (Fig 
5.3C), with a greater increase seen from baseline in the former.  This observation could be explained 
by my previous data showing a significant increase in RXFP1 expression in the renal vasculature and 
parenchyma in both cirrhosis models.  Alternatively, it could be explained by the observation in 
hypertensive rats and humans that RLN preferentially dilates pre-constricted vessels (Debrah, 
Conrad et al. 2005; Teichman, Unemori et al. 2009).   
 
A potential criticism of any invasive in vivo animal experiment is that there are confounding factors 
related to surgery (e.g.  insensible fluid loss). To overcome this, I used two non-invasive modalities 
to monitor changes in RBF indirectly.  VTI is an USS measurement of blood flow and confirmed the 
results seen with invasive flow probes (Fig 5.5).  Measuring RI was a different way to monitor 
dynamic vascular modulation by quantifying the resistance to blood flow.  This latter parameter is a 
well-established USS measurement and has been suggested as a potential clinical marker of renal 
dysfunction/HRS.  Currently, although USS is utilised in the diagnosis of HRS by ruling out an 
obstructive or structural cause, RI is not routinely measured.  RI was reduced with RLN by 60 
minutes corresponding to the time point when the VTI and RBF were maximally increased (Fig 5.6).  
Furthermore, BOLD MRI measurement of tissue deoxygenated haemoglobin levels also indicated 
dynamic modulation of RBF with RLN treatment compared to vehicle (Fig 5.7 and 5.8). Using these 
different but complementary techniques allowed me to conclude with confidence that RLN is acting 
as a renal vasodilator.  
 
I used two distinct models of cirrhosis with reduced RBF and function to ensure that the effects seen 
with RLN were not model dependent.   I have shown that sustained (72 hour) s.c RLN infusion 
improves RBF and GFR compared to vehicle in both CCl4 and BDL cirrhosis (Fig 5.9 and 5.12). 
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The improvement in GFR is the most clinically relevant finding and probably the most important 
finding of these experiments.  The GFR in CCl4 cirrhosis was restored completely and in BDL was 
increased to 86% of sham controls.  The degree of improvement in GFR compared to that in RBF 
(CCl4: 59%, BDL 38%) is much greater and suggests, either RLN has increased the RBF enough 
beyond a threshold to substantially improve renal function, or it suggests that there may be other 
mechanisms involved in improving renal function, which I will try to address in the next chapter. 
 
This improvement in renal function is a novel finding in cirrhosis models and suggests that RLN 
could represent a promising therapy for HRS.  My experiment only assessed the effect of 72 hours of 
RLN. In normal rats the effect on RBF and GFR has been shown to be sustained for a further 12 
hours post infusion, but was fully normalised by 24 hours (Danielson and Conrad 2003).  However, 
one can only speculate whether this would be the same in cirrhotic rats. With more time it would 
have been interesting to study the effect of longer and shorter durations of therapy on RBF and GFR 
and compare pulsed intravenous therapy to a subcutaneous infusion.   However, I was trying to test 
proof of concept with the above experiments in cirrhotic rats to allow translation to cirrhotic humans, 
where the questions above could be answered more relevantly.  It has been shown in vitro  that, 
unlike most G protein coupled receptors RXFP,1 is poorly internalized and lacks the ability to recruit 
β-arrestins, so less receptor desensitization occurs with prolonged exposure suggesting no 
tachyphylaxis should occur with chronic treatment with RLN (Callander, Thomas et al. 2009). 
Additionally, to date, no neutralising antibodies have been detected to RLN in any of the recent 
clinical trials. 
 
Investigating the mechanism of action of RLN on RBF and GFR, it can be seen from my results that 
the improvement seen cannot be attributed to an improvement in liver injury as measured by serum 
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ALT (Fig 5.11A and 5.14A) or an improvement in fibrosis measured by CPA (Fig 5.11C and 
5.14C). The latter seemed unlikely given the duration of infusion was only 72 hours.  I did observe 
an improvement in albumin, which is a synthetic marker of liver function, in the CCl4 model treated 
with RLN (Fig 5.11B) which could suggest some improvement in hepatocyte function.  However, it 
was a marginal change and this was not seen in the BDL model (Fig 5.14B).  .  Furthermore, I 
witnessed in both models that portal pressure was reduced in the RLN treated rats (Fallowfield, 
Hayden et al. 2014).  Taken together, this raises the possibility that the RLN ligand-receptor axis 
could represent an integrated treatment target in chronic liver disease and leads to the question: are 
these effects on RBF and GFR purely via RLN’s direct acting renal vasodilatory effects or is the 
effect on portal pressure contributing to the improvement seen in RBF and GFR? This is a difficult 
question to answer and in the next Chapter I try to unpick the mechanism in greater detail. 
 
Summary of important findings: 
 
 Acute i.v. bolus of RLN rapidly increases RBF in cirrhotic rats without affecting the MAP  
 USS confirms rapid improvement in renal VTI and RI in response to RLN 
 BOLD MRI shows a reduction in deoxygenated haemoglobin in kidney in response to RLN 
 Sustained RLN infusion increases RBF and restores renal function in two distinct rat models of 
cirrhosis without changing the MAP 






Next steps:  
 
Having established the acute and sustained effects of RLN in vivo in models of cirrhosis I wanted to try to 
unpick its mechanism of action.  Before doing this, I wanted to use my models of cirrhosis with renal 
dysfunction to investigate the pathogenesis of renal vasoconstriction in cirrhosis.  My aim was to establish 






CHAPTER 6 - RESULTS - 
DEFINING THE PATHOGENESIS OF RENAL 






6.1 Overview of Chapter 
 
In this chapter I used the CCl4 and BDL rat models of cirrhosis to define the mechanism for renal 
vasoconstriction and renal dysfunction in experimental HRS.  To do this I used myography to 
measure changes in vascular reactivity and qPCR, Western blot, immunohistochemistry and ELISA 
to analyse changes to key vasoactive modulators.   
 
6.2 Author contributions 
 
I performed all the experiments in this Chapter with significant help initially from Dr Patrick Hadoke 
(University of Edinburgh/BHF Centre for Cardiovascular Science) to learn the techniques of vessel 




Functional renal arterial vasoconstriction is hypothesised to be the central mechanism underlying 
HRS pathophysiology (Epstein, Berk et al. 1970; Platt, Ellis et al. 1994). This vasoconstriction is 
thought to occur due to the haemodynamic consequences of cirrhosis (splanchnic and peripheral 
arterial vasodilatation) and the impairment of cardiac function (cirrhotic cardiomyopathy).  
Eventually, these lead to a reduction in effective circulating volume and subsequent compensatory 
activation of the renin-angiotensin-aldosterone system, sympathetic nervous system and increased 
activity of antidiuretic hormone (Schrier, Arroyo et al. 1988; Krag, Bendtsen et al. 2010). 
Additionally, pooling of blood in the dilated splanchnic circulation (so-called ‘splanchnic steal 
syndrome’) may also alter gut permeability and induce bacterial translocation, with the release of 
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endotoxin and various cytokines which amplify the dysregulated circulation in cirrhosis (Newby and 
Hayes 2002).  Progression of these haemodynamic alterations in cirrhosis and an intra-renal 
imbalance between vasoconstrictor and vasodilator systems, results in renal blood flow becoming 
critically dependent on arterial blood pressure, with small changes in perfusion pressure translating 
into intense renal vasoconstriction and the precipitation of HRS (Stadlbauer, Wright et al. 2008).  
 
At a cellular level in the cirrhotic liver, liver sinusoidal endothelial cells (LSECs) appear to play an 
important role in contributing to the dynamic component of raised intrahepatic vascular resistance.  It 
has been shown that LSECs in cirrhosis display an abnormal phenotype.  Central to this abnormal 
phenotype is an imbalance in the liver with increased production of vasoconstrictors (e.g. endothelin-
1) and reduced release of endogenous vasodilators (mainly NO) (Bhathal and Grossman 1985; de 
Franchis 2000; Iwakiri and Groszmann 2007).  Pivotal to this increase in intrahepatic vascular tone is 
the endothelial nitric oxide synthase (eNOS)/ NO pathway.  Previous work has suggested that either 
decreased expression of eNOS protein, decreased phosphorylation of eNOS by the serine-threonine 
kinase AKT, the presence of inhibitory substances (e.g. asymmetric dimethylarginine, ADMA) or 
hyporesponsiveness to NO may underlie this intrahepatic liver sinusoidal endothelial dysfunction 
(Rockey and Chung 1998; Laleman, Omasta et al. 2005; Iwakiri 2011). In contrast, extra-hepatic 
endothelial cells have the opposite phenotype, producing excessive NO which contributes to 
increased portal blood flow and splanchnic pooling.  Further work has explored receptor expression 
changes in the liver and portal vein in cirrhosis.   It has been shown that the relative expression of the 
Endothelin Type A (ETA) receptor in the portal vein (Ling, Kuc et al. 2012), urotensin 2 receptor 
(Liu, Chen et al. 2010) and angiotensin 2 receptor (Grace, Herath et al. 2012) in the liver are all 
upregulated in cirrhosis contributing to the increased vasoconstrictor activity and subsequent 




Despite growing evidence about intrahepatic endothelial dysfunction, the key cellular players and 
receptors involved in HRS development remain to be fully elucidated. The difficulty and limiting 
step in achieving this is a lack of access to the human ‘HRS’ kidney vasculature. Therefore, for the 
following body of work I have used my models of cirrhosis and their clear renal phenotypes to try to 




 To assess renal vascular reactivity in normal and cirrhotic rats 





6.5 A failure of endothelium-dependent vasorelaxation underlies the impaired renal blood flow 
in both rat cirrhosis models  
 
Extra-renal arteries and intra-renal arteries (segmental, interlobar and arcuate) and 3rd order 
mesenteric arteries were isolated from 16 week CCl4 rats and their olive oil controls and mounted on 
a wire myograph and their vascular reactivity measured.  Owing to how small the arcuate vessels 
were and subsequent problems with getting them onto the wire, I continued analysis without the 
latter group.  See Table 6.1 for summary of vessel characteristics. To compare vessel 
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responsiveness, I compared the concentration response curves (CRC) using 2-way ANOVA to 
ascertain the effect of cirrhosis and dose on vascular response. Additionally I analysed other 
parameters of vascular reactivity: sensitivity (-logIC50 or -logEC50: the concentration of vasodilator or 
vasoconstrictor, respectively, needed to produce a 50% response) and maximal vaso-
dilation/constriction (Emax).  Renal arteries from 16 week CCl4 cirrhotic rats showed a markedly 





compared to arteries isolated from control rats (Fig 6.1A; p<0.001), with a reduced sensitivity and 
reduced maximal dilatation (Emax).  This marked attenuation in response to ACh was also seen in 
the intra-renal segmental and interlobar arteries (Fig 6.1B-C).  With the vasoconstrictor 
phenylephrine (PE; 10-9 to 10-5M) the CRCs were not significantly different, however the intra-renal 
segmental artery from the CCl4 rats had higher –logEC50 suggesting less sensitivity to PE (Table 
6.1). The Emax was not different.  There was no difference in CRC, sensitivity or Emax in response 
to the endothelium-independent vasodilator sodium nitroprusside (SNP; 10-9 to 10-5M) (Fig. 6.2A-F). 
The mesenteric arteries showed no difference in CRCs, sensitivity or Emax to ACh or SNP but did 
show greater sensitivity to PE, with an enhanced CRC though Emax were the same between cirrhosis 




  RA RA Segmental Segmental Interlobar Interlobar MA MA 
  CCl4 OO CCl4 OO CCl4 OO CCl4 OO 
 Number 8 10 11 11 7 5 8 10 
PE -logEC50 5.97±0.1 
 
6.33±0.08 6.15±0.07** 6.37±0.03 6.29±0.06 6.31±0.19 6.19±0.04* 6.01±0.04 

















5.56 ± 0.71 3.77 ± 0.59 3.73 ± 0.79 3.35 ± 0.79 3.05 ± 1.90 1.21 ± 0.39 4.49±0.98 6.79±1.42 
ACH -log Ic50 6.42±0.14** 6.88±0.11 6.31±0.12* 7.12±0.17 6.56±0.19* 7.23±0.21 7.37±0.19 7.34±0.07 





SNP -log Ic50 7.31±0.09 7.13±0.05 7.36±0.06 7.314±0.11 7.42±0.08 7.54±0.18 7.99±0.13 7.93±0.13 













Table 6.1 The Effect of CCl4 Cirrhosis on Vascular Reactivity 
 
The extra- renal artery (RA) and intra-renal segmental, interlobar and 3
rd
 order mesenteric arteries were isolated from 16 week CCl4 rats and 
their olive oil (OO) controls. Viability was measured with response to KPSS and responses to vasoconstrictor (PE), endothelium-dependent 
vasodilator (ACh) and endothelium-independent vasodilator (SNP) were measured. Parameters included sensitivity (-logIC50 or -logEC50:  
measured the concentration of vasodilator or vasoconstrictor, respectively, needed to produce a 50% response) and maximal vaso-
dilation/constriction (Emax).  For PE the Emax was measured relative to % contraction with KPSS and with the vasodilators measured relative 






Figure 6.1 Concentration Response Curves to ACh in Renal Arteries 
from 16 week CCl4 rats and Olive Oil Controls 
Renal arteries (A) extra-renal, (B) intra-renal segmental and (C) intra-renal interlobar were isolated 
from 16 week CCl4 cirrhotic rats and olive oil controls, pre-constricted with phenylephedrine and 




M). Data expressed as % 
contraction, relative to pre-constriction with PE, analysed by 2-way ANOVA with post-hoc 











Figure 6. 2 Concentration Response Curves to PE and SNP in Renal 
Arteries from 16 week CCl4 rats and Olive Oil Controls 
Renal arteries (A, D) extra-renal, (B, E) intra-renal segmental and (C, F) intra-renal interlobar were 
isolated from 16 week CCl4 cirrhotic rats and olive oil controls, exposed to increasing doses of the 
vasoconstrictor phenylephedrine (PE; 10-9 to 10-5M A-C). Data expressed as % contraction relative 
to KPSS (Potassium rich physiological salt solution). After pre-constriction with PE, arteries were 





M; D-E). Data expressed as % contraction, relative to pre-constriction with PE and 
analysed by 2-way ANOVA with post-hoc Bonferroni test comparing individual concentrations. 










Figure 6.3 Concentration Response Curves in Mesenteric arteries from 
16 week CCl4 and Olive Oil Control rats 
3
rd
 order mesenteric arteries were isolated from 16 week CCl4 cirrhotic rats and olive oil controls and 
after pre-constriction with PE, were exposed to increasing doses of  the endothelium-dependent 




M; A), sodium nitroprusside – an endothelium-




M; C). Data expressed  as % contraction, relative to pre-
constriction with PE. (B) Mesenteric arteries were also exposed to increasing doses of the 
vasoconstrictor phenylephedrine (PE; 10-9 to 10-5M; B). Data expressed  as % contraction relative to 
KPSS and analysed by 2-way ANOVA with post-hoc Bonferroni test comparing individual 
concentrations. *p<0.05 **p<0.01 ***p<0.001. 
 
To demonstrate that this was not a model dependent observation, I recreated the same experiment in 
28 day BDL rats (n=6) and compared them to sham operated controls (n=8). Again, throughout the 





M), with reduced sensitivity throughout (Table 6.2) and a reduced 
Emax in the segmental artery compared to arteries isolated from control rats (Fig 6.4A-C).  There 





M) in the extra-renal artery or interlobar artery.  However, the segmental artery from 
28 day BDL rats was more responsive to PE, with a higher Emax but no difference in the –logEC50.   
Finally, there was no difference in CRC, sensitivity or Emax to the endothelium-independent 




M) in the extra-renal artery or interlobar, however 
although the CRC was no different to shams, the segmental artery from 28 day BDL was less 
sensitive to SNP with a higher –logIC50 (Fig. 6.5A-E). The mesenteric arteries showed no difference 
in the CRC, sensitivity or Emax to Ach (Fig.6.6A), PE (Fig.6.6B) though mesenteric arteries from 
BDL rats showed reduced response and a higher –logIC50  to SNP compared to sham controls 
(Fig.6.6C),  
 
  RA RA Seg Seg IL IL MA MA 
  BDL Sham BDL Sham BDL Sham BDL Sham 
 Number 6 7 6 7 5 7 4 4 
PE -logEC50 6.26±0.12 6.14±0.09 6.30±0.09 6.28±0.06 6.19±0.23 6.43±0.11 
6.32 ± 0.11 6.16 ± 0.07 
 Emax  
(%KPSS) 
124.9 ± 4.56  124.5 ± 6.52 137.6 ± 6.74 
** 
112.7 ± 2.67 120.0 ± 
22.14 




ACH -log Ic50 6.29 ± 
0.12*** 
6.52±0.05 6.4 ± 0.24* 7.28±0.19 6.56 ± 0.53* 7.09±0.19 7.62 ± 1.13 7.78 ±0.28 












SNP -log Ic50 7.07±0.06 7.69±0.71 7.17±0.06**
* 
7.83±0.21 7.59±0.23 7.78±0.14 7.57 ± 0.15 8.7 ± 0.18 








Table 6.2 The Effect of BDL Cirrhosis on Vascular Reactivity 
 The extra- renal artery (RA) and intra-renal segmental, interlobar and 3
rd
 order mesenteric arteries were isolated from 28 day rats and their sham 
controls. Vessels viability was assessed by response to KPSS and then responses to a vasoconstrictor (PE), endothelium-dependent vasodilator 
(ACh) and endothelium-independent vasodilator (SNP) were measured. Parameters included sensitivity (-logIC50 or -logEC50:  measured the 
concentration of vasodilator or vasoconstrictor, respectively, needed to produce a 50% response) and maximal vaso-dilation/constriction (Emax).  
For PE the Emax was measured relative to % contraction with KPSS and with the vasodilators measured relative to % preconstruction with PE. 
Data expressed as mean±SEM, analysed by Students t test, *p<0.05 **p<0.01 ***p<0.001. Significant values in bold.
 
 
It can be seen from these results that the predominant feature that was observed specifically in the 








Figure 6.4 Concentration Response Curves to ACh in Renal Arteries 
from 28 day BDL and Sham Controls 
Renal arteries (A) extra-renal, (B) intra-renal segmental and (C) intra-renal interlobar were isolated 
from 28 day BDL rats and sham controls, pre-constricted with phenylephedrine and exposed to 




M). Data expressed as % contraction, relative to 
pre-constriction with PE and analysed by 2-way ANOVA with post-hoc Bonferroni test comparing 












Figure 6.5 Concentration Response Curves to PE and SNP in Renal 
Arteries from 28 Day BDL rats and Sham Operated Controls 
Renal arteries (A, D) extra-renal, (B, E) intra-renal segmental and (C, F) intra-renal interlobar were 
isolated from 28 day BDL cirrhotic rats and sham controls, exposed to increasing doses of the 
vasoconstrictor phenylephedrine (PE; 10-9 to 10-5M A-C). Data expressed  as % contraction relative 
to KPSS (Potassium rich physiological salt solution). After pre-constriction with PE, arteries were 





M; D-E). Data expressed as % contraction, relative to pre-constriction with PE and 
analysed by 2-way ANOVA with post-hoc Bonferroni test comparing individual concentrations. 











Figure 6.6 Concentration Response Curves in Mesenteric arteries from 
28 day BDL Rats and Sham Controls 
3
rd
 order mesenteric arteries were isolated from 28 day BDL cirrhotic rats and sham controls and 
after pre-constriction with PE, were exposed to increasing doses of  the endothelium-dependent 




M; A), sodium nitroprusside – an endothelium-




M; C). Data expressed as % contraction, relative to pre-
constriction with PE. (B) Mesenteric arteries were also exposed to increasing doses of the 
vasoconstrictor phenylephedrine (PE; 10-9 to 10-5M; B). Data expressed as % contraction relative to 
KPSS and analysed by 2-way ANOVA with post-hoc Bonferroni test comparing individual 




6.6 Nitric oxide synthase is critical to endothelium-dependent renal arterial vasodilation in 
normal and cirrhotic rats 
 
Having observed that endothelium-dependent vasodilatation is impaired in both models of cirrhosis, I 
needed to establish the mechanism. In order to do this, I firstly needed to delineate the pathway(s) 
responsible for normal renal arterial endothelium-dependent function.  I used isolated extra-renal 
renal arteries from normal (uninjured) rats (n=6) and pre-treated them for 45 minutes with inhibitors 
of the major pathways known to be responsible for endothelium-dependent vasodilatation in different 
vascular beds. Vessels were exposed to the nitric oxide synthase (NOS) inhibitor L-NAME (1x10
-4
 
M), the cyclo-oxygenase (COX) inhibitor indomethacin (1x10
-5
M) and the endothelium-derived 
hyperpolarisation factor (EDHF) inhibitors apamin (1x10
-4
 M) and charybdotoxin (1x10
-5
M) before 
stimulation with ACh and SNP.  Apamin and charybdoxin have been shown to inhibit calcium-
activated potassium channels, selectively inhibiting the smooth muscle response to EDHF (Quinard 
et al., 2000). From the literature, the relative contribution of different pathways varies between 
different arteries.  In normal uninjured renal arteries endothelium-dependent vasodilation was 
abrogated by L-NAME pre-treatment and blunted by EDHF inhibitors (Fig 6.7A), whereas COX 
inhibition had no effect.  
 
I repeated this experiment with extra-renal arteries from 16 week CCl4 (n=6) cirrhotic rats.   The 
vasodilatory response to ACh was completely abolished by L-NAME (Fig 6.7B). Pre-treatment with 
EDHF inhibitors alone appeared to have a more modest effect on ACh-mediated vasodilation in 16 
week CCl4 rats compared to normal uninjured rats.  In contrast, COX inhibition enhanced 








Figure 6.7 Ach Concentration Response Curves in Normal Uninjured 
Controls and 16 week CCl4 cirrhotic rats with inhibitors of NOS, COX 
and EDHF 
Extra-renal renal arteries from control rats (A) and 16 week CCl4 rats (B) were treated with L-
NAME (1x10-4M) to block NOS, indomethacin (1x10-5M) to block COX, and apamin (1x10-4M) 





M). Data expressed as % contraction, relative to pre-constriction with PE analysed by 2-way 
ANOVA with post-hoc Bonferroni test comparing individual concentrations. *p<0.05 **p<0.01 
***p<0.001. 
 
To show the selectivity for these inhibitors to the endothelium, in each of the above experiments 
using the same rings, I created a CRC with SNP in the presence of these inhibitors. In Fig 6.8A-B it 
can be seen that L-NAME and Indomethacin had no effect on endothelium independent vasodilation, 
suggesting the selectivity of their effects to endothelium dependent function. However Apamin and 
Charybdotoxin abrogated, more in normal than cirrhotic renal arteries, the smooth muscle response 
to SNP.   As the initial abnormality between control and cirrhotic renal arteries, from both models, 
appeared to be response to endothelium-dependent vasodilators and the purpose of this experiment 
was to delineate the mechanism by which renal arteries endothelium dependent vasodilation was 









Figure 6.8 SNP Concentration Response Curves in Normal Uninjured 
Controls and 16 week CCl4 cirrhotic rats with inhibitors of NOS, COX 
and EDHF 
Extra-renal renal arteries from control rats (A) and 16 week CCl4 rats (B) were treated with L-
NAME (1x10
-4
M) to block NOS, indomethacin (1x10
-5










M). Data expressed as % contraction, relative to pre-constriction with PE analysed by 2-way 
ANOVA with post-hoc Bonferroni test comparing individual concentrations. *p<0.05 **p<0.01 
***p<0.001. 
 
Overall, these findings suggested that renal arteries, from both normal and cirrhotic CCl4 rats, 
predominantly required NOS to mediate endothelium-dependent relaxation, though there is a definite 
contribution from EDHF.  The relative contributions cannot be delineated from this experiment as I 
would have needed to repeat this experiment but with multiple inhibitors together. 
 
6.7 NOS activity is reduced in the kidneys of cirrhotic rats 
 
As NOS appears critical for renal endothelium-dependent vasodilatation and there is a marked 
abnormality in endothelium-dependent vasodilatation in renal arteries from the cirrhotic rats, I 
decided to initially focus my attention on the NOS pathway. Using protein extracted from whole 
kidney from cirrhotic rats versus their respective controls (n=4/per group) I performed Western 
blotting and densitometry analysis to quantify the levels of phosphorylated eNOS. In CCl4 kidneys 
there was a trend to reduction in p-eNOS (Fig 6.9A-B), though this did not reach statistical 
significance, whereas in BDL kidneys there was a definite reduction (Fig 6.9C-D).  Given Western 
blotting only determines protein expression levels, I went on to quantify NOS activity in whole 
kidney extracts from control and cirrhotic rats (n=6-8 per group).  It should be noted that this assay 
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measured whole NOS activity.  Although the predominant isoform measured will be eNOS there 
may be some contribution from iNOS.  NOS activity was markedly reduced in CCl4 kidneys (Fig 
6.10A) relative to controls (p<0.05) and in BDL kidneys (Fig 6.10B) there was a consistent trend to 
reduction in NOS activity relative to sham controls, although this was not statistically significant 








Figure 6.9 Phosphorylated-endothelial NOS Expression in Rat Models 
of Cirrhosis 
Protein was extracted from whole kidney from both models and their respective controls 
(n=4/group). Western Blot was performed to assess expression of p-eNOS/eNOS. (A) CCl4 model 
Western Blot with (B) densitometry analysis (C) BDL model Western Blot with (D) densitometry 







Figure 6.10 NOS Activity Assay in Rat Models of Cirrhosis 
Protein was extracted from whole kidney from 16 week CCl4 and 28 day BDL kidneys and their 
respective controls (n=6-8/group). NOS activity was measured using the modified Greiss Reaction to 
measure total Nitrite produced over time in (A) CCl4 model and (B) BDL model relative to their 
controls. Data expressed as mean % activity ±SEM relative to mean activity of control and analysed 





Taken together, these results showed a reduction in both phosphorylated eNOS protein expression 
and NOS activity in cirrhotic rat kidneys. This may provide a major explanation for the aberrant 
vasomotor phenotype observed in cirrhotic renal vessels. 
 
6.8 Inhibitors of NOS are upregulated in the kidneys in cirrhosis 
 
To elucidate the mechanism(s) resulting in reduced kidney NOS activity and p-eNOS expression in 
cirrhosis, I studied transcriptional changes in potentially relevant genes. As an initial unbiased 
screening tool I used a Hypertension qPCR array (Qiagen) that included 96 different genes involved 
in vasodilatation and vasoconstriction.  I again used whole kidney from 16 week CCl4 cirrhotic rats 
versus controls (n=3-6/group).  All genes that had a fold regulation relative to control of ≥2 with a 
p<0.05 were considered significant. Fig 6.11A and B shows genes that were differentially regulated 
in cirrhosis.  In cirrhosis, the following key genes were upregulated: endothelin receptors ETA 
(Ednra) and ETB (Ednrb) - both key regulators of vascular tone; the arginine vasopressin receptor 1a 
(Agtr1a) - responsible for water and sodium retention; and, interestingly, key regulators of NOS 
(Arg2 (arginase II) and Cav1 (caveolin I).   Given the results above, which suggested the importance 
of functioning NOS in endothelium-dependent vasodilation, I decided to  focus on genes that were 
involved predominantly with its synthesis and receptors already implicated in the altered vascular 
tone occurring in cirrhosis, ETA and ETB.  To ensure this was not a model dependent result I 
performed qPCR for genes of interest using kidneys from 4 week BDL versus sham controls 
(n=4/group) and these showed a similar expression profile, with up-regulation of Arg2 (Fig 6.12A), 








Figure 6.11 Gene Regulation in CCl4 Model of Cirrhosis 
RNA was extracted from whole kidney from 16 week CCl4 cirrhotic and Olive oil controls, 2µg 
RNA was transcribed and the RT2 Hypertension Profile PCR Array (Qiagen) undertaken. All genes 
that had a fold regulation relative to control of equal to or of  ≥2 with a p<0.05 were considered 







Figure 6.12 Gene Regulation in BDL Model of Cirrhosis 
RNA was extracted from whole kidney from 28 day BDL cirrhotic and sham controls, 2µg RNA was 
transcribed and qPCR performed for genes of interest (A) Arginase 2, (B), Caveolin I, (C) ETA, (D) 
ETB. Data expressed as mean ± SEM relative to average expression of respective control, and 
analysed by Students t test. *p<0.05, **p<0.01. 
 
Arginase II is a mitochondrial enzyme that inhibits NOS metabolism by competing for its 
predominant substrate arginine. Without arginine, NOS is unable to produce NO.  It has increasingly 
been shown to play a role in the endothelial dysfunction seen in diabetes, obesity and hypertension 
(Johnson, Peyton et al. 2015) via competition with NOS leading to arterial vasoconstriction.  Its role 
in cirrhosis and particularly HRS has not been defined, but the increase in gene expression made it an 
interesting factor to study in more detail. Staining of kidney tissue showed its expression was 
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predominantly in the medulla and in tubular cells (Fig 6.13A).  Morphometric pixel analysis of 
kidney sections (n=5/group) stained for arginase II, confirmed increased expression in cirrhosis (Fig 
6.13B).  To confirm this I went on to perform Western blot analysis of arginase II in whole kidney of 
both cirrhosis models versus their respective controls (n=4/group). The results from Western blot 









Figure 6.13 Effect of Cirrhosis on Kidney Arginase II Expression 
 
(A)Arginase II staining in kidney sections from olive oil and 16 week CCl4 rats (representative 
images). (B) Quantification of Arginase staining (n=5/group) by morphometric pixel analysis. Data 
expressed as mean % stained per section ±SEM. (C)Western Blot and densitometry for Arginase II 
of protein extracted from whole kidney from olive oil and 16 week CCl4 (n=4/group). (D) Western 
Blot and densitometry for Arginase II of protein extracted from whole kidney from sham and 28 day 
BDL (n=4/group). Data expressed relative to GAPDH as mean±SEM, and analysed by Students t 
test. **p<0.01. 
 
Caveolin I is a scaffolding protein that is thought to bind eNOS and in the bound form it is inactive 
(Minshall, Sessa et al. 2003). Therefore one could hypothesize that increasing amounts of Caveolin I 
may limit eNOS activity in these models.  I stained for Caveolin in kidney tissue and it was 
predominantly expressed in the endothelium and smooth muscle (Fig 6.14A). Quantification of renal 
Caveolin I protein expression by Western blot and densitometry showed an increase in BDL cirrhosis 









Figure 6.14 Effect of Cirrhosis on Kidney Caveolin I Expression 
(A)Caveolin I staining in kidney sections from olive oil and 16 week CCl4 rats (representative 
images). (B)Western Blot and densitometry for Arginase II of protein extracted from whole kidney 
from olive oil and 16 week CCl4 (n=4/group). (C) Western Blot and densitometry for Arginase II of 
protein extracted from whole kidney from sham and 28 day BDL (n=4/group). Data expressed 
relative to GAPDH, as mean±SEM, and analysed by Student’s t-test. **p<0.01. 
 
In these cirrhosis models there was up-regulation of potential inhibitors of NOS that may account, at 
least in part, for the endothelial dysfunction observed ex vivo.  I did not investigate the regulation of 
these NOS inhibitory proteins or the cellular source, but they represent an interesting focus for future 
studies.   
 
6.9 Serum TNFα is increased in rat cirrhosis models 
 
TNFα is a major pro-inflammatory cytokine that has been shown in numerous studies (Picchi, Gao et 
al. 2006; Zhang, Xu et al. 2006) to contribute to endothelial dysfunction.  I therefore decided to 
measure circulating TNFα levels in my models.  Fig 6.15A and B show increased levels of serum 
TNFα in both models, particularly in BDL.  The serum was taken from the peripheral circulation so 
represents ‘systemic’ TNFα.  At present, I have only shown an association between high circulating 
levels of TNF and endothelial dysfunction in these models, but future work could focus on a causal 






Figure 6.15 Serum TNFα level in Cirrhosis Models 
Circulating serum TNFα levels were measured from blood  taken from the femoral artery in (A) olive 
oil and CCl4 rats (5-6/group). (B) sham and 28 day BDL (4-7/group). Date expressed as mean±SEM, 









In this Chapter I investigated vascular reactivity and gene and protein expression changes in the 
kidneys of cirrhotic rats to identify potential mechanisms underlying the renal vasoconstriction 
observed in these models. The first observation, that I will term ‘endothelial dysfunction’, is that 
renal arteries from cirrhotic rats showed impairment of endothelium-dependent vasodilatation (Fig 
6.1A-C, Fig 6.4A-C) and this was seen throughout the renal artery circulation. Importantly, this did 
not appear to be a systemic phenomenon as the mesenteric arteries did not show the same 
abnormality (Fig 6.3 and 6.6).  Previous studies have used myography to assess vascular reactivity 
in cirrhosis, but this has focussed primarily on other arteries, particularly the portal vein (Hadoke and 
Hayes 1997).  These studies have highlighted that inter-species differences undoubtedly influence 
individual vascular responses.  Ideally, I would have studied vascular responses in human renal 
arteries from patients with HRS to establish whether this was a species-specific phenomenon. 
Unfortunately research into this important condition has been limited as kidneys are rarely explanted 
in patients with HRS and biopsies are not performed as part of routine clinical care. Moreover, 
biopsy tissue would not permit rings of renal artery to be tested by myography. 
 
From interrogating the pathways important for renal endothelium-dependent vasodilatation, NOS 
appears critical to vasodilatation in both normal and cirrhotic rats as blocking NOS with L-NAME 
abrogated normal renal vasodilatation.  Interestingly, prostacyclins were previously thought to be 
integral to renal arterial vasodilatation, but in both normal and cirrhotic renal arteries I observed no 
impact on endothelium-dependent vasodilatation by inhibition of this pathway. This finding is 
supported to a certain extent, by clinical data showing that no improvement in renal function was 




I have shown that p-eNOS expression and NOS activity are reduced in cirrhotic kidney (Fig. 6.9-10) 
which may account for the abnormality in endothelium dependent vasodilation seen in the renal 
arteries.  It is worth noting that these results are from whole kidney and so aren’t specific to 
endothelial cell or renal arterial expression but are inclusive of all kidney cells. The reason I took this 
approach was that the amount of tissue needed for successful protein extraction, Western blotting and 
NOS activity assay precluded the use of tiny renal artery segments.  Further to this, I have shown that 
inhibitors of NOS (arginase II, caveolin I) are increased in kidneys from cirrhotic rats and these may 
account, at least in part, for the abnormal vascular responses observed.  The results above are all 
descriptive and without in vivo experiments specifically blocking arginase II, caveolin I or TNFα and 
determining whether RBF  improves and/or there is preservation of endothelial function, I cannot 
infer the extent to which they contribute.  Additionally, as arginase II and caveolin I are abundantly 
expressed, simply blocking them could cause systemic off-target effects limiting the focus of the 
experiment.   
 
This renal endothelial dysfunction may account for the reduced RBF and vasoconstricted circulation 
seen in both the rat models and in human HRS. One could hypothesise that a reduced ability to 
respond to endothelial vasodilators leads to an increasingly unopposed response to circulating 
vasoconstrictors, which have been shown to be circulating in abundance in cirrhosis (Ring-Larsen, 
Hesse et al. 1982; Schrier, Arroyo et al. 1988). Additionally, I have shown increased transcript levels 
of the ETA and ETB receptor in both models.  Both receptors are expressed on smooth muscle cells, 
with the ETB receptor also being expressed on the endothelium.  The former, on activation with 
endothelin, induces vasoconstriction, whilst the latter also induces vasodilation. It has been shown 
that in the liver parenchyma in cirrhosis there is a shift to increased ETB expression, and in the portal 
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vein a down-regulation of ETB relative to ETA in the smooth muscle (Ling, Kuc et al. 2012). One 
could postulate that the hepatic parenchymal and portal vein receptor expression changes in cirrhosis 
represent a ‘protective mechanism’ to try to reduce the raised intravascular resistance by increasing 
vasodilation in the liver and reducing inflow via the portal vein.  Further implicating the ETA and 
ETB receptors in the pathogenesis of endothelial dysfunction is a recent study investigating 
endothelial function in patients with type 2 diabetes and coronary artery disease, which found that 
selective ETA and combined ETA/ETB blockade improved endothelium-dependent forearm 
vasodilation (Rafnsson, Shemyakin et al. 2014).   
 
The abnormalities defined in the results above, in renal endothelial function, are very similar to that 
which has been proposed in the hepatic sinusoidal endothelial cells (Rockey and Chung 1998). 
Although I have shown a potential role for NOS in the evolution of this endothelial dysfunction and 
subsequent renal vasoconstriction, the underlying mechanisms require further study. In addition to 
NOS dysregulation, the relative balance of vasoconstrictor/vasodilator receptor expression, the 
sympathetic nervous system, and other circulating cytokines will also play important roles. This 
needs further delineation. Improved understanding of the major contributors to this endothelial 









Summary of important findings: 
 
 Endothelium-dependent vasodilation was blunted in the extra and intra renal arteries from 
two distinct models of cirrhosis characterized by renal vasoconstriction and renal dysfunction 
 Ex vivo normal and cirrhotic renal arteries required NOS to respond to endothelium-
dependent vasodilators 
 In kidneys from both cirrhosis models p-eNOS expression and NOS activity were reduced  
 The expression of  negative regulators of NOS (Arginase II and Caveolin I) was increased in 
the kidneys of cirrhotic rats 




In Chapter 5 I showed that both acute and sustained RLN treatment improved RBF and GFR.  In 
this Chapter I have shown that renal arteries from cirrhotic rats exhibit abnormal endothelium-
dependent vasodilatation and that this ‘endothelial dysfunction’ may be partially explained by 
changes in NOS activity due to increased expression of negative regulator proteins. I next wanted to 







CHAPTER 7 – DEFINING  THE MECHANISM OF 






























In this Chapter I used the CCl4 and BDL models of cirrhosis and used myography to measure 
changes in vascular reactivity and qPCR, Western blot and ELISA to analyse changes to key 
vasoactive modulators to establish how RLN mediates the in vivo haemodynamic effects reported in 
Chapter 5.   
 
7.2 Author contributions 
 




As covered in detail in the Introduction, all mechanistic work with RLN to date has been in 
undertaken in pregnant or normal rats and in humans with cardiac failure.  A consistent feature in 
these studies was the observation that RLN increases RBF, which I have also shown in cirrhotic rats 
with renal dysfunction.  
 
The vasoactive effects of RLN are mediated through a number of downstream mechanisms including 
a reduction in myogenic reactivity of vessels, enhanced nitric oxide (NO) signaling and antagonism 
of vasoconstrictors such as angiotensin-II (Danielson, Kercher et al. 2000; Novak, Ramirez et al. 
2002; McGuane, Debrah et al. 2011).  Through inhibitory in vivo and in vitro experiments, pivotal 
factors have been identified in mediating the  sustained vasodilatory effects of RLN including NOS 
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(Danielson, Sherwood et al. 1999), endothelial ETB receptor (Danielson, Kercher et al. 2000), arterial 
gelatinases (MMP2, MMP9) (Jeyabalan, Novak et al. 2003), and vascular endothelial growth factor 
(VEGF) (McGuane, Danielson et al. 2011).  Rapid vasodilatory effects of RLN have been shown to 
be mediated through Gαi/o protein coupling to Pi3K, Akt and endothelial NOS, but not via VEGF 
(Fisher, MacLean et al. 2002).  
 
I wanted to establish in my rat models, in which I had shown robust renal haemodynamic changes in 
response to RLN, whether the mechanisms mediating its beneficial effects were consistent with 




 To assess the effects of H2-RLN on renal vascular reactivity 




7.4 Isolated renal arteries from cirrhotic rats show no acute vasodilation response to RLN ex 
vivo 
 
In Chapter 5, I showed that RLN rapidly increased RBF in vivo. To elucidate the underlying 
mechanism, I took the isolated renal arteries from both control uninjured and 16 week CCl4 cirrhotic 
rats and after checking viability with KPSS, and endothelial function with ACh I then pre-constricted 







M) and observed the degree to which they vasodilated.  The dose range was based on 
previously published work using RLN and wire myography where acute vasodilation was 
demonstrated in gluteal arteries (Fisher, MacLean et al. 2002).  Interestingly, I observed no acute 
vasodilation response to RLN ex vivo in arteries from either control or cirrhotic rats (CCl4 and BDL), 
even with an extended dose range in the latter (Fig 7.1A-D).  There are several reasons why this may 
be the case. Firstly, although the above study showed vasodilation, it was not performed in renal 
arteries.  Furthermore, previous studies showing acute RLN induced vasodilation in small rat renal 
arteries ex vivo used manometry rather than wire myography (McGuane, Debrah et al. 2011) and 
measured the % change in diameter, which is more sensitive than change in pressure.  Finally, 
isolating the artery per se may have destroyed potentially important cell-to-cell interactions. 
 
To establish that this was not just an experimental artefact I needed a positive control. It has been 
shown previously by wire myography that RLN induced vasodilation ex vivo in the uterine artery 
from pregnant rats (Longo, Jain et al. 2003).  I repeated the above experiment with vascular rings 
obtained from 2 pregnant rats and saw no response (data not shown).  Additionally, I modified the 
degree of vessel pre-constriction (reduced to EC50) and still saw no response to RLN.  In all of the 
above experiments the arteries were viable and responded predictably to ACh and SNP, albeit that 








Figure 7.1 Relaxin Concentration Response Curves in Renal Arteries 
from Normal, Olive Oil, 28 Day BDL and 16 Week CCl4 
Renal arteries extra-renal, intra-renal segmental and intra-renal interlobar were isolated from Normal 
(A), Olive Oil (B), 28 day BDL (C) and 16 week CCl4 (D) rats. After pre-constriction with PE, 




M).  Data expressed as mean % 








7.5 Renal arteries isolated from 72 hour RLN treated cirrhotic rats showed restoration of 
normal endothelium-dependent vasodilation 
 
Having seen no effects by myography in renal arteries isolated from cirrhotic rats treated ex vivo with 
RLN, I reviewed the literature and decided to change my approach.  I had shown in vivo that 72 
hours of s.c. RLN improved RBF and GFR (Chapter 5) and, additionally, that both cirrhosis models 
exhibited an impairment of endothelium-dependent vasodilatation (Chapter 6).  In a model of TNFα 
induced endothelial dysfunction RLN fully restored endothelial function (Dschietzig, Brecht et al. 
2012). I hypothesised that the in vivo renal haemodynamic effects induced by RLN in rat cirrhosis 
models could be, at least in part, due to correction of underlying endothelial dysfunction.  I harvested 
extra renal and segmental renal arteries from 16 week CCl4 rats that had been treated for 72 hours 
with  s.c RLN or vehicle (n=6-7/group) and assessed their vascular functional responses by wire 
myography.  Vessels from RLN treated rats showed restoration of the endothelium-dependent 
response to ACh in the extra-renal renal arteries with increased sensitivity to ACh (-log Ec50 :  RLN 
6.86±0.08 vs vehicle 6.51±0.11; p=0.032), restoring the arteries to similar values of olive oil controls 
(Table 6.1).  No such response was seen in vessels from vehicle treated rats (Fig 7.2A).  
Interestingly this response to RLN was not seen to the same degree in the segmental arteries (Fig 
7.2B) and the -log Ec50 was also not different.  Furthermore, RLN treatment did not alter 
endothelium-independent vasodilation or vasoconstriction responses in corresponding renal vessels 
(Fig 7.3A-D). This result suggests that RLN specifically augments endothelium-dependent 
vasodilatation in the extra-renal artery.  However, there are clearly subtle differences in the extra- 











Figure 7.2 ACh Concentration Response Curves after 72 hours of in 
vivo Relaxin 
Extra renal (A) and intra-renal segmental (B) arteries were harvested from 16 week CCl4 rats that had been 
treated for 72 hours with s.c RLN or vehicle (n=6-7/group). After pre-constriction with PE, arteries 




M .  Data expressed as mean % contraction ± 
SEM, relative to pre-constriction with PE. All analysed by 2-way ANOVA with post-hoc Bonferroni 









Figure 7.3 PE and SNP Concentration Response Curves after 72 hours 
of in vivo Relaxin 
Extra renal (A-B) and intra-renal segmental arteries  (C-D) were harvested from 16 week CCl4 rats that had 
been treated for 72 hours with s.c RLN or vehicle (n=6-7/group). (A,C) vessels were exposed to 
increasing doses of the vasoconstrictor phenylephedrine (PE; 10-9 to 10-5M; ). Data expressed as % 
contraction relative to KPSS.  (B, D) After pre-constriction with PE, arteries were exposed to 




M .  Data expressed as mean % contraction ± SEM, relative to 
pre-constriction with PE.  All analysed by 2-way ANOVA with post-hoc Bonferroni test comparing 






7.6 RLN induces renal arterial vasodilation through activation of the AKT/eNOS/NO signaling 
pathway 
 
The results from Western blotting and NOS activity assay in cirrhotic rat kidneys indicated that a 
reduction in activated p-eNOS and NOS activity could account for the endothelial dysfunction seen 
with myography. Given that RLN appeared to restore a normal endothelial phenotype in the renal 
artery, I went on to explore this further.  I firstly used Western blotting to quantify changes in whole 
kidney protein expression, focusing on the AKT/eNOS/NO signaling pathway, given my earlier 
observations on perturbation of this axis in cirrhosis.  In both cirrhosis models, I showed increased 
levels of p-eNOS and p-AKT in kidney after 72hrs RLN treatment compared with vehicle (Fig. 
7.4A-D). Repeating the NOS assay performed above, in both CCl4 and BDL kidneys treated with 72 
hrs of RLN, there was a marked increase in NOS activity compared with vehicle, such that near-
normal levels were restored (CCl4: RLN 122±31% vs. vehicle 5±3%, p<0.01; BDL: RLN, 86±22% 










Figure 7. 4 Effect of 72 Hours of Relaxin in vivo on Renal 
AKT/eNOS/NO Signalling Pathway 
Quantification of eNOS, p-eNOS, AKT and p-AKT protein by Western blotting and densitometry in 
whole kidney extracts from 72hr relaxin or vehicle treated CCl4 (A, C) and BDL (B, D) rats 
(n=4/group). Data expressed as mean±SEM, analysed by two-tailed unpaired Student’s t-test; *p<0.5 






Figure 7. 5 Effect of 72 Hours of Relaxin in vivo on Renal NOS Activity 
NOS activity in whole kidney extracts from cirrhotic rats after 72 hrs relaxin or vehicle treatment 
(n=6-8/group). Bars represent mean±SEM relative to respective controls, analysed by two-tailed 
unpaired Student’s t-test; *p<0.5 **p<0.01 ***p<0.001. 
 
To confirm NOS dependency in RLN mediated renal vasodilation, I repeated the 72hr RLN in vivo 
analyses in subgroups of CCl4 cirrhotic rats (n=4-8/group) co-treated with L-NAME (250mg/L p.o.).  
L-NAME abrogated the effects of RLN treatment on RBF (RLN 3.8±0.3 mL/min vs. RLN+L-
NAME 2.5±0.3 mL/min, p<0.01; Fig. 7.6A) and GFR (RLN 2.9±0.3 mL/min vs. RLN+L-NAME 
1.8±0.1 mL/min, p<0.05; Fig. 7.6B). In contrast, L-NAME had no significant effects on RBF or 
GFR in vehicle treated rats.  In all rats treated with L-NAME I observed an increase in MAP (Fig. 
7.6C). For this experiment I confirmed inhibition of eNOS expression and activity at the level of the 







Figure 7. 6 Effect of NOS Inhibition on Relaxin in vivo Haemodynamic 
Effects 
Subgroups of 16 week CCl4 cirrhotic rats were co-treated with L-NAME with RLN or vehicle for 72 
hours and effects on RBF (A) and GFR (B) measured by perivascular flow probe and inulin 
clearance, respectively (n=4-8/group). MAP was measured via a femoral arterial line (C). Data 
expressed as individual rats with mean±SEM, analysed by one-way ANOVA with post-hoc 







Figure 7.7 Effect of L-NAME Administration on eNOS Expression and 
NOS Activity in 16 week CCl4 Rat Kidneys 
Subgroups of 16 week CCl4 rats randomized to 72 hr s.c. relaxin or vehicle were co-treated with L-
NAME. (A) eNOS protein expression (relative to GAPDH loading control) evaluated by Western 
blotting and quantified by densitometry in whole kidney extracts from 16 week CCl4 rats treated with 
serelaxin±L-NAME, and (B) vehicle±L-NAME (n=4/group). Data expressed as mean±SEM, 
analysed by two-tailed unpaired Student’s t-test; *p<0.05, ***p<0.001. (C) Nitric oxide synthase 
(NOS) activity in corresponding whole kidney extracts (n=4-8/group). Data expressed as 





7.7 Relaxin downregulates key vasoconstrictor receptors in kidney 
 
Having observed that key inhibitors of eNOS were upregulated at both the gene and protein level in 
both cirrhosis models (Chapter 6), I wanted to establish if RLN was mediating effects on NOS 
activity by inhibiting these pathways. As an unbiased initial approach I repeated the Hypertension 
qPCR array (Qiagen).  Again I used whole kidney from 16 week CCl4 rats (n=5/group) treated with 
RLN or vehicle (72hrs), extracted RNA and performed the Hypertension array. Genes that had a fold 
regulation of over 2 or less than -2 with a significance of <0.5 were included.  Fig 7.8 shows the 
genes that were differentially regulated by RLN.  In the kidney from 16 week CCl4 treated rats, RLN 
down-regulated expression of the ETA receptor, which I had previously shown to be increased in 
both cirrhosis models (Chapter 6).   Activation of ETA by endothelin I increases vascular tone 
(Davenport, Kuc et al. 1995).  Additionally, RLN down-regulated expression of the urotensin 2 
receptor and urotensin 2 itself.  Urotensin is a potent vasoconstrictor of large conductive vessels, but 
paradoxically it has also been shown to relax mesenteric vessels.  In the liver, urotensin and its 
receptor localize to endothelial cells, bile ducts and Kupffer cells (Leifeld, Clemens et al. 2010).  
Urotensin levels have been shown to increase in cirrhosis (Pawar, Kemp et al. 2011) and urotensin 
inhibition appears to reduce fibrosis in rats (Liu, Wang et al. 2009). Furthermore, inhibition of 
urotensin in rats reduced portal pressure, increased renal blood flow and sodium and water excretion 
in BDL rats (Trebicka, Leifeld et al. 2008). Finally, RLN also down-regulated expression of the 
arginine vasopressin receptor 1b (AVR1b).  In cirrhosis, due to peripheral vasodilatation and a 
perceived low volume state, there is increased circulating antidiuretic hormone (ADH) which binds 
to AVR1b inducing reabsorption of water from the collecting ducts, with associated sodium retention 
from activation of the RAA and SNS.  Inhibition of ADH with Vaptans has been shown to improve 
ascites in cirrhosis by inhibiting ADH induced reabsorption in the renal collecting ducts, thereby 
increasing electrolyte free urine excretion (Gines, Wong et al. 2010).  RLN had no significant effect 
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on Arginase II or Caveolin I gene transcription and quantification of IHC staining also showed no 
difference (data not shown). 
 
 
Figure 7.8 Effect of 72 Hours of Relaxin on Kidney Gene Regulation 
RNA was extracted from whole kidney from 16 week CCl4 cirrhotic rats treated with 72hrs of RLN 
or vehicle.  2µg of RNA was transcribed and the RT2 Hypertension Profile PCR Array (Qiagen) 
undertaken. All genes that had a fold regulation relative to control of equal to or greater than 2 with a 
p<0.05 were considered significant and shown. 
 
Overall, at the mRNA level at least, RLN regulates some physiologically relevant target genes that 






7.8 Relaxin reduces serum TNFα levels 
 
As circulating TNFα levels were increased in both cirrhosis models I investigated the effect of RLN 
on TNFα levels.  Serum analyzed from 16 week CCl4 rats treated with 72 hours of s.c RLN (n= 4-
5/group) showed a reduction in TNFα compared to vehicle (Fig. 7.9A;p<0.01). I repeated this 
analysis in serum from BDL rats treated with 72 hours of s.c. RLN (n=6/group) and circulating 





Figure 7. 9 Effect of 72 Hours of Relaxin Treatment on Serum TNFα 
levels 
Circulating serum TNFα levels were measured from blood taken from the femoral artery in (A)  16 
week CCl4 rats (4-5/group), and (B) 21 day BDL (6/group) treated with 72 hrs of RLN or vehicle. 






I have shown that RLN had no vasodilatory effect ex vivo in isolated renal arteries from normal and 
cirrhotic rats (Fig. 7.1).  The possible reasons for this include, firstly, that the increase in RBF seen 
by 1 hour in vivo is due to arterial changes that take longer than a few minutes to occur.  It has been 
shown previously (Fisher, MacLean et al. 2002) that RLN can rapidly (within minutes) vasodilate 
small human systemic resistance arteries but this was not the case in pulmonary resistance arteries.  It 
may be a similar situation in renal arteries using this myography technique.  Furthermore, it may be 
that the mechanism of action of RLN on the renal circulation in cirrhosis is related to its vasodilatory 
effects in the liver (i.e. reducing portal pressure (Fallowfield, Hayden et al. 2014)), antagonism of 
angiotensin II  (Danielson, Sherwood et al. 1999; Sasser, Molnar et al. 2011), or down-regulation of 
key vasoconstrictor receptors (ETA, Urotensin 2) and that shorter time frame, absence of circulating 
factors and influence of the liver-renal axis reduces its effects to a level that simply cannot be 
detected by wire myography.  Reviewing the literature, the published DRC’s to RLN are relatively 
modest even with manometry (McGuane, Debrah et al. 2011).   
 
Further to this, having isolated renal arteries from RLN and vehicle treated 16 week CCl4 cirrhotic 
rats, I have shown that the blunted endothelium-dependent vasodilation seen in renal arteries from 
both models of cirrhosis was restored to near normal in the extra-renal renal artery, though this was 
not seen in the segmental renal artery (Fig 7.2).  My results are supported by recently published data 
also showing that endothelial dysfunction was improved in mesenteric arteries from rats treated with 
a single dose of RLN (Leo, Jelinic et al. 2014).  The mechanism of this improvement has not been 
fully delineated though it appeared to be through increased p-eNOS and improved NOS activity, as 
both were increased in rats treated with RLN compared to vehicle (Fig 7.4-5). Additionally, I have 
shown increased pAKT expression in rats treated with RLN for 72 hrs versus those treated with 
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vehicle, suggesting a role for the pAKT/eNOS/NO pathway in RLN mediated effects.  Indeed, 
mechanistic studies in normal rat renal arteries have suggested that the PI3K/pAKT/NOS axis is 
pivotal to the rapid haemodynamic effects of RLN (McGuane, Debrah et al. 2011).  I did not perform 
separate Western blots looking at differential expression of pAKT/p-eNOS after an acute i.v. bolus 
of RLN.  However, a recent study has also shown similar findings with increased p-eNOS in 
mesenteric arteries exposed to RLN (Leo, Jelinic et al. 2014), suggesting the validity of this result.  
As a proposed alternative mechanism, there is evidence that RLN reduces levels of the circulating 
NOS inhibitor asymmetric dimethylarginine (ADMA) in a rat model of angiotensin II induced 
hypertension (Sasser, Cunningham et al. 2014), which could account for the increased NOS activity 
observed in my studies.  The central importance of NOS activity in mediating the haemodynamic 
effects of RLN is indicated by the experiments using L-NAME co-treatment.  Blocking NOS in vivo 
abrogated the beneficial effects on RBF and GFR observed in RLN treated rats (Fig 7.6-7.7), 
whereas no such effect was seen in vehicle controls.  
 
Finally, serum analysed from both cirrhosis models showed reduced TNFα levels in rats treated for 
72 hrs with RLN.  The potential importance of TNFα has been discussed in Chapter 5, in particular 
the role of TNFα in causing endothelial dysfunction (Dschietzig, Brecht et al. 2012).  Additionally, it 
has been shown that reducing gut translocation of microbes with antibiotics reduces kidney TNFα 
with subsequent protection of rat BDL kidneys from further injury induced by sepsis (Shah, Dhar et 
al. 2012).  Therefore, TNF is strongly implicated in HRS development. It is therefore encouraging 
that RLN also reduces levels of TNF and defining the mechanism for this anti-inflammatory effect 




Summary of important findings 
 
 RLN treatment does not induce vasodilatation in the renal arteries of cirrhotic rats  ex vivo  
 Sustained RLN treatment in vivo restores endothelium-dependent vasodilatation in harvested 
renal arteries from cirrhotic rats 
 Sustained RLN treatment increases p-eNOS expression and NOS activity, and down-
regulates key genes associated with increased vascular tone and water retention in cirrhotic 
rats 
























In this thesis, I have established that by targeting the kidney vasculature with H2-RLN it is possible 
to improve renal vasoconstriction and impairment of renal function.  Both these features characterize 
HRS, a condition that if untreated or unresponsive to current treatment leads to death in nearly 100% 
by 3 months (Moreau, Durand et al. 2002).  I have provided a proof-of-concept using two distinct rat 
models of cirrhosis, both with profound renal vasoconstriction and reduction in GFR, that RLN 
(serelaxin) functions as a potent and selective renal vasodilator.  This appears to be through 
augmentation of intra-renal NOS signaling and restoration of endothelium-dependent vasodilation, 
both of which I have shown to be abnormal in these models.  Critical for potential translation to 
humans, RLN did not induce systemic hypotension even in the model of decompensated biliary 
cirrhosis. 
 
As discussed in detail in Chapter 1, the prevalence of cirrhosis is increasing and as a result more 
patients are presenting with complications of cirrhosis and PHT, in particular HRS.  Renal 
dysfunction/AKI occurs in approximately 20% of hospitalized patients with decompensated cirrhosis 
(Garcia-Tsao, Parikh et al. 2008), conferring a 7 fold increase in death (Fede, D'Amico et al. 2012) 
and it is often hard to differentiate the cause.  HRS occurs in 11 % of patients with cirrhosis and 
ascites (Planas, Montoliu et al. 2006) and the degree to which other causes of AKI lead to HRS is 
still relatively unclear (Belcher, Parikh et al. 2013).  Current pharmacological therapy is not targeted 
at the renal circulation but is aimed at increasing MAP and renal perfusion by increasing circulating 
volume with HAS and by reducing splanchnic vasodilatation with Terlipressin. Although this 
treatment does reverse HRS in 40-50% of patients (Nazar, Pereira et al. 2010), it does not improve 
overall survival and is importantly associated with ischaemic complications rendering it unsuitable 
for some patients. Whereas, RLN has been shown to directly induce renal vasodilatation, increasing 
the GFR in pregnant rats (Sherwood 2004), importantly this has been recapitulated using exogenous 
RLN in non-pregnant rats (Conrad 2010), healthy human volunteers (Smith, Danielson et al. 2006) 
231 
 
and more recently in acute (Teerlink, Cotter et al. 2013) and chronic heart failure studies (Dschietzig, 
Teichman et al. 2009).  Hence I sought to establish whether in cirrhosis RLN could be used as a 
targeted renal vasodilator. 
 
As renal vasoconstriction is central to the pathogenesis of HRS (Epstein, Berk et al. 1970), I needed 
to establish robust and reproducible models of cirrhosis and portal hypertension with renal 
vasoconstriction and renal dysfunction. In Chapter 3 as shown in Fig 3.1- 3.5 twice weekly i.p. CCl4 
injections induced progressive fibrosis with increased portal pressure by 8 weeks and renal 
vasoconstriction and dysfunction by 16 weeks. These rats all remained pre-ascitic and showed no 
signs of histological renal damage to account for the profound renal dysfunction observed. As the 
majority of patients with HRS have ascites, and this is now part of the diagnostic criteria for HRS 
(Angeli, Gines et al. 2015), I also sought as a means of comparison to CCl4, to evaluate the BDL 
model of decompensated biliary cirrhosis.  As shown in Fig 3.6 – 3.10 BDL produced a rapidly 
evolving biliary fibrosis, with jaundice, increased portal pressure, renal vasoconstriction and renal 
dysfunction developing by 14 days. By 28 days all rats had ascites.  As in previous studies (Shah, 
Dhar et al. 2012) there was evidence of renal ischaemia, demonstrated by histological features of 
ATN in the kidneys of BDL rats. As renal vasoconstriction in cirrhosis has been shown to be 
progressive, with reducing RBF seen well before there is a decrease in GFR (Ring-Larsen 1977), 
these two models serve to represent different stages of this process. In patients with cirrhosis, GFR 
may be maintained at normal or low/normal levels by a compensatory increase in filtration fraction 
(likely by angiotensin-II (Ang-II) induced efferent arteriole vasoconstriction) such that the effect of 
reduced RBF on GFR may be masked (Kew, Brunt et al. 1971).  Thus, it is unknown at which stage 




Having established that there was a robust renal phenotype in these models, I next investigated the 
expression and distribution of RXFP1. Levels of transcripts for the RLN receptor Rxfp1 in whole 
liver, kidney and renal artery extracts were increased in rat cirrhosis models (Fig 4.2) Moreover, in 
CCl4 cirrhotic rats RXFP1 localized to renal vascular endothelial cells, smooth muscle cells and 
pericytes (Fig 4.8-10). This is consistent with RXFP1 cellular localization data in normal rat small 
renal arteries (Jelinic, Leo et al. 2014) and in normal human kidney biopsies in the current study (Fig 
4.11). All these cells are implicated in the regulation of RBF and GFR.  The factors which regulate 
renal parenchymal and arterial expression of RXFP1 in animal models and human disease are 
unknown, although a recent in vitro study showed that 1- and 1-adrenoceptors regulated cardiac 
expression of RXFP1 in mice (Moore, Su et al. 2014). I have not delineated the differential 
expression of RXFP1 in afferent and efferent arterioles, though the in vivo results suggest that the 
former must predominant otherwise such increases in RBF and GFR would not be seen. 
 
A single acute bolus and more prolonged treatment (for 72 hours) with RLN induced a significant 
increase in RBF in vivo (Fig 5.3).  This increase in RBF occurred without a change in MAP, which is 
critical to its translational potential as cirrhotic patients normally have low MAP and therefore do not 
tolerate systemic vasodilatation.  Conversely, I have shown in CCl4 cirrhosis that administration of a 
non-selective nitro-vasodilator (SNP) induced hypotension and a reduction in RBF (Chapter 5). 
Furthermore, studies of vasodilators in cirrhosis also showed hypotension and subsequent worsening 
of RBF (Salmeron, Ruiz del Arbol et al. 1993).  In my models I did not observe an increase in 
cardiac output in response to RLN (Fig 5.15) which in addition to the above adds evidence that RLN 
acts selectively on the renal vasculature.  Interestingly, when isolated renal arteries were exposed to 
RLN ex vivo, there was no acute vasodilatory response detected using wire myography (Fig 7.1). 
This poses the question: how is RLN acting on the renal circulation in my models?  It has been 
shown, measuring myogenic reactivity, that RLN can rapidly dilate small human gluteal arteries 
233 
 
(Fisher, MacLean et al. 2002)  and rat and mouse small renal and human subcutaneous arteries 
(McGuane, Debrah et al. 2011) within minutes, however using wire myography and directly 
exposing renal arteries from cirrhotic rats to RLN I saw no rapid response (Fig 7.1). It may be that 
this is related to a difference in individual vessel responses ex vivo or that myography is less sensitive 
than myogenic reactivity, or even that direct activation of endothelial/smooth muscle RXFP1 is not 
the sole mechanism by which RLN induces vasodilatation in vivo in these models.   
 
Of central importance is the observation that RLN improved renal function in both models of 
cirrhosis (Fig 5.9 and 5.14), as this is the primary endpoint in clinical trials for AKI/HRS.   The GFR 
in CCl4 cirrhosis was restored completely and in BDL was increased to 86% of sham controls.  The 
degree of improvement in GFR compared to that in RBF (59% for CCl4 rats, 38% for BDL rats) was 
much greater.  This raises the question: why is the improvement in GFR disproportionately greater 
than that of RBF?  It has previously been shown that RBF must reach a critical threshold level after 
which renal dysfunction and worsening GFR ensues (Ring-Larsen 1977). Therefore, it could be 
hypothesised that the improvement in RBF is sufficient to restore GFR without a complete 
restoration of RBF.   
 
In trying to understand the mechanism of RLN’s beneficial haemodynamic effects I needed to 
establish which changes associated with cirrhosis were responsible for the aberrant renal phenotype 
observed in both models (Chapter 3).  Given that renal vasoconstriction was common to both 
models, I decided to evaluate renal vascular reactivity using wire myography. In both rat cirrhosis 
models extra- and intra-renal arteries exhibited marked impairment in endothelium-dependent 
vasodilation ex vivo (Figure 6.1 - 6.4), with normal vasoconstrictor and smooth muscle responses.    
I also assessed renal arteries to establish the pathways responsible for ‘normal’ endothelium-
dependent vasodilatation and found that blocking NOS with L-NAME completely abrogated 
234 
 
endothelium-dependent vasodilation, indicating its pivotal role in renal vasodilatation.  In the 
kidneys of cirrhotic rats there was a marked reduction in p-eNOS expression and in NOS activity.  
Alongside this, increased expression of negative regulators of eNOS (arginase II, caveolin 1) and 
Endothelin receptors ETA and ETB was observed.  Arginase II has particularly been implicated in 
endothelial dysfunction from alternative causes such as hypoxia (Krause, Del Rio et al. 2015), 
hypertension and obesity (Johnson, Peyton et al. 2015).  Furthermore serum TNFα was increased in 
both cirrhosis models. TNFα has been shown to induce endothelial dysfunction (Dschietzig, Brecht 
et al. 2012) and reducing TNFα has been shown to prevent renal dysfunction in rodent models of 
cirrhosis (Shah, Dhar et al. 2012).  Opposing recent research has suggested that patients with 
decompensated cirrhosis have increased circulating prostaglandin E2 that drives immunosuppression 
and therefore reduced TNFα,  and that by targeting rodent models with COX inhibitors, or humans 
with albumin (that binds prostaglandin E2), increased pro-inflammatory cytokines, such as TNFα, 
are produced and subsequent rodent survival is longer (O'Brien, Fullerton et al. 2014).  The 
haemodynamics in the rodents and, in particular RBF, was not studied in this paper. Although a pro-
inflammatory response is clearly needed to ‘prevent’ infection I would hypothesize, based on my 
work and work by Shar et al, 2012, that excessive pro-inflammatory cytokines will lead to worsening 
renal dysfunction.   
 
These results implicate renal endothelial dysfunction in the renal phenotype seen in both models, 
which is likely secondary to abnormalities in NOS activity (Fig 8.1). This renal endothelial 
dysfunction appears to mimic that of the LSEC’s, which contributes to increased intrahepatic 
intravascular resistance (Iwakiri 2011). A recent study in cirrhotic humans also supports these 
findings, suggesting an association between endothelial dysfunction and HRS development as with 
improved renal function concomitant improved endothelial function was observed (Garcia-Martinez, 
Noiret et al. 2014).  Endothelial dysfunction is an aspect of HRS pathogenesis that to date has been 
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relatively under studied. Further work is needed to fully unravel the dysregulation of eNOS and its 
inhibitors at a cellular level.  
 
It is known that the molecular mechanisms of RLN induced vasodilation differ according to the 
duration of exposure to the peptide, but in both rodent and human tissues the final common pathway 
appears to converge on NO signaling (Conrad 2010).  In rats treated with RLN for 72 hours I showed 
improvement in endothelium-dependent vasodilatation in isolated extra-renal arteries using wire 
myography (Chapter 7). Furthermore, NOS activity and expression of p-eNOS protein was 
augmented following a 72 hour RLN infusion, though no change in arginase 2 or caveolin 1 
expression was observed.  The requirement for NOS in mediating the effects of RLN on RBF and 
GFR in cirrhosis models was demonstrated through co-treatment with L-NAME.  Similarly, L-
NAME administration has also been shown to abrogate renal vasodilation in pregnant rats (Danielson 
and Conrad 1995) and in RLN treated non-pregnant rats (Danielson, Sherwood et al. 1999).  
Furthermore, RLN reduced kidney expression of urotensin 2 receptor, ETA receptor and the 
vasopressin V1b receptor - all involved in renal vasoconstriction and sodium conservation.  
Additionally, I have shown in both models serum TNFα is reduced in rats treated with RLN 
(Chapter 7).  Consistent with this, RLN also improved endothelial dysfunction in a rat aortic ring 
model of LPS-TNFα induced endothelial dysfunction (Dschietzig, Brecht et al. 2012).  In summary, 
my findings suggest that RLN reverses endothelial dysfunction in the renal vasculature, potentially 
by locally regulating eNOS activity, reducing inflammation, down-regulating expression of 
vasoconstrictor receptors in the kidney, and in turn restores physiological responses to endothelium-
dependent vasodilators (Fig 8.2).  
 
I have shown that that RLN decreases PHT in rat cirrhosis (Fig 5.10 and 13) and our group has 
recently shown that RLN also reduces contractility and pro-fibrotic gene expression in human 
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hepatic myofibroblasts (Fallowfield, Hayden et al. 2014).  Given that PHT drives the development of 
HRS (Jalan, Forrest et al. 1997; Abraldes, Tarantino et al. 2003), it remains possible that the 
improvements in renal dysfunction detailed above are in part secondary to the portal hypotensive 
effect of RLN.  However, exogenous RLN treatment in normal rodents (Danielson and Conrad 2003) 
and humans (Smith, Danielson et al. 2006) also increased RBF, which suggests that the portal 
hypotensive effect of RLN cannot be the only mechanism responsible.  So far my work has explored 
the potential role of RLN as a treatment for established HRS, but it is also possible that RLN may be 
effective in the prophylaxis against HRS in high-risk patients.   
 
All animal studies are subject to the legitimate criticism that they cannot be considered to truly 
reflect events in the human condition. Nevertheless, my studies have shown a consistent pattern of 
renal vasoconstriction and renal dysfunction that recapitulate many of the central features of human 
HRS.  There is always concern that preclinical data will not translate to efficacy in human disease.  
Although it was not possible to confirm RXFP1 expression in human HRS kidney (as biopsies are 
not routinely performed for clinical diagnosis), RXFP1 was detected in normal human kidney tissue 
(Fig 4.11).  Recent clinical data also confer optimism with regard to the use of RLN in human HRS.  
Firstly, the observation that pharmacokinetic and safety profiles of RLN were not affected in patients 
with mild, moderate or severe hepatic impairment (Kobalava, Villevalde et al. 2014). Secondly, 
studies showing beneficial renal haemodynamic effects of RLN (increased RBF and reduced 
filtration fraction) in patients with chronic heart failure (Voors, Dahlke et al. 2014) and improvement 
of renal biomarkers (creatinine and cystatin-C) in patients with acute heart failure (Metra, Cotter et 
al. 2013).  To develop RLN as a treatment for human HRS, studies in carefully selected populations 
will be required. A phase-2 study in patients with cirrhosis and portal hypertension has recently been 
completed (NCT01640964; www.ClinicalTrials.gov) and will inform about the potential efficacy of 
RLN as a renal vasodilator, pharmacokinetics, immunogenicity and mechanistic biomarkers.  
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In conclusion, in this thesis I have shown proof-of-concept in clinically relevant rat models of 
cirrhosis and renal dysfunction that RLN improves renal function by ameliorating pathological renal 
vasoconstriction and reversing endothelial dysfunction and is therefore, a promising therapy to take 








Figure 8.1 Proposed Mechanism of Pathogenesis of Renal Endothelial 
Dysfunction in Cirrhosis and HRS Development 
 
The effect of cirrhosis and PHT on the renal endothelial cell is possibly through increased 
inflammatory cytokines, oxidative stress, increased cardiac output and shear stress which in turn may 
lead to increased production of inhibitors of phosphorylated- eNOS, arginase 2 and caveolin 1. As a 
result of reduced p-eNOS and reduced NOS activity there is less bioavailability of NO in smooth 
muscle leading to increased vascular tone. Additionally, it is known that there are more circulating 
vasoconstrictors in cirrhosis and an increase in vasoconstrictor receptor expression, such as the 
endothelin type A receptor. As a result of this imbalance in dilators/constrictors there is aberrant 





Figure 8.2 Proposed mechanism of Action of Relaxin on Renal 
Vascular Endothelial Function and RBF 
RLN has been shown to increase p-eNOS and augment NOS activity in the kidney, reduce ETA receptor and 
urotensin II expression, reduce serum TNFα, and inhibit the effect to circulating vasoconstrictors (e.g. Ang II), 
thereby improving the responsiveness of the kidney vascular endothelial cells to vasodilators, promoting renal 
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Abbreviation  Gene name 
Ace Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 
Ace2 Angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 
Acta2 Smooth muscle alpha-actin 
Adm Adrenomedullin 
Adra1b Adrenergic, alpha-1B-, receptor 
Adra1d Adrenergic, alpha-1D-, receptor 
Adrb1 Adrenergic, beta-1-, receptor 
Agt Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
Agtr1a Angiotensin II receptor, type 1a 
Agtr1b Angiotensin II receptor, type 1b 
Agtr2 Angiotensin II receptor, type 2 
Alox5 Arachidonate 5-lipoxygenase 
Arg2 Arginase type II 
Atp2c1 ATPase, Ca++ transporting, type 2C, member 1 
Atp6ap2 ATPase, H+ transporting, lysosomal accessory protein 2 
Avp Arginine vasopressin 
Avpr1a Arginine vasopressin receptor 1A 
Avpr1b Arginine vasopressin receptor 1B 
Bdkrb1 Bradykinin receptor B1 
Bdkrb2 Bradykinin receptor B2 
Bmpr2 Bone morphogenetic protein receptor, type II (serine/threonine kinase) 
Cacna1c Calcium channel, voltage-dependent, L type, alpha 1C subunit 
Calca Calcitonin-related polypeptide alpha 
Cav1 Caveolin 1, caveolae protein 
Chrna1 Cholinergic receptor, nicotinic, alpha 1 (muscle) 
Chrnb1 Cholinergic receptor, nicotinic, beta 1 (muscle) 
Clic1 Chloride intracellular channel 1 
Clic4 Chloride intracellular channel 4 
Clic5 Chloride intracellular channel 5 
Cnga1 Cyclic nucleotide gated channel alpha 1 
Cnga2 Cyclic nucleotide gated channel alpha 2 
Cnga3 Cyclic nucleotide gated channel alpha 3 
Cnga4 Cyclic nucleotide gated channel alpha 4 
Cngb1 Cyclic nucleotide gated channel beta 1 
Cps1 Carbamoyl-phosphate synthetase 1 
Drd3 Dopamine receptor D3 
Drd5 Dopamine receptor D5 
Ece1 Endothelin converting enzyme 1 
Edn1 Endothelin 1 
Edn2 Endothelin 2 
Ednra Endothelin receptor type A 
Ednrb Endothelin receptor type B 
Ephx2 Epoxide hydrolase 2, cytoplasmic 
Gch1 GTP cyclohydrolase 1 
Gchfr GTP cyclohydrolase I feedback regulator 
Gucy1a3 Guanylate cyclase 1, soluble, alpha 3 
Gucy1b3 Guanylate cyclase 1, soluble, beta 3 




Itpr1 Inositol 1,4,5-triphosphate receptor, type 1 
Itpr2 Inositol 1,4,5-triphosphate receptor, type 2 
Itpr3 Inositol 1,4,5-triphosphate receptor, type 3 
Kcnj8 Potassium inwardly-rectifying channel, subfamily J, member 8 
Kcnma1 Potassium large conductance calcium-activated channel, subfamily M, 
alpha member 1 
Mylk Myosin light chain kinase 
Mylk2 Myosin light chain kinase 2 
Mylk3 Myosin light chain kinase 3 
Nos3 Nitric oxide synthase 3, endothelial cell 
Nosip Nitric oxide synthase interacting protein 
Nostrin Nitric oxide synthase trafficker 
Nppb Natriuretic peptide precursor B 
Nppc Natriuretic peptide precursor C 
Npr1 Natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic 
peptide receptor A) 
Npy1r Neuropeptide Y receptor Y1 
P2rx4 Purinergic receptor P2X, ligand-gated ion channel 4 
Pde3a Phosphodiesterase 3A, cGMP inhibited 
Pde3b Phosphodiesterase 3B, cGMP-inhibited 
Pde5a Phosphodiesterase 5A, cGMP-specific 
Plcg1 Phospholipase C, gamma 1 
Plcg2 Phospholipase C, gamma 2 
Prkg1 Protein kinase, cGMP-dependent, type 1 
Prkg2 Protein kinase, cGMP-dependent, type II 
Ptgir Prostaglandin I2 (prostacyclin) receptor (IP) 
Ptgs1 Prostaglandin-endoperoxide synthase 1 
Ptgs2 Prostaglandin-endoperoxide synthase 2 
Ren Renin 
S1pr1 Sphingosine-1-phosphate receptor 1 
Scnn1a Sodium channel, nonvoltage-gated 1 alpha 
Scnn1b Sodium channel, nonvoltage-gated 1, beta 
Scnn1g Sodium channel, nonvoltage-gated 1, gamma 
Slc7a1 Solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 1 
Sphk1 Sphingosine kinase 1 
Sphk2 Sphingosine kinase 2 
Uts2 Urotensin 2 
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LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION
Relaxin Modulates Human and Rat Hepatic
Myofibroblast Function and Ameliorates Portal
Hypertension InVivo
Jonathan A. Fallowfield,1 Annette L. Hayden,2 Victoria K. Snowdon,1 Rebecca L. Aucott,1 Ben M. Stutchfield,3
Damian J. Mole,1 Antonella Pellicoro,1 Timothy T. Gordon-Walker,1 Alexander Henke,4 Joerg Schrader,1
Palak J. Trivedi,5 Marc Princivalle,6 Stuart J. Forbes,3 Jane E. Collins,2 and John P. Iredale1
Active myofibroblast (MF) contraction contributes significantly to the increased intrahepatic
vascular resistance that is the primary cause of portal hypertension (PHT) in cirrhosis. We
sought proof of concept for direct therapeutic targeting of the dynamic component of PHT
and markers of MF activation using short-term administration of the peptide hormone relaxin
(RLN). We defined the portal hypotensive effect in rat models of sinusoidal PHT and the
expression, activity, and function of the RLN-receptor signaling axis in human liver MFs. The
effects of RLN were studied after 8 and 16 weeks carbon tetrachloride intoxication, following
bile duct ligation, and in tissue culture models. Hemodynamic changes were analyzed by direct
cannulation, perivascular flowprobe, indocyanine green imaging, and functional magnetic res-
onance imaging. Serum and hepatic nitric oxide (NO) levels were determined by immunoas-
say. Hepatic inflammation was assessed by histology and serum markers and fibrosis by
collagen proportionate area. Gene expression was analyzed by quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) and western blotting and hepatic stellate
cell (HSC)-MF contractility by gel contraction assay. Increased expression of RLN receptor
(RXFP1) was shown in HSC-MFs and fibrotic liver diseases in both rats and humans. RLN
induced a selective and significant reduction in portal pressure in pathologically distinct PHT
models, through augmentation of intrahepatic NO signaling and a dramatic reduction in con-
tractile filament expression in HSC-MFs. Critical for translation, RLN did not induce systemic
hypotension even in advanced cirrhosis models. Portal blood flow and hepatic oxygenation
were increased by RLN in early cirrhosis. Treatment of human HSC-MFs with RLN inhibited
contractility and induced an antifibrogenic phenotype in an RXFP1-dependent manner. Con-
clusion: We identified RXFP1 as a potential new therapeutic target for PHTand MF activation
status. (HEPATOLOGY 2014;59:1492-1504)
See Editorial on Page 1223
T
he dynamic component of portal hyperten-
sion (PHT), mediated by active contraction
of myofibroblasts (MFs) predominantly
derived from activated hepatic stellate cells (HSCs),1,2
accounts for about 30% of the increased intrahepatic
vascular resistance (IHVR) in cirrhosis and is poten-
tially reversible.3,4 The increase in sinusoidal tone
reflects a functional disturbance of the liver circulation
in response to excessive production of contractile ago-
nists (e.g., endothelin-1 [ET-1]), reduced
Abbreviations: a-SMA, alpha-smooth muscle actin; ALT, alanine aminotransferase; BDL, bile duct ligation; BOLD-MRI, blood oxygen dependent-magnetic reso-
nance imaging; CCl4, carbon tetrachloride; CPA, collagen proportionate area; (e)NOS, (endothelial) nitric oxide synthase; ET-1, endothelin-1; (H2)-RLN,
(human2)-relaxin; (h)HSC, (human) hepatic stellate cell; ICG, indocyanine green; IHVR, intrahepatic vascular resistance; L-NAME, L-NG-Nitroarginine methyl
ester; MAP, mean arterial pressure; MF, myofibroblast; NO, nitric oxide; PHT, portal hypertension; RXFP, relaxin receptor family peptide.
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bioavailability of relaxant factors (mainly nitric oxide
[NO]), and impaired responses to NO.5,6 The struc-
tural component of IHVR may be decreased by effec-
tive etiological treatment,7 but this is not achievable in
the majority of patients with PHT. Current treatments
for PHT (vasopressin and somatostatin analogs, nonse-
lective beta-blockers) decrease portal pressure by
splanchnic vasoconstriction, but this may further com-
promise hepatic perfusion in cirrhosis and impair
organ function.8
Relaxin (RLN) is a naturally occurring peptide hor-
mone with a two-chain structure similar to insulin.9
Although initially identified as a hormone of preg-
nancy, gene knockout studies and observations in
rodents and humans treated with exogenous RLN have
revealed diverse effects in nonreproductive tissues in
both males and females.9 The product of the human
RLN2 gene, human gene 2-relaxin (H2-RLN), is the
major stored and circulating form. H2-RLN circulates
in women at low concentrations during the luteal
phase of the menstrual cycle (50 pg/mL) and at
increased levels (1 ng/mL) throughout pregnancy. In
men, H2-RLN is expressed locally in the prostate and
may also be present at very low levels (1-5 pg/mL) in
the circulation. The primary receptor for H2-RLN,
relaxin receptor family peptide-1 (RXFP1), is a mem-
ber of the leucine-rich repeat family of G-protein
coupled receptors10 and is widely distributed in many
tissues in both sexes. RLN is thought to mediate its
physiological actions in an autocrine or paracrine man-
ner, whereby activation of RXFP1 results in the stimu-
lation of multiple signal transduction pathways
including 30-50-cyclic adenosine monophosphate
(cAMP) (influenced by a variety of Ga isoforms),
extracellular signal-regulated kinases, tyrosine kinases,
and NO signaling.10,11 The effects of RLN on connec-
tive tissue remodeling in reproductive and nonrepro-
ductive tissues are well documented.9,12 Although
circulating RLN has been detected in patients with
chronic liver disease, serum concentrations were either
stable or rose very slowly over 15 years of follow-up
and did not correlate with the histological stage of
fibrosis (M. Mayo, pers. commun.).
A number of humoral agents that elicit either HSC
contraction or relaxation have been identified.1 In
human cirrhosis, circulating and tissue levels of the
HSC contractile agonist ET-1 are elevated13 and HSC
sensitivity to ET-1 is also enhanced. Exogenous NO
has been shown to abolish the contractile effects of
ET-1 in isolated perfused liver and in cultured
HSCs.14 Through binding to RXFP1, RLN may
induce activation of the NO pathway in target cells.
Furthermore, RLN has also been shown to inhibit the
vasoconstrictive properties of ET-1 and angiotensin-II
in rodent models.15,16
Here we show that RLN can modulate the dynamic
component of PHT, through effects on intrahepatic
NO and MF contractility; thereby identifying the
RLN-RXFP1 axis as a novel vasoactive target in
cirrhosis.
Materials and Methods
Tissue was used in accordance with the local ethical
review committees and the Human Tissue Act 2004.
Procedures involving animals were conducted with eth-
ical approval and in accordance with the Use of Ani-
mals in Scientific Procedures Act 1986.
Isolation and Culture of Cells. Primary HSCs and
hepatic sinusoidal endothelial cells (HSECs) were iso-
lated and cultured as described in the online Support-
ing Information.
Quantitation of HSC Apoptosis. Apoptosis of
human HSCs was assessed using acridine orange as
described in the online Supporting Information.
Quantitative Polymerase Chain Reaction
(qPCR). Total RNA was extracted using the RNeasy
kit (Qiagen, Manchester, UK) and qPCR performed.
Full details are provided in the online Supporting
Information and primer sequences listed in Supporting
Table 1.
Jonathan Fallowfield and Damian Mole are supported by Academy of Medical Sciences / The Health Foundation Clinician Scientist Fellowships. Annette
Hayden was funded jointly by Ferring Research Ltd as part of an industrial collaborative studentship with the Medical Research Council (MRC) UK and the
University of Southampton. Victoria Snowdon and Ben Stutchfield are funded by Scottish Translational Medicine and Therapeutics / Wellcome Trust Clinical
Research Fellowships. John Iredale gratefully acknowledges the support of the Medical Research Council and the Wellcome Trust.
Address reprint requests to: Professor John P. Iredale, BM (Hons), FMedSci, FRCP, FRSE, Medical Research Council/University of Edinburgh Centre for
Inflammation Research, Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK. E-mail: john.iredale@ed.ac.uk; fax: 144-
(0)131-242-6682.
Copyright VC 2014 by the American Association for the Study of Liver Diseases.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.26627
Potential conflict of interest: Nothing to report.
Additional Supporting Information may be found in the online version of this article.
HEPATOLOGY, Vol. 59, No. 4, 2014 FALLOWFIELD ET AL. 1493
cAMP Assay. Intracellular cAMP measurement in
HSCs was performed using the HitHunter cAMP II
kit (DiscoveRx, Birmingham, UK) following the man-
ufacturer’s instructions. Cells were resuspended in anti-
body solution at 10,000 cells/well with 0.5 mM
isobutylmethylxanthine (IBMX).
Cyclic Guanosine Monophosphate (cGMP) Immu-
noassay. cGMP in whole liver homogenates and
HSC lysates was measured by enzyme immunoassay
(Cayman Chemical, Cambridge, UK). Full details are
provided in the online Supporting Information.
Gel Contraction Assay. Activated passage-1 human
HSCs (hHSCs) suspended in Dulbecco’s Modified
Eagle Medium (DMEM; Gibco, Paisley, UK) / 10%
fetal bovine serum (FBS; Gibco) were layered on top
of type-1 collagen lattices at a density of 100,000
cells/well in 24-well flat-bottom tissue culture plates
and contractility assessed in response to 1 lM H2-
RLN 6 RXFP1 small interfering RNA (siRNA). Full
details are provided in the online Supporting
Information.
NO Measurement. Rat serum was centrifuged at
13,000g for 2 minutes before filtration using a 10,000
Da molecular weight cutoff filter (Millipore, Watford,
UK). NO/NO3
-/NO2
- determination was performed
using a Parameter Kit (R&D Systems, Abingdon, UK).
Histology, Immunohistochemistry, and Confocal
Microscopy. Full details are provided in the online
Supporting Information.
Western Blotting. Full details are provided in the
online Supporting Information and antibody dilutions
listed in Supporting Table 3.
Rat Carbon Tetrachloride Models. Cirrhosis and
PHT was induced in age-matched male Sprague-
Dawley rats by 8 or 16 weeks administration of carbon
tetrachloride (CCl4; Sigma). Littermates (250-300 g
body weight) were randomly allocated to treatment
with either twice-weekly injections of intraperitoneal
CCl4 (0.1 mL/100g CCl4 for 2 weeks then 0.05 mL
CCl4/100g for 6-14 weeks) or sterile vehicle (olive oil;
Sigma). 72h RLN Model: Twenty-four hours after the
final injection of CCl4 or olive oil (“peak fibrosis”),
rats either underwent portal pressure measurement
(n 5 4-6/group) or insertion of subcutaneous osmotic
minipumps (2ML2 Alzet; Durect, Cupertino, CA)
under isoflurane anesthesia. Minipumps were pre-
loaded with recombinant human H2-RLN (0.5 mg/
kg/day; Corthera, San Carlos, CA) or vehicle (sodium
acetate pH 5) for 72h continuous infusion (n 5 10).
Subgroups of rats (n 5 5) were also coadministered L-
NG-Nitroarginine methyl ester (L-NAME; Sigma) 250
mg/mL in drinking water starting 24h before
minipump insertion and continuing for the 72h infu-
sion period. Serum RLN levels were measured using
the Quantikine Human Relaxin-2 Immunoassay (R&D
Systems). Blood was collected from the inferior vena
cava (systemic blood) or portal vein (splanchnic blood),
tissues were fixed in 10% buffered formalin or snap-
frozen in liquid nitrogen. Acute RLN Model: Groups
of CCl4 or olive oil treated anesthetized rats were ran-
domly allocated to treatment with intravenous RLN (4
lg/mL over 2 minutes) or equivalent volume of vehicle
by way of an internal jugular vein catheter (PE-50;
Durect), with continuous hemodynamic monitoring for
180 minutes. Animals were warmed using a heat pad
and received intraoperative 0.9% NaCl 10 mL/kg/h.
Rat Bile Duct Ligation Model. Liver fibrosis and
PHT was induced in age-matched male Sprague-
Dawley rats (250-300 g) by bile duct ligation (BDL)
under isoflurane anesthesia. Briefly, the common bile
duct was exposed after laparotomy, ligated with 7-0
silk and cut. Intraoperatively, animals were warmed
and received 0.9% NaCl 10 mL/kg/h. Eighteen days
post-BDL, animals were randomly allocated to 72h
subcutaneous treatment with RLN (0.5 mg/kg/day) or
vehicle by minipump (n 5 5).
Hemodynamic Measurements. Hemodynamic data
were recorded from the femoral artery by way of a PE-
50 catheter and portal vein by way of a 24G cannula
or indwelling PE-50 catheter using Powerlab 4/35
with LabChart 7 Pro software (ADInstruments,
Oxford, UK). Portal blood flow was measured using a
perivascular flowprobe (Transonic MA1.5PRB;
ADInstruments).
Dynamic Indocyanine Green (ICG) Imaging.
Noninvasive in vivo imaging was performed using the
IVIS Spectrum Imaging System and Living Image v.
3.2 software (PerkinElmer, Waltham, MA). Hepatic
uptake and peripheral disappearance rate of 2.5 mg/kg
ICG (Cardiogreen; Sigma) was assessed by dynamic
fluorescence imaging in anesthetized 8-week CCl4 rats
after pretreatment with 4 lg/mL intravenous H2-RLN
or vehicle. Full details are provided in the online Sup-
porting Information.
Blood Oxygen Level-Dependent Magnetic Reso-
nance Imaging (BOLD-MRI). BOLD-MRI uses the
paramagnetic properties of deoxyhemoglobin to
acquire images sensitive to local tissue oxygen concen-
tration.17 MRI data were acquired using a 7-Tesla pre-
clinical MRI scanner (Agilent Technologies,
Edinburgh, UK) in anesthetized 8-week CCl4 rats, 30
and 60 minutes after administration of 4 lg/mL intra-
venous H2-RLN or vehicle. Full details are provided
in the online Supporting Information.
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Statistics. GraphPad Prism 5 was used for statisti-
cal analysis. Data are presented as mean 6 standard
error of the mean or 95% confidence intervals. Para-
metric data were compared by unpaired t test or one-
way analysis of variance (ANOVA) with post-hoc
Tukey test for multiple groups, and nonparametric
data by equivalent methods.
Results
RXFP1 Is Expressed in Rat and Human Cirrhotic
Liver and MFs Are the Major Cellular Source. We
studied hepatic expression of the primary receptor for
RLN, RXFP1, in progressive rat CCl4 fibrosis. Rxfp1
messenger RNA (mRNA) was barely detectable in
Fig. 1. (A) Hepatic expression of Rxfp1 mRNA in progressive rat CCl4 injury (**P< 0.01, ***P< 0.001; NS, not significant; n 5 4). (B) Dual
immunofluorescence in activated rat HSCs (a-SMA, red; RXFP1, green; DAPI (diamidino-2-phenylindole) nuclear stain, blue). (C) Hepatic RXFP1
immunostaining in rat fibrosis models (TAA, thioacetamide). Positive staining indicated in fibrotic scars and sinusoids (arrows). (D) Representative
gels showing gene expression by RT-PCR in hHSCs activated on plastic (P) and deactivated on Matrigel (M) (COL1A2, procollagen-1; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase). (E) RXFP1 immunofluorescence in activated hHSCs. (F) Immunostaining for RXFP1 in normal and
cirrhotic (explanted) human liver, with localization to areas of fibrotic scarring (arrows). ALD, alcohol-related liver disease; AI, autoimmune.
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normal rat liver but transcripts were increased 38-fold
and 44-fold, respectively, after 8 weeks and 16 weeks
of CCl4 (Fig. 1A). Quiescent primary rat HSCs did
not express Rxfp1 mRNA (data not shown) but
RXFP1 and alpha-smooth muscle actin (a-SMA) colo-
calized in culture-activated rat HSCs (Fig. 1B). Nei-
ther hepatocytes nor hepatic macrophages expressed
RXFP1 (data not shown). Expression of RXFP1 pro-
tein was shown in a range of mechanistically distinct
rat liver fibrosis models (Fig. 1C) in areas of fibrosis
and within the sinusoids. No RXFP1 protein was
detected in olive oil-treated (Fig. 1C) or normal rat
liver (data not shown). Quiescent human HSCs
(hHSCs) did not express RXFP1 or other HSC activa-
tion markers, but culture-activated hHSCs expressed
RXFP1 mRNA (Fig. 1D) and protein (Fig. 1E). We
have previously demonstrated that the activated HSC
is not a committed phenotype and HSCs can effec-
tively become “deactivated” in vitro after replating
onto a synthetic basement membrane-type matrix.18
Culture of activated hHSCs on Matrigel abrogated
expression of RXFP1 and COL1A2 mRNA. (Fig. 1D).
In addition, human sinusoidal endothelial cells
(HSECs) isolated from fibrotic liver also expressed
RXFP1 (Supporting Fig. 2D). Finally, we showed that
RXFP1 was undetectable in normal human liver but
abundant in areas of fibrous scarring within explanted
cirrhotic livers (Fig. 1F). Taken together, these data
indicate that expression of RXFP1 is restricted to acti-
vated HSC-MFs and HSECs in fibrotic liver.
Fig. 2. Effect of 72h RLN treatment on portal pressure, hepatic inflammation, and fibrosis in 8-week CCl4 rats. (A) Portal pressure
(***P 5 0.0003) and (B) spleen size (**P 5 0.01) were compared after 72h subcutaneous RLN (0.5 mg/kg/day) or vehicle (veh; sodium ace-
tate pH 5) (n 5 8-9). (C) Serum ALT, (D) hepatic histological inflammation score (0 (absent), 1 (<2 foci), 2 (2-4 foci), 3 (>4 foci), and (E) col-
lagen proportionate area (CPA) (n 5 5-10). (F) Relative hepatic expression of profibrotic genes by qRT-PCR (mean 6 95% confidence intervals;
*P< 0.05 for Col1a2 (procollagen-1), Mmp3 (matrix metalloproteinase-3) and Acta2 (a-smooth muscle actin). Col3a1, procollagen-3; Lox, lysyl
oxidase; Timp1, tissue inhibitor of metalloproteinases-1; n 5 6.
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RLN Treatment Reduces Portal Pressure in 8-
Week CCl4 Rats. Cirrhosis and preascitic PHT was
induced by 8 weeks CCl4 (Supporting Fig. 1A-D).
After 72h subcutaneous RLN the mean serum concen-
tration was 62 6 10 ng/mL, whereas in controls it was
undetectable. Rats receiving RLN had lower portal
pressures (Fig. 2A; 9.7 6 0.28 mmHg versus
11.7 6 0.29 mmHg) and a reduction in splenomegaly
(Fig. 2B; spleen:body weight ratio 0.20 6 0.01 versus
0.27 6 0.03). Livers were assessed for hepatocellular
injury and fibrosis (Supporting Fig. 1E,F). There was
no difference in serum alanine aminotransferase (ALT)
level (Fig. 2C), hepatic necro-inflammatory score (Fig.
2D), or collagen proportionate area (CPA; Fig. 2E)
between RLN-treated rats and controls. Acknowledg-
ing that matrix remodeling was unlikely within the
short time-frame chosen for our hemodynamic study,
we quantified hepatic expression of profibrogenic
marker genes (Fig. 2F). Relative to control, transcripts
for all profibrotic genes were reduced by RLN.
RLN Increases Intrahepatic But Not Systemic NO
Levels in 8-Week CCl4 Rats. To define the role of
NO in mediating the portal hypotensive effect of
RLN, we measured serum NO metabolites and intra-
hepatic cGMP as a surrogate index of NO bioavailabil-
ity. We found no difference in total nitrite levels in
systemic venous (Fig. 3A) and portal venous blood
(data not shown), but RLN-treated rats had increased
intrahepatic cGMP levels compared to controls (Fig.
3B). Hepatic expression of phosphorylated Akt (Ser473)
(Supporting Fig. 2A) and phosphorylated
eNOS(Ser1179) protein (Fig. 3C) were also increased.
The eNOS regulatory protein caveolin-1 is abundant
in cirrhotic liver but, relative to control, RLN reduced
caveolin-1 mRNA and protein (Fig. 3D). These data
indicate that RLN can stimulate intrinsic NO genera-
tion in fibrotic liver by activating the Akt/eNOS/
cGMP pathway. The pivotal role of NO was con-
firmed by showing that NOS inhibition with L-
NAME inhibited hepatic eNOS expression (Support-
ing Fig. 2B) and abrogated the effect of RLN on por-
tal pressure (Fig. 3E) and splenomegaly (Supporting
Fig. 2C). We went on to demonstrate that primary
HSECs cultured from fibrotic human liver expressed
RXFP1 (Supporting Fig. 2D) and increased NO pro-
duction when treated with RLN (Supporting Fig. 2E).
Fig. 3. Effect of 72h RLN treatment on NO bioavailability and signaling in 8-week CCl4 rats. (A) Serum total nitrite (P 5 0.9372) and (B) intra-
hepatic acetylated cGMP (**P 5 0.0018) levels were compared after 72h subcutaneous RLN (0.5 mg/kg/day) or vehicle (veh; sodium acetate
pH 5) (n 5 6). (C) Relative p-eNOS protein by western blotting and densitometry (*P 5 0.0125; n 5 6). (D) Hepatic caveolin-1 (Cav1) mRNA by
qRT-PCR (**P 5 0.0059) and representative photomicrographs showing protein by immunohistochemistry with quantitation by morphometry
(*P 5 0.0253) (n 5 6). (E) Effect of cotreatment with the NOS inhibitor L-NAME on portal pressure (*P< 0.05; n 5 5-8).
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RLN Treatment Down-Regulates Expression of
Cytoskeletal Filament Proteins in 8-Week CCl4
Rats. Liver fibrosis is characterized by increased con-
tractile filament expression and increased cytoskeletal
tension. After 72h RLN, we observed a profound
reduction in hepatic a-SMA protein by immunostain-
ing (Fig. 4A) and western blotting (Fig. 4C). Desmin
filaments run between anchorage points of the con-
tractile apparatus in cells (the foci of mechanical stress)
and are also a marker of the activated HSC-MF phe-
notype.19 We also observed a marked reduction in
desmin protein by immunostaining (Fig. 4B) and
western blotting (Fig. 4D) following RLN. In contrast,
glial fibrillary acidic protein (GFAP), predominantly a
marker of quiescent HSCs, did not decrease signifi-
cantly (Supporting Fig. 3A). Additionally, treatment of
activated rat HSCs with a range of RLN doses in vitro
had no effect on cell numbers (Fig. 4E). Indeed, we
observed no difference in apoptotic markers in liver
(TUNEL staining [Fig. 4F] and cleaved caspase-3 lev-
els [Supporting Fig. 3B]), indicating that the observed
decrease in hepatic a-SMA and desmin by RLN
Fig. 4. Effect of 72h RLN treatment on hepatic expression of cytoskeletal proteins in 8-week CCl4 rats. Representative photomicrographs of
(A) a-SMA (*P 5 0.026) and (B) desmin (P 5 0.0422) immunostaining in liver after 72h subcutaneous RLN (0.5 mg/kg/day) or vehicle (veh;
sodium acetate pH 5) with quantitation by morphometry (n 5 6). Representative western blots showing (C) a-SMA and (D) desmin protein
expression in whole liver extracts. (E) Effect of RLN on numbers of activated rat HSCs by MTS assay (P< 0.001; n 5 4). (F) Representative
image showing TUNEL (green) immunofluorescence from a vehicle-treated CCl4 rat liver with DAPI (blue) nuclear counterstain. Enlarged panels
show TUNEL-positive cells within a fibrotic band (arrow) and in liver parenchyma (arrowhead) (n 5 6).
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involved a specific reduction of fibrotic markers in
these cells. We found no evidence for inhibition of
hepatic Rho/Rho-kinase by RLN in our study (Sup-
porting Fig. 4A,B).
The major profibrogenic cytokine responsible for
initiation and perpetuation of HSC activation is trans-
forming growth factor beta-1 (TGFb1). After 72h sub-
cutaneous RLN we showed reduced hepatic expression
of TGFb1 mRNA and protein and reduced transcrip-
tion of other genes associated with TGFb activity and
signaling (Supporting Fig. 3C-E).
Acute Intravenous RLN Treatment Decreases
Portal But Not Systemic Pressure in 8-Week CCl4
Rats. To exclude the impact of systemic hypotension
on the apparent portal hypotensive effect of RLN, we
measured the hemodynamic effects of intravenous
RLN in 8 week CCl4 rats (Fig. 5A). Dose-response
studies had previously been undertaken by our group
(data not shown) and others.15,20 Rats were monitored
for 180 minutes after injection of RLN (4 lg/mL over
2 minutes) or vehicle. RLN induced a rapid (<60
minutes) and robust reduction in portal pressure
(mean change from baseline 28 6 6% versus
26.2 6 1.5%), an increase in heart rate (mean change
from baseline 16 6 3% versus 21 6 2.5%), and mod-
est increase in mean arterial pressure (MAP; mean
change from baseline 20 6 6.4 versus 26 6 9.5%).
Vehicle had no significant hemodynamic effects (Fig.
5A). There was no difference is spleen size between
RLN and vehicle-treated rats in this acute model.
Fig. 5. Acute hemodynamic effects of RLN treatment in 8-week CCl4 rats. (A) Mean change in portal pressure (PP; **P 5 0.0035), heart rate
(HR; *P 5 0.0324), and mean arterial pressure (MAP; P 5 0.0869) from baseline after intravenous RLN (4 lg/mL) or vehicle (veh; sodium ace-
tate pH 5) (n 5 4). (B) Effect of RLN on portal venous blood flow by perivascular flowprobe (*P 5 0.0352 baseline versus 60 minutes; n 5 5).
(C) Representative whole-animal fluorescence images in an RLN-treated CCl4 rat pre-ICG, 30 seconds and 20 minutes after tail vein ICG injection
(2.5 mg/kg) with regions of interest indicated over liver (*), abdominal wall (background; #), right paw (red box). (D) Hepatic ICG uptake rate
after pretreatment with 100 lL intravenous RLN (4 lg) or equivalent volume of vehicle (*P 5 0.0303; n 5 5). (E) BOLD-MRI showing change in
R2* (1/T2*) after 1 mL intravenous vehicle (P 5 0.3343 baseline versus 60 minutes; n 5 5) and (F) after intravenous RLN (4 lg/mL)
(*P 5 0.0346 baseline versus 60 minutes; n 5 4).
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Acute Intravenous RLN Treatment Increases Por-
tal Venous Blood Flow and Hepatic Oxygenation in
8-Week CCl4 Rats. Given its effects on intrahepatic
NO, we went on to study portal blood flow and
hepatic oxygenation in response to RLN. By perivascu-
lar flowprobe we demonstrated an increase in portal
venous flow in response to RLN in 4 of 5 rats studied
(Fig. 5B; baseline 12.8 6 0.42 mL/min versus 60
minutes 15.0 6 1.1 mL/min), but no significant
change was observed in controls (data not shown).
Injection of ICG with dynamic fluorescence imaging21
was used to measure blood flow noninvasively (Fig.
5C,D; Supporting Fig. 5A). Hepatic uptake of ICG at
20 minutes was increased in rats pretreated with RLN
compared to vehicle (Fig. 5D), as was peripheral disap-
pearance rate, although the difference was not statisti-
cally significant (Supporting Fig. 5B). Assessment of
tissue oxygenation by BOLD-MRI (Fig. 5E,F) showed
that RLN decreased R2* (1/T2* 5 deoxyhemoglobin)
after 60 minutes, whereas vehicle had no effect.
Fig. 6. Effect of 72h RLN treatment in 16-week CCl4-treated and bile duct ligated rats. (A) Portal pressure (*P 5 0.0414), (B) MAP
(P 5 0.8574), (C) Sirius red staining and serum ALT levels (P 5 0.8808) were compared in 16-week CCl4 rats after 72h subcutaneous RLN (0.5
mg/kg/day) or vehicle (veh; sodium acetate pH 5) (n 5 5). (D) Portal pressure (**P 5 0.0067), (E) MAP (P 5 0.3072), (F) Sirius red staining
and serum alkaline phosphatase (ALP) levels (P 5 0.8713) were compared in 3-week BDL rats after 72h subcutaneous RLN (0.5 mg/kg/day) or
vehicle (veh; sodium acetate pH 5) (n 5 5).
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RLN Reduces Portal But Not Systemic Pressure
and Improves Liver Function in Advanced Cirrho-
sis. We then confirmed that RLN mediated a portal
hypotensive effect in advanced CCl4 cirrhosis and also
in a mechanistically distinct model of fibrosis (BDL).
Rats injured for 16 weeks with CCl4 had PHT but no
significant ascites. Treatment with subcutaneous RLN
for 72h reduced portal pressure (Fig. 6A; 6.1 6 1.1
mmHg versus 9.12 6 0.9 mmHg), but not spleen size
(Supporting Fig. 6A), heart rate (Supporting Fig. 6B),
or MAP (Fig. 6B). Serum albumin levels were
increased following RLN (Supporting Fig. 6C;
27.4 6 0.54 g/L versus 24.7 6 0.67 g/L), but there was
no difference in liver fibrosis (Fig. 6C) by CPA (Sup-
porting Fig. 6D), or hepatocellular injury by serum
ALT (Fig. 6A) and histology (data not shown).
The livers of BDL rats were intensely scarred and
inflamed and PHT was marked with most rats devel-
oping ascites. Treatment with 72h subcutaneous RLN
reduced portal pressure (Fig. 6D; 8.8 6 0.73 mmHg
versus 14.13 6 1.28 mmHg), although there was no
significant difference in spleen:liver weight ratio
Fig. 7. Effects of RLN on human HSCs in vitro. (A) cAMP accumulation in hHSCs after stimulation with RLN for 90 minutes (cps 5 counts per
second; n 5 6). (B) Effect of RXFP1 siRNA pretreatment on RLN-induced cAMP accumulation (n 5 3). (C) Effect of RLN (1 lM) on 10% serum-
induced hHSC contraction by collagen gel contraction assay (*P< 0.05; n 5 4) and (D) after pretreatment with RXFP1 siRNA (n 5 2). (E) Repre-
sentative photomicrographs showing hematoxylin and eosin (H&E)-stained hHSCs in collagen gel lattices after RLN and vehicle treatment. Arrows
indicate long cellular processes. (F) Intracellular cGMP levels after 30 minutes treatment with 100 ng/mL RLN or vehicle (*P< 0.05 versus
hHSCs incubated with vehicle/untreated hHSCs/DMSO control; n 5 3).
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(Supporting Fig. 7A), heart rate (Supporting Fig. 7B),
or MAP (Fig. 6E). There were no significant differen-
ces in fibrosis (Fig. 6F; Supporting Fig. 7C), hepato-
cellular injury (Supporting Fig. 7D,E), serum alkaline
phosphatase (ALP; Fig. 6F), or albumin (Supporting
Fig. 7F).
RXFP1 Activation and Signaling in Human
HSCs In Vitro. Functional activity of RXFP1 was
investigated by cAMP accumulation assay following
treatment with exogenous RLN. hHSCs exhibited a
full cAMP dose-response curve with the preferential
RXFP1 ligand H2-RLN (Fig. 7A). Transfection of
hHSCs (and LX-2 cells, not shown) with RXFP1
siRNA inhibited the cAMP response to RLN (Fig.
7B). No significant effects were observed following
treatment with RXFP1 siRNA in H2-RLN unstimu-
lated forskolin-spiked assays (data not shown).
Modulation of hHSC Contraction by RLN In
Vitro Supports a Role for a Portal Hypotensive
Effect in Humans. In collagen gel contraction assays,
RLN reduced basal (10% serum-induced) hHSC con-
tractility by 40% after 72h measured by final gel
area (Fig. 7C). Visualization of hHSCs seeded into
collagen lattices revealed morphological differences
associated with RLN treatment, including a reduction
in the number of cytoplasmic protrusions (Fig. 7E).
Knockdown of RXFP1 with siRNA completely inhib-
ited the cell relaxation effect of RLN, indicating that
this was mediated by way of RXFP1 (Fig. 7D). Treat-
ment with RLN also increased intracellular cGMP in
hHSCs (Fig. 7F).
Exogenous RLN Induces an Antifibrotic Phenotype
in Activated Human HSCs. Treatment of activated
hHSCs with RLN for 72h decreased expression of pro-
fibrotic genes and increased expression of MMPs in an
RXFP1-dependent manner (Supporting Fig. 8A,B).
Additionally, RLN reduced TGFb1 mRNA and pro-
tein expression (Supporting Fig. 8C), and inhibited
basal and TGFb-stimulated a-SMA protein expression
in hHSCs (Supporting Fig. 8D), but had no effect on
hHSC apoptosis (Supporting Fig. 8E).
Discussion
In this study we show comprehensively that RLN
induced a selective and significant portal hypotensive
effect in the most relevant rodent model of sinusoidal
PHT (CCl4),
22 through augmentation of intrahepatic
NO signaling and down-regulation of contractile fila-
ment expression. Critically, reduction in portal pres-
sure was also reproduced in advanced cirrhosis and a
second mechanistically distinct model of fibrosis
(BDL). Finally, we showed that activated hHSCs
expressed functional RLN receptors in vitro and that
stimulation with exogenous RLN decreased cellular
contractility and induced an antifibrogenic phenotype.
Therapeutic deployment of RLN in diseases such as
cirrhosis that are characterized by fibrosis and patho-
logical vasoconstriction is therefore an appealing
approach. Increased IHVR, resulting from structural
changes related to scarring and increased vascular tone
mediated by dynamic contraction of hepatic MFs, is
the primary cause of PHT in cirrhosis. As such, it is
the ideal target for treatment.
The primary (H2-)RLN receptor, RXFP1, was
undetectable in normal rat liver and quiescent HSCs
but highly expressed in fibrotic liver and HSC-MFs.
By subcutaneous infusion in cirrhotic rats we gener-
ated steady-state serum RLN concentrations compara-
ble to midterm pregnancy levels, when gestational
renal vasodilation is maximal,23 and induced a portal
hypotensive effect that would be clinically meaningful
if translated in humans. Reduction in portal pressure
was not due to regression of fibrosis or inflammation
(both of which contribute to the mechanical compo-
nent of PHT) or loss of HSC-MFs by apoptosis.
Recent studies have demonstrated hepatic MF plastic-
ity even in an advanced activated phenotype.24 We
conclude that RLN altered the fibrogenic state of MFs
rather than influencing cell numbers, consistent with
studies in renal and cardiac models.25
In experimental cirrhosis and human disease,
impaired NO production by eNOS contributes to
increased IHVR. Decreased expression of eNOS pro-
tein, decreased phosphorylation of eNOS by the
serine-threonine kinase Akt, and inhibition of eNOS
by enhanced expression of caveolin-126 underlies this
endothelial dysfunction. Replenishing NO in cirrhotic
liver by NOS gene transfer or drug therapy in rats and
humans27 has been shown to ameliorate PHT. In treat-
ing cirrhotic rats with RLN, we increased hepatic
eNOS, Akt-dependent eNOS phosphorylation, and
cGMP levels, and down-regulated caveolin-1 expres-
sion. Inhibition by L-NAME demonstrated the impor-
tance of this axis in mediating the portal hypotensive
effect of RLN in vivo. Clinical application of nonselec-
tive NO donors such as nitrates in cirrhosis is compli-
cated by impairment of systemic hemodynamics and
subsequent risk of kidney dysfunction.28 However, we
showed that 72h subcutaneous RLN did not signifi-
cantly increase systemic or portal venous nitrite levels
and did not reduce MAP, even in advanced cirrhosis,
indicating that RLN may represent a new liver-
selective NO donor. Interestingly, RLN has been
1502 FALLOWFIELD ET AL. HEPATOLOGY, April 2014
shown to preferentially dilate preconstricted vessels and
vasodilatory effects were observed in small renal
arteries of rats and mice but not in mesenteric or coro-
nary septal arteries.29
We demonstrated a rapid and robust reduction in
portal pressure following acute intravenous RLN with
no effect on MAP. This is in agreement with rodent30
and human31 studies, where RLN elicited hemody-
namic effects consistent with vasodilatation without
inducing hypotension. The goal of therapy in PHT is
to reduce portal pressure below critical thresholds
without further deteriorating liver function. We
showed that RLN infusion in early cirrhosis increased
portal venous flow and tissue oxygenation while
decreasing portal pressure, indicating a reduction in
IHVR. Furthermore, in advanced CCl4 cirrhosis serum
albumin levels were significantly increased.
We went on to underscore the potential for RLN in
human disease by showing RXFP1 expression in
explanted human cirrhosis specimens and activated
hHSC-MFs, and confirmed H2-RLN as the cognate
ligand for RXFP1 in these cells. Treatment with exoge-
nous RLN in vitro inhibited HSC contractility and
induced an antifibrogenic gene expression profile in an
RXFP1-dependent manner. Compared to contraction,
relatively little is known about the signaling pathways
which regulate HSC or MF relaxation.1 Both an
increase in intracellular cAMP32 and cGMP6 have
been shown to reduce HSC contraction. We showed
that RLN increased intracellular cAMP and cGMP in
hHSC-MFs. Interestingly, the observation that a-SMA
expression in rat HSCs is regulated by NO and cGMP
production33 may provide a link between RLN
induced intrahepatic NO generation and down-
regulation of a-SMA protein in HSC-MFs in vivo.
Indeed, we also showed that human HSECs isolated
from fibrotic liver expressed RXFP1 in vitro and
increased NO production in response to RLN treat-
ment. Further work will define the HSEC response to
RLN and crosstalk between HSECs and HSCs.
Our data demonstrate that short-term RLN treat-
ment effectively down-regulates HSC-MF contractile
filament expression and contractile function and exerts
a significant portal hypotensive effect in vivo even in
advanced cirrhosis models (Supporting Fig. 9).
Although initial application in humans would likely
involve short-term hemodynamic modulation (e.g., for
variceal bleeding), it is tempting to speculate that
longer-term targeting of RXFP1 might have dual
effects on PHT through relaxation and deactivation of
HSC-MFs, particularly as RXFP1 desensitization has
not been reported to occur.11 We have provided proof
of concept for the use of RLN in cirrhotic PHT and
other conditions associated with MF activation and
pathological vasoconstriction and, given its excellent
safety profile in clinical trials, support its evaluation in
selected patients in early-phase studies.
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